UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-K

xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31, 2014

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number 001-33397

SYNUTRA INTERNATIONAL, INC.

DELAWARE		13-4306188
(State or Other Jurisdiction of Incorporation or Organization)		I.R.S. Employer Identification No.
	2275 Research Blvd., Suite 500 Rockville, Maryland 20850
(Address of Principal Executive Offices, Zip Code)
(301) 840-3888
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name of Each Exchange on Which Registered
Common Stock $0.0001 Par Value	NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes o    No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes xNo o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark if disclosure of delinquent filers in response to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer    o Accelerated filer    x Non-accelerated filer    o Smaller reporting company   o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based on the closing sales price of the registrant’s common stock on September 30, 2013 (the last business day of the registrant’s most recently completed second fiscal quarter), as reported on the NASDAQ Global Select Market, was $112.9 million. For purposes of this disclosure, shares of common stock held by persons who hold more than 10% of the outstanding shares of common stock and shares held by officers and directors of the registrant have been excluded in that such persons may be deemed to be affiliates. This determination is not necessarily conclusive for other purposes.

As of June 16, 2014, there were 57,300,713 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS

Page

PART I

Item 1. Business	2
Item 1A. Risk Factors	18
Item 1B. Unresolved Staff Comments	37
Item 2. Properties	38
Item 3. Legal Proceedings	39
Item 4. Mine Safety Disclosures	39
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	40
Item 6. Selected Financial Data	41
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations	42

Item 7A. Quantitative and Qualitative Disclosures About Market Risk	59
Item 8. Financial Statements and Supplementary Data	60
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	92
Item 9A. Controls and Procedures	92
Item 9B. Other Information	94
PART III
Item 10. Directors, Executive Officers and Corporate Governance	95
Item 11. Executive Compensation	99
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	102
Item 13. Certain Relationships and Related Transactions, and Director Independence	104
Item 14. Principal Accounting Fees and Services	107
PART IV
Item 15. Exhibits, Financial Statement Schedules	108
Signatures	109

CONVENTIONS THAT APPLY TO THIS ANNUAL REPORT ON FORM 10-K

Except where the context otherwise requires and for purposes of this Annual Report on Form 10-K only:

●  “we,” “us,” “our company,” “our,” and “Synutra” refer to Synutra International, Inc., and its consolidated subsidiaries;

●  “China” or “PRC” refers to the People’s Republic of China, excluding Taiwan and the Special Administrative Regions of Hong Kong and Macau;

●  all references to “ton” or “tons” are to “tonne” or “metric ton”;

●  all references to “Renminbi” or “RMB” are to the legal currency of China; and

●  all references to “U.S. dollars,” “dollars,” or “$” are to the legal currency of the United States.

Amounts may not always add to the totals due to rounding.

Unless otherwise noted, all translations from Renminbi to U.S. dollars and all translations from EUR to U.S. dollars were made at the mid rate published by the People’s Bank of China, or the mid rate, as of March 31, 2014, which was RMB 6.1521 to $1.00 and EUR 0.7271 to $1.00, respectively. We make no representation that the Renminbi and EURO amounts referred to in this Annual Report on Form 10-K could have been or could be converted into U.S. dollars at any particular rate or at all. On June 9, 2014, the mid rate was RMB 6.1485 to $1.00 and EUR 0.73815 to $1.00.

PART I

This Annual Report on Form 10-K, or Form 10-K, contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on our current expectations, assumptions, estimates and projections about us and our industry. All statements other than statements of historical fact in this Form 10-K are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “is/are likely to,” “may,” “plan,” “should,” “will,” “aim,” “potential,” “continue,” or other similar expressions. The forward-looking statements included in this Form 10-K relate to, among others:

●  our goals and strategies;

●  our future business development, financial condition and results of operations;

●  the expected growth of the nutritional products and infant formula markets in China;

●  market acceptance of our products;

●  the safety and quality of our products;

●  our expectations regarding demand for our products;

●  our ability to stay abreast of market trends and technological advances;

●  competition in the infant formula industry in China;

●  PRC governmental policies and regulations relating to the nutritional products and infant formula industries; and

●  general economic and business conditions in China.

These forward-looking statements involve various risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may turn out to be incorrect. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth in the “Item 1. Business,” “Item 1A. Risk Factors,” “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and other sections in this Form 10-K.

The forward-looking statements are made as of the date of this Form 10-K. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

1

ITEM 1.  BUSINESS

General Development and Narrative Description of Business

We are a leading infant formula company in China. We principally engage in the production, distribution and sales of dairy based nutritional products under the “Shengyuan” or “Synutra” line of brands in the PRC. We focus on selling powdered formula products for infant and adults, and also engage in other nutritional product offerings, such as prepared foods and certain nutritional ingredients and supplements. We sell most of our products through an extensive nationwide sales and distribution network covering all provinces and provincial-level municipalities in mainland China. As of March 31, 2014, this network comprised over 670 independent distributors and over 550 independent sub-distributors who sell our products in approximately 24,000 retail outlets.

We currently have four reportable segments which are:

●  Powdered formula segment: Powdered formula segment covers the sale of powdered infant and adult formula products. Major brands include Super, U-Smart, My Angel and Dutch Cow;

●  Foods segment: Foods segment covers the sale of prepared baby foods for babies, children and adults under the brand of Huiliduo. In June 2013, we introduced prepared adult foods for patients with special nutritional needs after surgical operations;

●  Nutritional ingredients and supplements segment: Nutritional ingredients and supplements segment covers the production and sale of nutritional ingredients and supplements such as chondroitin sulfate to third parties, and microencapsulated Docosahexanoic Acid (“DHA”) and Arachidonic Acid (“ARA”) to powdered formula segment.

●  Other business segment: our other business includes non-core businesses such as ancillary sales of excess or unusable ingredients and materials to industrial customers.

2

Our Corporate Structure and History

Synutra International, Inc is a Delaware holding company that conducts its business through its operating subsidiaries in China. It owns all or a majority of the equity interests in its operating subsidiaries, directly or indirectly, through Synutra, Inc., or Synutra Illinois, an intermediate holding company, and Synutra International Company Limited. Synutra Illinois was incorporated in Illinois in 2000 and has no significant assets or other operations of its own. Our corporate structure reflects common practice for companies with operations in the PRC where separate legal entities are often used for tax or administrative reasons.

On July 15, 2005, Synutra Illinois completed a reverse acquisition transaction with Vorsatech Ventures, Inc., or Vorsatech. Upon the consummation of this share exchange transaction, Vorsatech’s total issued and outstanding common stock equaled 50,000,713 shares, including 48,879,500 shares issued pursuant to the reverse acquisition transaction and 1,121,213 shares owned by Vorsatech’s existing stockholders. Thereafter, Synutra Illinois became Vorsatech’s wholly owned subsidiary and Vorsatech became the reporting entity for our business. We subsequently changed the name of the reporting entity to Synutra International, Inc.

On May 24, 2007, we entered into a Common Stock Purchase Agreement with Warburg Pincus Private Equity IX, L.P., or Warburg, pursuant to which we sold 4,000,000 shares of our common stock for an aggregate purchase price of $66 million. The closing of the transaction took place on June 15, 2007.

On June 30, 2010, we completed an offering (“Offering”) of 3,300,000 shares of common stock at a price to public of $19.00 per share. The net proceeds from the Offering, after deducting underwriting discounts, commissions and offering expenses, totaled approximately $58.8 million.

The following is a brief description of our major operating subsidiaries:

●  Shengyuan Nutritional Food Co., Ltd., or Shengyuan Nutrition, located in Qingdao, Shandong, China, was established by Synutra Illinois in September 2001 and is engaged in the dry-mixing, packaging, shipping and distribution of all of our powdered formula products.

●  Zhangjiakou Chahaer Dairy Co., Ltd., or Zhangjiakou, formerly known as Zhangjiakou Shengyuan Dairy Co., Ltd., located in Zhangjiakou, Hebei, China, was established in March 2004 with Synutra Illinois and Sheng Zhi Da Dairy Group Corporation (“Sheng Zhi Da”) holding 40% and 60%, respectively, of its equity interests. Synutra Illinois acquired the remaining 60% ownership interest in Zhangjiakou from Sheng Zhi Da in April 2005. Zhangjiakou is mainly engaged in processing whey protein into high oil whey protein, an ingredient used in powdered formula production. We have entered into a share purchase agreement in May 2014 to dispose of this subsidiary. See note 19 Subsequent Event for details.

●  Inner Mongolia Mengyuan Food Co., Ltd., or Mengyuan, located in Fengzhen, Inner Mongolia, China, commenced operations in July 2007. Mengyuan was acquired by Zhangjiakou from its then shareholders in November 2006. Mengyuan is engaged in processing whey protein into high oil whey protein, an ingredient used in powdered formula production.

●  Inner Mongolia Huiliduo Food Co., Ltd., or Inner Mongolia Huiliduo, formerly known as Inner Mongolia Shengyuan Food Co., Ltd., located in Zhenglanqi, Inner Mongolia, China, was established in September 2006. Inner Mongolia Huiliduo began operations in August 2010 to produce prepared baby food, using the Huiliduo brand.

●  Meitek Technology (Qingdao) Co., Ltd., or Meitek, located in Qingdao, Shandong, China, was established in November 2006 to produce certain nutritional ingredients and supplements. Meitek began operations in October 2008.

●  Beijing Shengyuan Huimin Technology Service Co., Ltd., or Huimin, a variable interest entity which was incorporated on July 10, 2008, provides genetic diagnostic services for new born babies in cooperation with medical institutions, together with its subsidiary. The purpose of these activities is primarily marketing in nature to support our brand and product promotion. The operations and assets and liabilities associated with these consolidated variable interest entities are insignificant.

●  Beijing Shengyuan Huiliduo Food Technology Co., Ltd., or Beijing Huiliduo, located in Beijing, China, was established in July 2008 to produce prepared baby food. Beijing Huiliduo began operations in March 2009, and ceased operations in November 2012.

●  Synutra France International SAS, or Synutra France, located in Carhaix, France, was established in June 7, 2012 to manufacture powdered milk and fat-enriched demineralized whey protein powder. Synutra France is currently under construction and in pre-operating stage.

3

The following chart reflects our organizational structure as of March 31, 2014. Unless specifically indicated otherwise, our subsidiaries are organized in mainland China.

Organization chart of Synutra International, Inc.

The following chart shows the structure of our control agreements and the affiliated entities consolidated into our group consolidated financial results as a result of the control agreements:

*  Control Agreements include:

(a)  Exclusive Consulting and Service Agreement entered into by and between Shengyuan Nutrition and Huimin;

(b)  Business Operating Agreement entered into by and among Shengyuan Nutrition, Huimin, Jibin Zhang (who is our Director of Treasury) and Yunpeng Jiang (who is our Director of Strategic Development);

(c)  Call Option Agreement entered into by and among Shengyuan Nutrition, Huimin, Jibin Zhang and Yunpeng Jiang;

(d)  Pledge Agreement entered into by and among Shengyuan Nutrition, Jibin Zhang and Yunpeng Jiang; and

(e)  Entrustment Agreement entered into by and among Shengyuan Nutrition, Jibin Zhang and Yunpeng Jiang.

For a more detailed description of the control agreements, see “Item 13. Certain Relationships and Related Transactions, and Director Independence.”

4

Our Brands

We primarily market our products under the Synutra, or Shengyuan, brand which has been associated with infant formula products in China for more than 10 years. In addition to the Synutra, or Shengyuan brand, our products are marketed in China under brands that we have developed through our national sales and marketing efforts.

Brands for Powdered Formula Products

Powdered formula product brands include several of China’s leading infant and adult formula brands, which mainly include Super, U-Smart, My Angel and Dutch Cow. We have positioned these brands as high quality brands, providing unique, clinically supported health and developmental benefits. Our infant powdered formula products include DHA and ARA, which support brain and immune system development of infants.

Complementary Brands

Building upon the strength of our formula brands, we are extending into the prepared baby food and adult food market, using the Huiliduo brand.

We market under the Meitek brand to meet the nutritional needs of the broader consumer population in China. The products of our Meitek brand use raw materials of type II collagen, which are believed to help relieve joint discomfort, and glucosamine and chondroitin, which clinical studies indicate may help slow down the aging of joints.

In addition, we have launched Chondro Gold and Chodro Cal brands of chondroitin sulfate sodium and chondroitin sulfate calcium materials intended for the dietary ingredients industry in North America and the rest of the world. We believe these two branded materials lead the industry and differentiate our dietary ingredients from the rest of the field and feature our unique and proprietary manufacturing processes at Meitek that help to ensure material purity and quality with innovation.

Stages of Development

Generally, there are five stages of pediatric development and we produce different products for each of these stages. The general stages of pediatric development are as below:

Stage 0:	For expectant and nursing mothers
Stage 1:	For infants 0-6 months old
Stage 2:	For infants 6-12 months old
Stage 3:	For children 13-36 months old
Stage 4:	For children 3-7 years old

Our Dutch Cow brand also provides powdered formula products for adults, including special products for students, women and older people, to address their respective needs.

5

Our Products

Our products are grouped by category of production process and usage as well as internal resource allocation: (1) Powdered Formula, (2) Foods, (3) Nutritional Ingredients and Supplements, and (4) Other business. Sales of Powdered Formula, Foods, Nutritional Ingredients and Supplements, and Other business comprised 85%, 0%, 6%, and 9% of our net sales for the fiscal year ended March 31, 2014, respectively.

Powdered Formula Products

Infant Formula

Our infant formula products include formulas for regular feeding and specialty formula products. The following illustrates our key infant formula brands and products:

Regular Infant Formula

l Super

l U-Smart

l My Angel

l Dutch Cow

We design regular infant formula as a breast milk substitute for healthy, full-term infants without special nutritional needs, both for use as the infant’s sole source of nutrition and as a supplement to breastfeeding. We endeavor to develop regular infant formula closer to breast milk.

Each product is referred to as a “formula,” as it is formulated for the specific nutritional needs of an infant of a given age. Generally, our regular infant formula has the following four main components: (1) protein from cow’s milk that is processed to have an amino acid profile similar to human milk, (2) a blend of vegetable fats (including DHA/ARA) to replace bovine milk fat in order to better resemble the composition of human milk, (3) a carbohydrate, generally lactose from cow’s milk and (4) a vitamin and mineral “micronutrient” pre-mix that is blended into the product to meet the specific needs of the infant at a given age. Patterned after breast milk, which changes composition to meet the infant’s changing nutritional needs, we produce stage 1 & 2 infant formulas for babies from new born to twelve months old.

6

Specialty Infant Formula

l Lactose Free

l Formulas for Preterm and Low Birth Weight Infants

l Formulas addressing Calcium, Iron or Zinc Deficiency

l Formulas of Partially Hydrolyzed Whey Protein

l Subscription only Medical Grade Formulas addressing digestive or metabolic disorder

In March 2012, we obtained the license to produce specialty infant formulas in five categories from Shandong Bureau of Quality and Technical Supervision and were the first, and currently the only domestic manufacturer in China to receive such a license. Special infant formulas are designed for infants with special conditions who cannot consume regular infant formulas. We market these products under the Super Formula brand name.

Lactose free formulas are designed for infants that are lactose intolerant. Lactose is substituted by maltodextrin in this formula, and it is mainly for infants with diarrhea.

Formulas for preterm and low birth weight infants are designed to meet these infants’ unique needs. Typically, such infants need extra assistance obtaining the requisite nutrition. They require a higher density of nutrients and calories because they cannot take in enough volume of breast milk or regular infant formula. We have formula for infants both when they are under intensive care in the hospital, and after they are discharged from the hospital.

We designed formulas addressing calcium, iron or zinc deficiency for infants with special needs from stage 1 to stage 3.

Formulas of partially hydrolyzed whey protein are designed for use by infants that are allergic to the protein in cow’s milk. We introduced this product to the market in April 2013.

We produce medical grade formula, or formulas for special medical purposes, for nutritional management of infants who are born with rare digestive or metabolism disorders.

Children’s Formula (Stage 3 and Stage 4)

We market children’s formula products under the Synutra family of brands. Super, U-Smart, My Angel, Dutch Cow and Super brand formulas addressing Calcium, Iron or Zinc Deficiency are produced for stage 3 and 4. We design these products to meet the changing nutrition needs of children at different stages of development. We offer products at stages 3 and 4 that are designed for children’s nutritional needs at one to three years of age and three to seven years of age, respectively. These products are not breast milk substitutes and are not designed for use as the sole source of nutrition but instead are designed to be a part of a child’s appropriate diet. Our use of the Synutra brand allows for a consistent image across our stages 3 and 4 products.

We produce rice cereal products as supplements for children over 6 months. Currently we have ten formulas of rice cereal products which are produced using rice, fruit, vegetable, meat, vitamins and minerals. We believe that rice cereal products are essential supplements to formula milk.

Adult Formula

We produce Stage 0 powdered formulas for expectant and nursing mothers under Super and U-Smart brand. Our products for expectant or nursing mothers provide the developing fetus or breastfed infant with vitamin supplements and/or an increased supply of DHA for brain development. These products also supplement the mother’s diet by providing either DHA or ARA with increased proteins, as well as vitamins and minerals.

We produce powdered formulas for adult, such as formula with multi-vitamin, formula with high calcium, formula for the elderly, formula for women, and formula for students under the Dutch Cow brand. These products are developed to address specific types of consumer profiles and nutritional needs.

7

Food Products

Food segment covers the sale of prepared pureed food for babies and children, and starting in fiscal 2014, we expanded the segment to include sales of prepared pureed adult food. Baby food products are designed to be part of a child’s healthy diet with enhanced nutritional value. Adult food products are designed mainly for patients with special nutritional needs after surgical operations.

Nutritional Ingredients and Supplements

Nutritional ingredients and supplements segment covers the production and sale of nutritional ingredients and supplements such as chondroitin sulfate, collagen, microencapsulated DHA and ARA. Chondroitin sulfate and collagen is mainly for industrial sales and export, with a small portion used in our self-developed nutritional products. Microencapsulated DHA and ARA powders are produced mainly for internal use in powdered formula production process.

Other business

Other business principally includes ancillary sales of surplus milk powder and whey protein to industrial customers.

Production

Powdered Formula Processing

In the fiscal year ended March 31, 2014, we imported all of the whole milk powder used for our powdered formula products from Fonterra Co-operative Group (“Fonterra”) in New Zealand. We imported all of the whey powder used for infant powdered formula products from Eurosérum S.A.S (“Eurosérum”) in France. We purchased other ingredients for our formula from domestic suppliers.

If the high oil whey protein purchased from Eurosérum is not enough for our production, we use whey protein and oil to produce high oil whey protein at our Zhangjiakou and Fengzhen facilities, or engage a third party to produce high oil whey protein using whey protein and oil provided by us. In rare cases, when whey protein powder is in short supply, we use whey protein concentrates and lactose instead in the production.

At our Qingdao facility, milk powder is mixed in large automated mechanical mixers with high oil whey protein powder and other additives in a method known as dry-mixing. Our dry-mixing equipment can automatically adjust the level of ingredients to achieve the complex formulations required by our premium products. The resulting milk powder is then checked to ensure proper granule size before packaging and distribution.

In fiscal year 2014, imported Super product was contract manufactured by Fonterra, a New Zealand company, and Dutch Cow infant formula product was contract manufactured by FrieslandCampina, a Dutch company. These products are produced according to our specification and the quality standards of both companies/countries.

8

Production and Packaging Facilities

Our processing and packaging facilities, which are all owned by us, are located in various locations in China, including Qingdao, Zhangjiakou, Fengzhen and Zhenglanqi. These facilities encompass approximately 137,000 square meters of office, plant, and warehouse space. Our distribution center located in Qingdao includes approximately 25,000 square meters of owned space. All of our production facilities are built based on the GMP standard, with equipment imported from Europe and all of our facilities that have commenced operations have ISO9000 and HACCP series qualifications with some also being ISO14000 certified.

Qingdao, Zhangjiakou and Fengzhen facilities are for our powdered formula production. As of March 31, 2014, we had high oil whey protein processing capacity of approximately 18,800 tons per year for the Zhangjiakou facility and the Fengzhen facility, and had packaging capacity of approximately 75,000 tons per year and dry-mixing processing capacity of approximately 78,000 tons per year for the Qingdao facility.

Our Qingdao facility serves as our dry-mixing and packaging plant. Various ingredients, such as milk powder, high oil whey protein powder and nutritional additives arrive at our Qingdao facility from our production facilities and our suppliers, and are mixed using the dry-mixing method. Qingdao facility packages the mixed ingredients into retail-size tin canisters or stand up/display pouches or sealed packages in boxes. This packaging facility also provides inventory control and logistics management, product quality monitoring and product development assistance.

Our production facility for prepared foods is located in Zhenglanqi. As of March 31, 2014, the Zhenglanqi facility had a processing capacity for prepared foods of 9,000 tons per year.

Our production facility for nutritional ingredients and supplements is located in Qingdao. As of March 31, 2014, this facility had a processing capacity of 500 tons per year for chondroitin sulfate, 500 tons per year for collagen protein, and 700 tons for microencapsulated DHA and ARA powders.

For information with respect to the installed capacity, location and function of our processing and packaging facilities, see “Item 2. Properties”.

Retail Packaging

The bulk of our powdered formula and other nutritional products come in three types of retail packaging: tin canisters, standup/display pouches, or sealed packages in a box. All packaging labels carry product information, nutritional profile, user instructions, product tracing data and shelf life date, product certification status, quality control and assurance remarks, manufacturer contact information, as well as customer service information that comply with PRC labeling requirements. Selected products are also retail-packaged in single-use sizes. Before any product leaves our packaging facility to distributors, we engage in an extensive testing and inspection of the final product.

Raw Materials and Suppliers

Raw Materials

Our business depends on maintaining a regular and adequate supply of high-quality raw materials. In the aftermath of the melamine contamination incident, we decided to use 100% imported milk powder for the production of our powdered formula products. Currently, all of the milk powder used in our production is from New Zealand. Milk powder constitutes approximately 20% to 40% of the final powdered infant formula product by weight, depending on the product stage.

Oil-wrapped whey powder is the other key ingredient used in the production of our powdered infant formula products. Oil-wrapped whey powder is produced from whey powder and blended vegetable oil. Like all powdered milk producers, we use oil-wrapped whey powder as the active ingredient to help reconstituted dairy-based formula to mimic the consistency of breast milk. Whey powder constitutes approximately 44% to 55% of the final powdered infant formula product by weight, and blended vegetable fats constitute approximately 10% to 20%, depending on the product stage. Whey powder is a byproduct of cheese-making processes, and is difficult and costly to produce as a stand-alone product. Since China is not a large consumer or producer of cheese and cheese products, Chinese infant formula manufacturers typically obtain whey powder in volume from overseas sources. In fiscal year 2014 to achieve the oil-wrapping for the whey powder, we used blended vegetable fats in our spray-drying powder infant formula production processes as a binder for the dry ingredients, helping to diminish the occurrence of “lumpiness” or uneven texture when reconstituting powdered infant formula. We purchased blended vegetable fats within China.

Based on our experience, prices of milk powder can fluctuate over relatively short periods of time depending on market conditions. Our sourcing team monitors price movements and makes major purchases at times when prices are attractive, subject to projected customer order flow and other factors.

Our powdered milk products, including our powdered infant formulas, also include additives such as DHA and ARA fatty acids and other nutritional additives, which constitute approximately 5% of the final powdered infant formula product by weight. DHA and ARA fatty acids are long-chain poly-unsaturated fatty acids found in breast milk that are believed to aid in the development of an infant’s brain, eyes and nervous system. Studies have suggested that DHA and ARA fortification can replicate some of the nutritional benefits of breast milk in infant formulas. Currently we purchase DHA oil and ARA oil from third parties, and produce microencapsulated DHA and ARA powders at our Meitek facility for internal use.

We purchase animal cartilage from third-party suppliers for the production of chondroitin sulfate, a substance that provides nutrients for joints, tendon, ligaments and bones, in our Meitek facility.

9

Suppliers and Supplier Arrangements

Currently, we purchase all of our milk powder from Fonterra in New Zealand. The purchase prices are determined through Fonterra’s online auction process and we do not sign long term contracts with our suppliers.

We purchase all of our whey powder from Eurosérum. The purchase prices are determined through Eurosérum quotation process and we do not sign long term contracts with our suppliers.

On September 17, 2012 we entered into a partnership agreement, a milk supply agreement, a whey supply agreement, a whey powder supply agreement, and a technical assistance agreement with Sodiaal Union, a French agricultural cooperative company (“Sodiaal”), and Euroserum SAS, a wholly-owned subsidiary of Sodiaal (“Euroserum”). Under these agreements, we intend to build a new drying facility in Carhaix, France, to manufacture milk powder and fat-filled demineralized whey powder(the “French Project”). For details, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources”.

Sales and Distribution

Sales

We generally sell our products to distributors and in limited circumstances directly to retailers such as supermarkets. With the introduction of My Angel series infant powdered formula products in the fourth quarter of fiscal year 2011, we began to sell directly to baby stores. Our sales and marketing approach combines advertising, brand-building and store-level promotions. Our customer relations management team, or CRM, uses our customer relations management database in order to acquire, process, and manage targeted customer information.

We have built a sales network that covers all the provinces and provincial-level municipalities in mainland China. Our sales group is divided into multiple sub-sales regions. Each sub-sales region covers between eight to twenty urban sales areas which act as independent operating units, while each urban sales area covers three to twenty county sales areas. As of March 31, 2014, we had a sales and marketing force of approximately 1,800 employees, complemented by approximately 8,700 full time or part time commissioned field nutrition consultants or retail site promoters employed by our distributors and sub-distributors to promote and sell our products.

Our sales teams work directly with each retail outlet to manage the sales process and to collect customer and purchasing related data. We use multiple criteria to select our distributors, including reviewing each potential distributor’s financial condition. City managers are rotated periodically among various cities. We have set up a sales budget management team to manage our sales expenses and to supervise the execution of our budgeting plan. This team reports directly to the director of marketing and sales.

We compensate our sales personnel through a combination of fixed salaries and bonuses based on sales volume. Our targeted sales incentive programs compensate our sales personnel on a product-specific level, thereby enabling us to incentivize our sales personnel to focus their sales and promotion efforts on certain product lines, such as our premium product lines or larger product packages.

10

Distribution

We primarily work directly with over 670 independent distributors, who in turn work with over 550 independent sub-distributors, and approximately 24,000 retail outlets. Our dry-mixing and packaging subsidiary, Shengyuan Nutritional Food Co., Ltd., also serves as our national distribution center for our distributors in China. Through the personal digital assistant (“PDA”) devices and cell phone applications we installed for each distributor, we can monitor their inventory level closely. We accept purchase orders each month from the distributors. Our sales personnel also regularly inspect and perform stocktaking on distributors’ inventories to identify and control any potential inventory buildup. We employ trucking companies locally and nationally to distribute retail packaged products to various regional and provincial distributors.

Distributors normally have exclusive distribution rights in their respective regions and cities to distribute our products, and are also responsible for developing the sub-distributors in their own region and cities. We typically enter into a contract with each of our distributors that establishes the range of sales obligations and their respective discount level on top of our standard manufacturer’s prices. However, our obligation to sell and the distributor’s obligation to purchase arise only at the time a purchase order is accepted. We seek to carefully manage our distributors through an evaluation system that monitors and grades each distributor with respect to performance criteria such as monthly sales and investment in promotional activities. We seek to incentivize well-performing distributors by providing more discounts, larger sales territory and other incentives. While we do not directly manage our sub-distributors, we do track sub-distributor performance through coordinated efforts between our own sales personnel in the field and the distributors. We do not accept product returns except in the event of package damage during delivery and for certain supermarket retailers.

We currently distribute our nutritional products across mainland China. Our logistics center in our Qingdao facilities occupies an area of 25,000 square meters. This logistics center can currently dispatch 6,900 tons of our products for shipment to our distributors per month. Our Qingdao facility also has the capability to respond to urgent requests for product shipments within an average of five days.

We currently work with more than 20 transportation companies that transport our goods directly from our Qingdao facilities to distributors in a timely and efficient manner.

We have an enterprise resource planning system, or ERP system, which is a financial information system with an inventory module that manages and records inventory transactions.

In order to strengthen our management of sales channel, we have set up an inventory tracking system to track our products from the factory to the retail outlets in an effort to prevent distributors from selling out of their designated area.

Seasonality

Our business experiences some seasonal fluctuations. Summer time is typically a slow time for the infant formula market because Chinese parents tend to choose the summer time to switch from milk feeding to more concrete food for their babies. As a result, we generally experience weaker sales in our first and second fiscal quarters.

11

Marketing, Advertising and Promotion

Advertising

We advertise through various media, including television, print media and the Internet, with recent focus on e-commerce providers, mostly for our specialty infant formula products with special nutritional needs. Our advertising spending was $6.1 million, $11.9 million and $11.5 million for the fiscal years ended March 31, 2014, 2013 and 2012, respectively.

Marketing and Promotion

We have established a national customer service call center providing live assistance and a toll-free line to provide consumers with prenatal, nursing, baby care education, product information, and address complaints and dispute resolution.

We provide displays, posters and other printed promotional materials to retail outlets and sales consultants employed by our distributors at each point of sale. We also pay entry fees to various retail outlets to place our products within such outlets. We collect customer information through surveys voluntarily provided by each customer via the point of sale or via mailed forms provided to our customers in each product package. We also have promotional activities with supermarket chains and entertainment companies in order to reach our target market.

Quality Control

We place primary importance on quality. We have established quality control and food safety management systems for purchasing, acceptance checks, processing, packaging, storage and transportation. All of our processing facilities are equipped with in-house laboratories for quality assurance and quality control purposes. Our quality test laboratory in Qingdao has been qualified as a National Standard Laboratory by the China National Accreditation Service for Conformity Assessment.

In order to ensure the quality and safety of our ingredients and products, we have also installed testing equipment and have implemented control procedures at each stage of production, including at the initial raw material purchase stage. There are over 1,100 quality control points throughout the entire production process. We employ strict internal procedures and monitoring by highly trained employees during production, transportation and storage. Additionally, we have been increasing our investment in quality control equipment and training. All policies relating to quality control are subject to PRC laws and regulations.

In the dietary ingredients and supplements sector, our manufacturing facilities in Qingdao underwent stringent process, plant, and quality audits by all our key customers and by standard organizations including the United States Pharmacopeia (UPS) and received the USP-verified certification.  We have led the global industry in developing effective testing methodologies to help ensure the integrity of the supply chain and to detect and deter adulteration of chondroitin sulfate materials. In addition to our quality assurance laboratories in Qingdao, we also established a wet lab in Rockville, MD dedicated to dietary ingredients material screening and research on supplement products in the US market.

12

Highlights of our quality control procedures are summarized below, organized by the main stages of production:

Imported Milk Powder and Whey Powder:

●  Procurement staff inspects the Certificate of Analysis to ensure the products are manufactured and tested according to production countries’ national standard;

●  Entry-Exit Inspection and Quarantine of the People’s Republic of China performs quality test to ensure the products are up to national standard and issue a Sanitary Certificate; and

●  Quality test staff of the Company performs detailed test on quality and nutritional ingredients of the products before using them in production.

Powder Formula Production:

●  Compliance with production process control procedure, HACCP Plan implemented at all plants;

●  All raw materials are subject to prior inspection;

●  Detailed process designed for all parts of the production process including pretreatment, dry-mixing, powder receiving, and packaging;

●  Maintain hygiene standards for staff, equipment, environment and any other object; and

●  Inspection conducted throughout the production process.

Packaging, Storage and Transport:

●  Establishment and practice of total process management with respect to product identification and traceability;

●  Inspection before warehousing of products;

●  Maintain hygiene standards in the course of transport and storage; and

●  Products must be positioned according to their category during transport and storage.

13

Research and Development

Our research and development activities focus on new product formulation, new ingredient development, creation of new methods to incorporate certain nutrients in our products, and improvement in product tastes and ingredient shelf stabilities. We engage in regular product refinement and new product development for our dairy-based formula products, as well as other forms of foods and nutritional supplements.

We utilize our research and development facilities to engage in the effort of bringing our infant formula products closer to the quality of breast milk and to promote our brand image. We also engage third-party research institutions to research and develop such trial products for us.

We seek to leverage our research and development resources in order to extend our new product pipeline. We believe we can accomplish this goal with new formulations and product concepts in dairy-based formula products as well as other nutritional food products and supplements.

During each of the fiscal years ended March 31, 2014, 2013 and 2012, we spent approximately 1.1%, 1.0% and 0.3% of net sales per year on research and development, respectively.

Competition

The infant formula industry in China is highly competitive. We generally compete with both multinational and domestic infant formula producers. Competitive factors include brand recognition, distribution network, quality, advertising, formulation, packaging and price. Many of our competitors have significant market shares in the markets we compete in. Our principal competitors can be classified generally into the following two groups:

Multinational Brands

●  Abbot Laboratories’ Ross Products Division, a U.S. producer and distributor of infant formulas marketed under the brand names of Similac and Enfalac family of formulas;

●  Mead Johnson Nutrition Co., or Mead Johnson, formerly a Bristol-Myers Squibb Company Division, a U.S. producer and distributor of the Enfamil family of formulas;

●  Groupe Danone SA’s Numico division, or Numico, a Dutch producer of baby foods, which sells and markets infant formula products in China under the Dumex brand;

●  Nestlé Suisse SA, or Nestlé, a Swiss producer and distributor of starter and follow-up formulas, milk, cereals, oral supplements and performance foods marketed under Nestlé brands such as Carnation;

●  Royal FrieslandCampina N.V., a Netherland dairy company of the Friso family of formulas.

Domestic Brands

●  Biostime International Holdings Limited, or Biostime, a PRC producer of infant formula products and baby care products under their Biostime and BMcare brand;

●  Inner Mongolia Yili Industrial Group Co., Ltd., or Yili, a PRC producer and distributor of liquid and powdered milk under their Yili brand;

●  Beingmate Group Company Limited, or Beingmate, a PRC producer and distributor of infant formula products under their Beingmate brand;

●  Guangdong Yashili Group Co., Ltd., or Yashili, a PRC consumer brand marketer which sells a line of infant formula products under their Yashili brand; and

●  Feihe International, Inc., a PRC producer and distributor of milk formula products under their Feihe brand.

According to data collected by the PRC National Commercial Information Center, or CIC, an entity affiliated with the PRC General Chamber of Commerce responsible for collecting retail sales data, the top ten brands accounted for 83% of total infant formulas sold in China in calendar year 2013.

14

Intellectual Property

All of our product formulations have been developed in-house and are proprietary. We have not registered or applied for protections in China for most of our intellectual property or proprietary technologies relating to the formulations of our powdered infant formula. See Item 1A. Risk factors—Risks Related to Our Business—Failure to adequately protect our intellectual property rights may undermine our competitive position, and litigation to protect our intellectual property rights may be costly. Although we believe that, as of today, patents and copyrights have not been essential to maintaining our competitive market position, we intend to assess in the future whether to seek patent and copyright protections for those aspects of our business that provide significant competitive advantages.

As of March 31, 2014, we had 317 registered trademarks in China, and 5 registered trademarks in other districts and countries. Additionally, we had 76 trademark applications pending approval in China.

We rely on trade secret protection and confidentiality agreements to protect our proprietary information and know-how. Our management and each of our research and development personnel have entered into annual employment contracts, each of which includes a confidentiality clause and a clause acknowledging that all inventions, designs, trade secrets, works of authorship, developments and other processes generated by them on our behalf are our property, and assigning to us any ownership rights that they may claim in those works. Despite our precautions, it may be possible for third parties to obtain and use, without our consent, intellectual property that we own or are licensed to use. Unauthorized use of our intellectual property by third parties, and the expenses incurred in protecting our intellectual property rights, may adversely affect our business. See Item 1A. Risk factors—Risks Related to Our Business—Failure to adequately protect our intellectual property rights may undermine our competitive position, and litigation to protect our intellectual property rights may be costly.

Environmental Matters

Our manufacturing facilities are subject to various pollution control regulations in China with respect to noise, water and air pollution and the disposal of waste and hazardous materials. We are also subject to periodic inspections by local environmental protection authorities in China. We are not currently subject to any pending actions alleging any violations of applicable PRC environmental laws.

Our Employees

As of March 31, 2014, we employed approximately 3,200 employees in all of our facilities, with approximately 120 head office management staff and research and development employees, approximately 1,260 production employees, and approximately 1,820 sales and marketing employees. Our employees are not represented by a labor organization or covered by a collective bargaining agreement. We have not experienced any work stoppages.

We offer our employees both a base salary and a performance bonus. As required by PRC regulations, we participate in various employee benefit plans that are organized by municipal and provincial governments, including pension, work-related injury benefits, maternity insurance, medical and unemployment benefit plans. We are required under PRC law to make contributions to the employee benefit plans at specified percentages of the salaries, bonuses and certain allowances of our employees, up to a maximum amount specified by the local government from time to time. The pension amount is determined by a number of factors, including the member’s salary amount at retirement date, contribution period, social average salary level and price index.

15

Regulation

The food industry, of which nutritional and infant formula products form a part, and medical institutions, are subject to extensive regulations in China. This section summarizes the most significant PRC regulations governing our business in China.

Food Hygiene and Safety Laws and Regulations

As a producer of nutritional products, and particularly dairy-based infant formula products, in China, we are subject to a number of PRC laws and regulations governing the manufacturing (including composition of ingredients), labeling, packaging, safety and hygiene of food products:

●  the PRC Product Quality Law;

●  the PRC Food Safety Law;

●  the Implementation Rules on the PRC Food Safety Law;

●  the Dairy Product Industrial Policies (2009 Version);

●  the Regulation on the Supervision and Administration of the Quality and Safety of Dairy Products;

●  The Outlines of the Rectification and Revival of the Dairy Industry;

●  the Measures of the Administration on the New Food-Additives;

●  the Measures of the Filing of the Enterprise Standard of the Food Safety;

●  the Implementation Rules on the Administration and Supervision of Quality and Safety in Food Producing and Processing Enterprises;

●  the Regulation on the Administration of Production Licenses for Industrial Products;

●  the General Standards for the Labeling of Prepackaged Foods;

●  the Implementation Measures on Examination of Dairy Product Production Permits;

●  the Standardization Law;

●  the Raw Milk Collection Standard;

●  the Whole Milk Powder, Skimmed Milk Powder, Sweetened Whole Milk Powder and Flavored Milk Powder Standards;

●  the General Technical Requirements for Infant Formula Powder and Supplementary Cereal for Infants and Children;

●  Rules for the Examination of Licensing Criteria for Enterprises Producing Formula Milk Powder of Infant Use (2013 version); and

●  Rules for the Examination of Licensing Criteria for Enterprises Producing Milk Products (2010 version)

These laws and regulations set out safety and hygiene standards and requirements for various aspects of food production, such as the use of additives, production, packaging, handling, labeling and storage, as well as facilities and equipment. Failure to comply with these laws and regulations may result in confiscation of our products and proceeds from the sales of non-compliant products, destruction of our products and inventory, fines, suspension of production and operation, product recalls, revocation of licenses, and, in extreme cases, criminal liability.

On October 7, 2008, the State General Administration of Quality Supervision, Inspection and Quarantine (“AQSIQ”) issued a national standard on the detection of melamine in raw milk and dairy based products. On October 9, 2008, the State Council promulgated with immediate effect a Regulation for the Quality and Safety Supervision of Dairy Based Products, which, among other things, imposes more stringent requirements for inspection, production, packaging, labeling and product recall on dairy product producers. This regulation also established a “Black-List” system to ensure that illegal business operators in the dairy production chain are timely disclosed and severely punished.

On April 22, 2010, MOH issued 66 food safety national standards (“New National Standard”), including the national standard for infant powdered formula, which impose strict requirement for production of infant powdered formula.

On November 1, 2010, AQSIQ issued Rules for the Examination of Licensing Criteria for Enterprise Producing Formula Milk Powder of Infant Use (2010 version) and Rules for the Examination of Licensing Criteria for Enterprise Producing Milk Products (2010 version) to tighten the supervision of milk product quality and safety. Under the new rules, milk producers are required to pass higher safety and quality tests in order to have their licenses re-issued.

In December 2013, the Chinese State Food and Drug Administration updated the national guidance for the renewal and re-affirmation of production licenses for manufacturing infant-formula milk powder products in China. For any infant-formula milk powder manufacturer whose license is expiring in 2014, the renewal process needs to be completed by March 31, 2014. For any infant-formula milk powder manufacturer whose license expires in a later year, the re-affirmation needs to be completed by May 31, 2014. This regulation sets forth new rules and raises the bar on infant formula producers in nine areas, including product safety control, purchase of raw materials, formula product inspection, manufacturing process and product traceability. In particular, the requirement on a 100,000 grade clean space to meet the medical grade Good Manufacturing Practices is widely considered as the most challenging requirement. Our Qingdao facility and Zhangjiakou facility obtained the renewed production licensed in April and May 2014, respectively.

16

Environmental Regulations

We are subject to various governmental regulations related to environmental protection. The major environmental regulations applicable to us include:

●  the Environmental Protection Law of the PRC;

●  the Law of PRC on the Prevention and Control of Water Pollution;

●  Implementation Rules of the Law of PRC on the Prevention and Control of Water Pollution;

●  the Law of PRC on the Prevention and Control of Air Pollution;

●  Implementation Rules of the Law of PRC on the Prevention and Control of Air Pollution;

●  the Law of PRC on the Prevention and Control of Solid Waste Pollution; and

●  the Law of PRC on the Prevention and Control of Noise Pollution.

We are periodically inspected by local environmental protection authorities. Our operating subsidiaries have received certifications from the relevant PRC government agencies in charge of environmental protection indicating that their business operations are in compliance with the relevant PRC environmental laws and regulations.

Dairy Industry Access Conditions and Policies

In June 2009, the PRC National Development and Reform Commission, or the NDRC, and the Ministry of Industry and Information Technology, or the MIIT, jointly promulgated and issued Dairy Industry Policies (2009 Version), or the Policies. The Policies set forth the conditions an entity must satisfy in order to engage, or continue to engage, in the dairy products processing business, including technique and equipment, product quality, energy and water consumption, sanitation and environmental protection, as well as production safety. Any new or continuing dairy products processing projects or enterprises will be required to meet all the conditions and requirements set forth in the Policies.

The Policies also set forth some requirements relating to the location, processing capacity and raw milk source for any new or continuing dairy products processing project or enterprise. Any new or continuing dairy products processing projects or enterprises that fail to meet the requirements will not be able to procure land, license, permits, loan facility and electricity necessary for the processing of dairy products. We believe that all of our existing entities and facilities for powdered formula production meet the requirements under the Access Conditions. See Item 1A. Risk Factors—Risks Associated with Doing Business in China—Changes in the regulatory environment for dairy and infant nutrition products in China could negatively impact our business.

Medical Institutions

On February 26, 1994, the State Council promulgated the Regulations of Administration on Medical Institutions which established the regulations for establishing, managing and supervision of medical institutions. In particular, the regulations required a medical institution to be approved by and register with the applicable administrative department of public health prior to establishment. On December 14, 2009, the Ministry of Public Health promulgated the Standards of Medical Inspection Laboratory which set forth the standards for establishing and managing medical inspection laboratories. On January 15, 2014, we obtained the business license of Beijing Syclin Clinical Laboratory Co., Ltd., which is a wholly-owned subsidiary of Beijing Shengyuan Huimin Technology Service Co., Ltd., and commenced operation.

Financial Information about Segments and Geographic Areas

We have four reportable segments, which are powdered formula, foods, nutritional ingredients and supplements and other business. Other business includes non-core operations such as ancillary sales of excess or unusable ingredients and materials to industrial customers. Please refer to Note 16 to the Consolidated Financial Statements for further discussion about segments and geographic areas.

Available Information

Our Internet website address is www.synutra.com. We make available at this address, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the United States Securities and Exchange Commission, or SEC. Information available on our website is not incorporated by reference in and is not deemed a part of this Form 10-K. The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E., Washington, DC, 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issues that file electronically with the SEC at www.sec.gov.

17

ITEM 1A.  RISK FACTORS

Because of the following factors, as well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

You should carefully consider the following risks and other information in this Form 10-K before making an investment decision with respect to our common stock. The following risks and uncertainties could materially and adversely affect our business, results of operations and financial condition. The risks described below are not the only ones we face. Additional risks that we are not presently aware of or that we currently believe are immaterial may also impair our business operations.

Risks Related to Our Business

We may face liquidity challenges to meet our debt obligations and may require additional funding in the future.

We had loss before income tax expense of $27.0 million and negative cash flow from operation of $5.7 million for the fiscal year ended March 31, 2013. In addition, we had accumulated deficit of $104.6 million at March 31, 2014. Our operations rely heavily on debt, and at March 31, 2014, we had short-term debt of $115.9 million, long-term debt due within one year of $91.5 million and long term debt due between one and two years of $160.5 million. The asset liability ratio, which is defined as total liabilities divided by total assets, was 89% at March 31, 2014. In addition, in connection with our commitment to build a new drying facility in Carhaix, France, we will need additional funding but may not be able to secure financing on satisfactory terms, which could decrease our working capital. See “Liquidity and Capital Resources.” Our ability to meet our debt obligations will depend on our future performance, which will be affected by financial, business, domestic and foreign economic conditions and other factors, many of which we are unable to control. As a result, there can be no assurance that our operation will generate sufficient cash flows to meet our liquidity needs, and we therefore may have negative cash flows in the future. If our cash flow is not sufficient to service our debt, we may be required to obtain additional financing in the future, and such additional financing may not be available at times, in amounts or on terms acceptable to us or at all. We may not be able to repay such borrowings in full or at all when due and, if we were to default on the repayment of these borrowings, we may not be able to continue our operations as a going concern.

We are highly dependent upon consumers’ perception of the safety and quality of our products. Any ill effects, product liability claims, recalls, adverse publicity or negative public perception regarding particular ingredients or products or our industry in general could harm our reputation, damage our brand and adversely affect our results of operations.

We sell products for human consumption, which involves risks such as product contamination, spoilage and tampering. We may be subject to liability if the consumption of any of our products causes injury, illness or death. Adverse publicity or negative public perception regarding particular ingredients, our products, our actions relating to our products, or our industry in general could result in a substantial drop in demand for our products. This negative public perception may include publicity regarding the safety or quality of particular ingredients or products in general, of other companies or of our products or ingredients specifically. Negative public perception may also arise from regulatory investigations or product liability claims, regardless of whether those investigations involve us or whether any product liability claim is successful against us.

On September 16, 2008, China’s Administration of Quality Supervision, Inspection and Quarantine, or China AQSIQ, announced its finding that the formula products of 22 Chinese formula producers, including certain lots of our U-Smart products, were contaminated by melamine, a substance not approved for use in food and linked to the illness and deaths of infants and children in China. There were six reported deaths and approximately 300,000 children suffered kidney-related illnesses due to the contaminated infant formula of one of our competitors. This contamination incident resulted in significant negative publicity for the entire domestic dairy and formula industries in China and demand for domestically-produced dairy and formula products, including our products, declined significantly since September 2008 until late 2009. We recalled our affected U-Smart products as well as all other products produced at the same facilities in the Hebei and Inner Mongolia regions of China, where we believe the contaminated milk supplies originated. We also suspended production at our facilities in Qingdao, Hebei and Inner Mongolia for two weeks pending government and internal investigations. The total cost of this action was $100.6 million which was recognized as a charge to cost of sales, selling and distribution expenses and general and administrative expenses in our consolidated statement of income mostly in fiscal year 2009.

Although we have not confirmed any cases of kidney-related or other illnesses caused by our products, we cannot assure you that such cases will not surface in the future. The Chinese government has provided medical screening, treatment, and care for consumers affected by melamine contamination in infant formula products. We have contributed a net amount of $2.3 million to a compensation fund set up by China Dairy Industry Association to settle existing and potential claims arising in China from families of infants affected by melamine contamination. We cannot assure you that the Chinese government will not seek further reimbursement from dairy and formula product manufacturers, including us.

We believe the melamine contamination incident negatively impacted our brand and reputation in China. It also affected investor confidence in us as reflected by the significant decrease in our stock price after September 16, 2008. We cannot predict whether there will be similar future incidents and what impact such incidents may have on our operations and reputation.

18

In August 2010, several media reports alleging our infant formula products caused symptoms of hormone-triggered sexual prematurity in infants in the Hubei province of China. One of the media later issued an apology video clip on its official website acknowledging their allegation as without proof. Despite the apology, our business was significantly and negatively impacted since then as a result of these media reports, and our sales volume decreased significantly. We increased the spending on advertising after the prematurity event to repair our reputation and regain market share. As a result, we had a significant net loss for the fiscal year ended March 31, 2011.

In the past, there have also been occurrences of counterfeiting and imitation of products in China that have been widely publicized. We cannot guarantee that contamination or counterfeiting or imitation of our or similar products will not occur in the future or that we will be able to detect it and deal with it effectively. Any occurrence of contamination or counterfeiting or imitation could negatively impact our corporate and brand image or consumers’ perception of our products or similar nutritional products generally, particularly if the counterfeit or imitation products cause injury or death to consumers. For example, in April 2004, sales of counterfeit and substandard infant formula in Anhui, China caused the deaths of 13 infants as well as harming many others. Although this incident did not involve the counterfeiting of our products, it caused significant negative publicity for the entire infant formula industry in China. The mere publication of information asserting that infant formula ingredients or products may be harmful could have a material adverse effect on us, regardless of whether these reports are scientifically supported or concern our products or the raw materials used in our products.

We believe that the melamine contamination incident, the prematurity event and any other adverse news related to formula products in China will also result in increased regulatory scrutiny of our industry, which may result in increased costs and reduce our margins and profitability. The government has enhanced its regulations on the industry aimed to ensure the safety and quality of dairy products, including but not limited to compulsory batch by batch inspection. This is likely to increase our operating costs and capital expenditure.

If we fail to obtain raw materials in the quantity and the quality we need, and at commercially acceptable prices, our results of operations, financial condition and business prospects would be materially and adversely affected.

Our business requires certain key raw materials, such as milk powder and whey powder. We may experience a shortage in the supply of certain raw materials in the future, which could materially and adversely affect our production and results of operations. While our agreements with Sodiaal and Euroserum are intended to provide our supplies in the future, the drying facility in Carhaix, France is not expected to be operational until late 2015. See “Liquidity and Capital Resources”. Other than these agreements, we currently do not have guaranteed supply contracts with any other raw material suppliers, and some of our suppliers may, without notice or penalty, terminate their relationship with us at any time. We also rely on a small number of suppliers for some of our raw materials, such as whey powder and imported milk powder. We now use imported milk powder from New Zealand for all of our powered formula products as consumers have less confidence in domestically-produced milk powder. If any supplier is unwilling or unable to provide us with high quality raw materials in required quantities and at acceptable prices, we may be unable to find alternative sources or at commercially acceptable prices, on satisfactory terms, in a timely manner, or at all. Our inability to find or develop alternative sources could result in delays or reductions in production, product shipments or a reduction in our profit margins. Moreover, these suppliers may delay material shipments or supply us with inferior quality raw materials that may adversely impact the timely delivery or the quality of our products. If any of these events were to occur, our product quality, competitive position, reputation and business could suffer.

In addition, most of the raw materials used in our business are imported, such as whey powder and milk powder. Our imported raw materials are subject to various PRC governmental permit requirements, approval procedures and import duties, and may also, from time to time, be subject to export controls and other legal restrictions imposed by foreign countries. Should the PRC government refuse to issue the necessary permits or approvals to us or our suppliers, or take any administrative actions to limit imports of certain raw materials, or if we or our suppliers fail to pay any required import duties, or if governmental agencies or laws of foreign countries prevent the timely export of certain raw materials we require to China, our ability to produce and sell our products in China could be materially and adversely affected. In addition, import duties increase the cost of our products and may make them less competitive.

Finally, certain suppliers of raw materials within our supply chain may contaminate our raw material supplies or provide us with substandard raw material supplies that adversely impact the quality of our products exposing our customers to health risks and damaging our reputation, brand and financial condition. For a more detailed description of this risk, and in particular the impact of the melamine contamination incident in China, see Part 1 - Item 1A. Risk Factors — We are highly dependent upon consumers’ perception of the safety and quality of our products. Any ill effects, product liability claims, recalls, adverse publicity or negative public perception regarding particular ingredients or products or our industry in general could harm our reputation, damage our brand and adversely affect our results of operations.

19

Any interruption in our supply of milk powder could materially and adversely affect our results of operations, financial condition and business prospects.

We currently import all of the milk powder used in the powdered formula production from New Zealand. The continuity of the milk powder supplies is of critical importance to our business. The importation of milk powder is influenced by numerous factors beyond our control, including, among other: (1) export control policy in the originating countries, (2) China’s government policy and regulation on milk powder importation as well as China’s custom inspection standards and (3) acts of God such as natural disasters. Any interruption in our milk powder supplies could have a material adverse effect on our results of operations, financial condition and business prospects. In addition, we currently source all of our milk powder from one supplier, Fonterra. If Fonterra fails to deliver the milk powder we need on the terms we have agreed, we may not be able to find an alternative source at a comparable price or on other favorable terms, and any delays in securing an alternative source could result in production delays and late shipments of our products to distributors and end customers.

Our results of operations may be affected by fluctuations in availability and price of raw materials.

The raw materials we use are subject to price fluctuations due to various factors beyond our control, including increasing market demand, inflation, severe climatic and environmental conditions, commodity price fluctuations, currency fluctuations, changes in governmental and agricultural regulations and programs and other factors. We also expect that our raw material prices will continue to fluctuate and be affected by inflation in the future. Changes to our raw materials prices may result in increases in production and packaging costs, and we may be unable to raise the prices of our products to offset these increased costs in the short-term or at all. As a result, our results of operations may be materially and adversely affected.

20

We might face inventory write-downs if we are unable to effectively manage inventory levels and/or prices decline. We maintain inventories of raw materials and finished products, and our inventories may spoil.

Most of our finished products have an average shelf life of 18 to 24 months before the product is opened. Milk powder has a shelf life of 24 months. Whey powder has a shelf life of 12 months. Other additives have a shelf life from several months to several years. Our inventory levels are based, in part, on our expectations regarding future sales. We may in future periods experience inventory buildup if our sales slow for any reason. Any unexpected significant shortfall in sales may result in higher inventory levels of raw materials and finished products than we require, thereby increasing our risk of inventory spoilage and corresponding inventory write-downs and write-offs, which may materially and adversely affect our results of operations.

Any major outbreak of illness or disease relating to cows in the regions in which we import milk powder could lead to significant shortfalls in the supply of our milk powder, and could result in consumers avoiding dairy products, which could result in substantial declines in our sales and possibly substantial losses.

We import all of our milk powder from New Zealand, and all of our whey powder from France. A major outbreak of any illness or disease in cows globally could lead to a serious loss of consumer confidence in, and demand for, dairy products. A major outbreak of mad cow disease (bovine spongiform encephalopathy), bovine tuberculosis, or bovine TB, or other serious disease in the principal regions supplying milk powder could lead to significant shortfalls in the supply of milk powder. Furthermore, adverse publicity about these types of concerns, whether or not valid, may discourage consumers from buying dairy products or cause production and delivery disruptions. If consumers generally were to avoid our products, our sales would decline substantially and we could suffer substantial losses.

We may experience problems with product quality or product performance, or the perception of such problems, which could materially and adversely affect our reputation or result in a decrease in customers and revenue, unexpected expenses and loss of market share.

Our operating results depend, in part, on our ability to deliver high quality products on a timely and cost-effective manner. Our quality control and food safety management systems are complex. For example, there are over 1,100 quality control points throughout the whole production process. If the quality of any of our products deteriorated, it could result in delays in shipments, cancellations of orders or customer returns and complaints, loss of goodwill, and harm to our brand and reputation. In addition, following the melamine contamination incident, we purchase all of the milk powder used for our powdered formula products from New Zealand. We may be unable to exercise the same degree of quality control over this overseas supplier as we can over our own facilities. Any quality problems associated with the milk powder produced by this supplier would also affect our products’ quality and lead to negative publicity against us, materially and adversely affecting our reputation and brand, and causing a decrease in sales of our products and a loss of market share. For example, the melamine contamination incident in China has resulted in certain of our products being contaminated, impacting our brand and reputation.

21

Product liability claims against us could result in adverse publicity and potentially significant monetary damages.

As with other infant formula producers, we are also exposed to risks associated with product liability claims if the consumption of infant formula products we sell results in injury or death. We cannot predict what impact such product liability claims or resulting negative publicity would have on our business or on our brand image. The successful assertion of product liability claims against us could result in potentially significant monetary damages, diversion of management resources and require us to make significant payments and incur substantial legal expenses. We do not have product liability insurance for powdered formula products sold in China and have not made provisions for potential product liability claims. Therefore, we may not have adequate resources to satisfy a judgment if a successful claim is brought against us. Even if a product liability claim is not successfully pursued to judgment by a claimant, we may still incur substantial legal expenses defending against such a claim and our brand image and reputation would suffer. Finally, serious product quality concerns could result in governmental actions against us, which, among other things, could result in the suspension of production or distribution of our products, loss of certain licenses, or other governmental penalties.

Our sales, results of operations, brand image and reputation could be materially and adversely affected if we fail to efficiently manage our operations without interruption, or fail to ensure that our products are delivered on time.

Our business requires successful coordination of several sequential and complex processes, the disruption of any of which could interrupt our operations and materially and adversely affect our relationships with our distributors, sub-distributors and end-customers, our brand name and reputation, and our financial performance. Our operations involve the coordination of raw material sourcing from third parties, internal production processes and external distribution processes. We may face difficulties in coordinating the various aspects of our production processes, resulting in downtime and delays.

In addition, we may encounter interruptions in our production processes due to a catastrophic loss or events beyond our control, such as fires, explosions, labor disturbances, earthquakes or other natural disasters. If there is a stoppage in production at any of our facilities, even if only temporary, or delays in deliveries to our customers, our business and reputation could be materially and adversely affected. Along with many other producers of dairy and consumer products in China, we generally rely on third-party logistics companies and distributors for the delivery of our products. Delivery may be disrupted for various reasons, many of which are beyond our control, including natural disasters, weather conditions or social unrest and strikes, which could lead to delayed or lost deliveries. In addition, transportation and related infrastructure conditions are often generally under-developed in some of the regions where we sell our products. We currently do not have business interruption insurance to offset these potential losses, delays and risks, so a material interruption of our business operations could materially damage our business.

22

We rely primarily on third-party distributors and cannot assure you that their marketing and distribution of our products will be effective or will not harm our brand and reputation. Moreover, if we fail to timely identify and appoint additional or replacement distributors as needed, or are unable to successfully manage our distribution network, our operating results could suffer.

We primarily rely on third-party distributors and sub-distributors for the distribution and sales of our products. We sell our products through an extensive nationwide distribution and sales network covering all of the provinces and provincial-level municipalities in mainland China. As of March 31, 2014, this network comprised over 670 independent distributors and over 550 independent sub-distributors who sell our products in approximately 24,000 retail outlets. Our distributors normally have exclusive distribution rights in their respective regions, and are also responsible for developing the sub-distributors located in their own regions. In addition, our distributors are not required to exclusively distribute our products. We typically do not enter into long-term agreements with distributors and have no control over their everyday business activities. Consequently, our distributors may engage in activities that are prohibited under our arrangements with them, that violate PRC laws and regulations governing the dairy industry or other PRC laws and regulations generally, or that are otherwise harmful to our business or our reputation. Due to our dependence on distributors for the sale and distribution of our products to retail outlets, any one of the following events could cause material fluctuations or declines in our revenue and have a material adverse effect on our financial condition and results of operations:

●  reduction, delay or cancellation of orders from one or more of our distributors;

●  selection or increased sales by our distributors of our competitors’ products; and

●  our failure to timely identify and appoint additional or replacement distributors upon the loss of one or more of our distributors.

The competition for distributors is intense in our industry in China and many of our competitors are expanding their distribution networks in China. We may not be able to compete successfully against the larger and better-funded sales and marketing operations of some of our current or future competitors, especially if these competitors provide more favorable arrangements for distributors. As a result, we may lose some of our distributors to our competitors, which may cause us to lose some or all of our favorable arrangements with such distributors and may even result in the termination of our relationships with some of our distributors. While we do not believe we are substantially dependent upon any individual distributor, finding replacement distributors could be time-consuming and any resulting delay may be disruptive and costly to our business. In addition, we may not be able to successfully manage our distributors and the cost of any consolidation or further expansion of our distribution network may exceed the revenue generated from these efforts. The occurrence of any of these factors could result in a significant decrease in the sales volume of our products and therefore materially harm our financial condition and results of operations.

We initiated a “gold mining” marketing strategy (“Strategy“) in September 2012 to strengthen our management of the sales channel, the goal of which is to use marketing and promotional expenditures more effectively and to improve net profit by centrally monitoring the spending in each retail outlet. We have terminated our relationship with those retail outlets with low sales volume and a low yield rate on the slotting fees, to focus our resources on those retail outlets with high sales volume and a higher yield rate on the slotting fees. As a result, our number of retail outlets reduced from more than 60,000 at June 30, 2012 to approximately 27,000 at March 31, 2013. The Strategy had been substantially completed by March 31, 2013. We cannot be certain that the Strategy will produce the results as planned in the long term.

Our results of operations and business prospects may be impaired by changing consumer preferences if we do not develop and offer products to meet changing preferences.

Consumer preferences evolve over time and the success of our products depends on our ability to identify the tastes and nutritional needs of our customers and to offer products that appeal to their preferences. We introduce new products and improved products from time to time and incur significant development and marketing costs. If our products fail to meet consumer preferences, then our strategy to grow sales and profits with new products will be less successful.

More mothers may breastfeed their babies rather than use our products, resulting in reduced demand for our products and adversely affecting our revenues.

Our results of operations are affected by the number of mothers who choose to use our products rather than breastfeeding their babies. Much publicly available data suggests that breastfeeding has many health benefits for the baby that cannot be replicated by dairy-based infant formula products. Additionally, popular literature, cultural pressure, government policies and medical advice in China generally promote the benefits of breastfeeding. For example, on August 1, 2007, China’s Ministry of Health (“MOH”) issued an Infant Feeding Strategy which promoted breastfeeding and requested all local relevant departments to publicize the benefits of breastfeeding through radio broadcasting, television and newspapers during World Breastfeeding Week, which took place in early August 2007. In November 2011, the MOH of China submitted a proposal for public review that could ban promotions and advertising of infant formula for babies younger than six months. Thus, to the extent that private, public and government sources increasingly promote the benefits of breastfeeding, there could be a reduced demand for our products and our revenues could be adversely affected.

23

A severe and prolonged downturn in the Chinese or global economy or continued disruptions in the financial markets may adversely impact our business and results of operations and may limit our access to additional financing.

The infant formula industry can be affected by macro economic factors, including changes in national, regional, and local economic conditions, employment levels and consumer spending patterns.  A prolonged slowdown in the Chinese or global economy could erode consumer confidence which could result in changes to consumer spending patterns, which could be harmful to our financial position and results of operations.

In addition, if the capital and credit markets continue to experience volatility and the availability of funds remains limited, we will incur increased costs associated with equity and/or debt financing. It is possible that our ability to access the capital and credit markets may be limited by these or other factors at a time when we would like, or need, to do so, which could have an adverse impact on our ability to refinance maturing debt and/or react to changing economic and business conditions. In addition, fluctuations in interest rates could impact our floating rate debt negatively and increase our debt obligations.

Failure to execute our future expansion plan could adversely affect our financial condition and results of operations.

We may increase our annual production capacity in the future to meet any expected increase in demand for our products. Our decision to increase our production capacity is based in part on our projections of increases in our sales volume and growth in the size of the infant formula product market in China. If actual customer demand does not meet our projections, we will likely suffer overcapacity problems and have idle capacity, which may materially and adversely affect our financial condition and results of operations. Our future success depends on our ability to expand our business to address expected growth in demand for our current and future products. Our ability to add production capacity and increase output is subject to significant risks and uncertainties, including:

●  the availability and cost of additional funding to expand our production capacity, build new processing and packaging facilities, make additional investments in our subsidiaries, acquire additional businesses or production facilities, purchase additional fixed assets and purchase raw materials on favorable terms or at all;

●  delays and cost overruns as a result of a number of factors, many of which may be beyond our control, such as problems with equipment vendors and suppliers of raw materials;

●  failure to maintain high quality control standards;

●  global or local shortage of raw materials, such as raw milk or whey powder;

●  our inability to obtain, or delays in obtaining, required approvals by relevant government authorities;

●  diversion of significant management attention and other resources; and

●  failure to execute our expansion plan effectively.

As our business grows, we will need to implement a variety of new and upgraded operational and financial systems, procedures and controls, including improvements to our accounting and other internal management systems by dedicating additional resources to our reporting and accounting functions, and improvements to our record keeping and contract tracking system. We will need to respond to competitive market conditions and continue to enhance existing products and develop new products, and retain existing customers and attract new customers. We will also need to recruit more personnel and train and manage our growing employee base. Furthermore, we will need to maintain and expand our relationships with our current and future customers, suppliers, distributors and other third parties, and there is no guarantee that we will succeed.

If we encounter any of the risks described above, or are otherwise unable to establish or successfully operate additional production capacity or to increase production output, we may be unable to grow our business and revenues, reduce our operating costs, maintain our competitiveness or improve our profitability, and our business, financial condition, results of operations and prospects may be adversely affected.

As discussed in “Liquidity and Capital Resources”, we entered into a series of agreements with Sodiaal Union and Euroserum SAS relating to a long-term industrial and commercial partnership. Under the agreements, we are committed to building a new drying facility in Carhaix, France, intended to manufacture powdered milk and fat-enriched demineralized whey powder. The updated estimated cost to build the facility is approximately € 136.0 million (equivalent to $187.0 million). We have unused long term loan facilities of €64.5 million (equivalent to $88.7 million) with banks, for €53.0 million of such loans, the bank has required preconditions which included obtaining the formal approval of a study on the environmental impact once the project starts operation. There is no assurance whether we will be able to obtain further financing on satisfactory terms. In addition, we cannot be certain whether the facility will produce the quality and quantity of products as planned and whether the facility will encounter any mechanical or other issues in the future. Any of these issues could have a material adverse impact on our future operations and financial results.

24

Any future expansion into new markets that we are currently not significantly represented may be costly, time-consuming and difficult. If we do not successfully expand into new, high growth markets we have identified, our results of operations and prospects may be materially and adversely affected.

Our future success may depend upon our ability to successfully expand into markets that we currently have low penetration rates. To further promote our brand and generate demand for our products in such markets, we may increase our spending on marketing and promotion in specific geographical areas or channels. We may be unable to attract a sufficient number of distributors or penetrate a sufficient number of retail outlets to justify the spending on marketing and promotion in these markets, or our selected distributors or outlets may not be suitable for selling our products in these markets for other reasons. We may also fail to attract new customers in such markets who may have less familiarity with our brand and products. Furthermore, we may fail to anticipate and address competitive conditions in these new markets that are different from those in our existing primary markets. These competitive conditions may make it difficult or impossible for us to effectively operate in these markets. If our expansion efforts in existing and new markets are unsuccessful, our results of operations and prospects may be materially and adversely affected.

Part of our strategy involves the development of new products and new business segments, and if we fail to timely develop new products or we incorrectly gauge the potential market for new products, our financial results would be adversely affected.

We plan to utilize our in-house research and development capabilities to develop new products that could become new sources of revenue for us in the future and help us to diversify our revenue base. We have also entered into new business segments such as the prepared foods segment, and the nutritional ingredients and supplements segment. Our future research and development efforts will focus on further expanding our product offerings beyond dairy-based nutritional products. If we fail to timely develop these and other new products or if we incorrectly gauge market demand for such new products, we may not be able to grow our sales revenue at expected growth rates and may incur expenses and capital expenditure costs relating to the development of new products that do not generate a positive return on the investment.

We operate in a competitive environment, which may lead to declining revenue growth or other circumstances that would negatively affect our results of operations.

The market for pediatric nutritional products is competitive, and we believe that competition in this market will continue to intensify. We believe that the principal competitive factors in our markets are brand recognition, quality, advertising, formulation, packaging, and price. We face significant competition from a number of competitors, including multinational companies, such as Abbot Laboratories’ Ross Products Division, Mead Johnson, Nestle, FrieslandCampina, Numico and Wyeth, and domestic companies, such as Biostime, Beingmate, Yashili, Feihe and Yili. See “Item 1. Business—Competition”. Many of our competitors have longer operating histories, greater name recognition, significantly larger market shares, access to larger customer bases and significantly greater financial resources and economies of scale in financial, sales and marketing, production, distribution, technical and other resources than we do. Some of these competitors have used, and we expect will continue to use, more aggressive pricing strategies, greater amounts of incentives and subsidies for distributors, retailers and customers and more advanced processes and technologies. Furthermore, consolidation among industry participants in China may potentially result in stronger domestic competitors that are better able to compete as end-to-end suppliers as well as competitors who are more specialized in particular areas and geographic markets. This could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, as a result of the melamine contamination incident, customers have lost confidence in infant formula produced by domestic companies for the time being, which gives multinational infant formula companies an advantage over us.

In order to compete successfully in our markets, we will need to continue to restore customer confidence in our brand and products, develop new products and enhance our product offerings while maintaining price competitiveness. Even if we successfully restore customer confidence, if and to the extent we fail to develop new products that differentiate us from our competitors, we may need to compete largely on price, which may cause our operating margins to decline. Our inability to compete successfully against competitors and pricing pressures could result in lost customers, loss of market share and reduced operating margins, which would adversely impact our results of operations.

25

If we grant employee stock options and other stock-based compensation in the future, we will be required to recognize stock-based compensation expense, which would adversely affect our results of operations.

As of the date of this Form 10-K, we have not granted any stock-based compensation and thus have not been required to reflect any such expenses in our results of operations. We adopted a stock -based compensation plan in June 2008 and may grant certain employees and directors stock-based compensation, which we believe could be important to attract and retain key personnel. We will be required to account for compensation costs for all stock options, including stock options granted to our directors and employees, using the fair value method and recognize the expense in our consolidated statement of operations, which may have a material adverse effect on our results of operations.

We may be exposed to liabilities under the Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act could have a material adverse effect on our business.

We are subject to the Foreign Corrupt Practice Act, or the FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments and their officials and political parties by U.S. persons and issuers as defined by the statute for the purpose of obtaining or retaining business. We have operations, agreements with third parties and make sales in China, which may experience corruption. Our activities in China create the risk of unauthorized payments or offers of payments by one of the employees, consultants, sales agents or distributors of our company, because these parties are not always subject to our control. It is our policy to implement safeguards to discourage these practices by our employees. However, our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants, sales agents or distributors of our Company may engage in conduct for which we might be held responsible. Violations of the FCPA may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition. In additions, the government may seek to hold our Company liable for successor liability of FCPA violations committed by companies in which we invest or that we acquire.

If we are unable to maintain an effective system of internal control over financial reporting, we may be unable to accurately report our financial results, or prevent fraud.

We have previously experienced certain material weaknesses and significant deficiencies in our internal control over financial reporting. In connection with our management's assessment of the effectiveness of our internal control over financial reporting as of March 31, 2012, a material weakness was identified. A material weakness is defined by the Public Company Accounting Oversight Board, or PCAOB, as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

We have taken steps to remediate the material weakness in our internal control over financial reporting, and we believe that the material weakness previously identified has been fully remediated as of March 31, 2013. However, there can be no assurance that any current or future deficiencies will not contribute to, or cause, possible material weaknesses in the future or, that we will be able to implement effectively new or improved controls. In addition, our management or our independent registered public accounting firm may determine that our internal control over financial reporting is not effective in the future.

 Moreover, a lack of effective internal control over financial reporting in the future could cause us to fail to provide accurate financial statements or fail to meet our reporting obligations, either of which could cause investors to lose confidence in our reported financial information, and have a negative effect on the trading price of our common stock. Our failure to meet our reporting obligations in a timely fashion may also lead to the delisting of our common stock by the NASDAQ Global Select Market.

26

Our success depends to a substantial degree upon our senior management and key personnel, and our business operations may be significantly and negatively affected if we fail to attract and retain highly competent senior management and key personnel.

Our future success depends substantially on the continued services of our key personnel including, particularly, Liang Zhang, our chairman and chief executive officer. We rely substantially on their experience in the dairy and nutritional products industry, and on their relationships and ability to work with our suppliers and distributors and other customers. If we lose the services of one or more of these key personnel, we may not be able to replace them readily, if at all, with suitable or qualified candidates, and may incur additional expenses to recruit and retain new officers and key personnel, which could severely disrupt our business and growth. We do not maintain key-man life insurance for any of our key personnel.

In addition, if any of these key personnel joins a competitor or forms a competing company, we may lose some of our distributors. We have entered into employment agreements with each of these key personnel, which contain confidentiality and non-competition provisions. However, if any disputes were to arise between these key personnel and us, it is not clear, in light of uncertainties associated with the PRC legal system, what the court decisions would be and the extent to which these court decisions could be enforced in China, where most of these key personnel reside and hold some of their assets. See “Item 1A. Risk Factors—Risks Associated with Doing Business in China—Uncertainties with respect to the PRC legal system could limit the legal protections available to you and us.” Furthermore, as we expect to continue to expand our operations and develop new products, we will need to continue attracting and retaining experienced management and key research and development personnel.

Competition for experienced management and research and development personnel in China is intense, and the availability of experienced, suitable and qualified candidates is limited. Competition for these individuals may require us to pay higher compensation and other benefits in order to attract and retain them, which could have a material adverse effect on our financial condition and results of operations. We may also be unable to attract or retain the personnel necessary to achieve our business objectives, and any failure in this regard could severely disrupt our business and growth.

Liang Zhang’s association with other businesses could impede his ability to devote sufficient time to our business and could present potential conflicts of interest.

Liang Zhang, our founder, chairman, chief executive officer and principal beneficial stockholder, controls several other companies in China. Liang Zhang devotes most of his time to our affairs and the remainder of his time to the affairs of the other companies. Liang Zhang’s decision-making responsibilities for these other companies are similar in the areas of public relations, risk management and strategic planning. As a result, conflicts of interest may arise from time to time and we cannot assure you that they will be resolved in our favor. Additionally, even though Liang Zhang devotes most of his time to our affairs and is further accountable to us and our stockholders as a fiduciary, which requires that he exercise good faith and due care in handling our affairs, we cannot assure you this will always be the case and his existing responsibilities to other businesses and entities may limit the amount of time he can spend on our affairs.

Our chairman and chief executive officer, Liang Zhang, beneficially owns a substantial amount of our common stock and will have significant influence over our corporate affairs.

Our founder, chairman and chief executive officer, Liang Zhang, beneficially owns approximately 62.8% of our outstanding common stock through a company owned by his wife as of March 31, 2014. Accordingly, Liang Zhang will be able to direct the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions such as:

· our merger with or into another company;

· a sale of our assets; and

· amendments to our certificate of incorporation.

The decisions of Liang Zhang may conflict with our interests or the interests of our other stockholders.

27

We have committed to certain capacity expansion projects that require significant capital investment. Such capital may not be available on favorable terms or at all.

We have, in the past, obtained loans and sold our common stock to raise additional capital. We have committed to certain capacity expansion projects, in particular the French Project which requires a total investment of €136.0 million (equivalent to $187.0 million). Although we believe that our current cash, and cash flow from operations will be sufficient to meet our present and reasonably anticipated cash needs, there is no assurance that we will be able to generate the required equity portion of the investment in the French Project from our operation cash flow, or raise the required debt portion of the French Project investment. Failure to do so may cause us to delay or abandon the French Project, which in turn will lead to penalties by Euroserum and Sodiaal as permitted under the partnership agreement, the deterioration of our relationship with Euroserum and Sodiaal, and potentially other material adverse impact on our business. Any additional equity financing may be dilutive to stockholders and such additional equity securities may have rights, preferences or privileges that are senior to those of our existing common stock. The incurrence of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that would restrict our operations. If we are unable to generate sufficient cash flow from operating activities or obtain funds for required payments of interest and principal on such additional indebtedness, we will be in default. Financing may not be available in amounts or on terms acceptable to us, if at all. Any failure by us to raise additional funds on terms favorable to us, or at all, could limit our ability to expand our business operations and could harm our overall business prospects.

We have limited property insurance coverage and do not carry any business interruption insurance.

Operation of our facilities involves many risks, including equipment failures, natural disasters, industrial accidents, power outages, labor disturbances and other business interruptions. Furthermore, if any of our products are faulty or contaminated, then we may become subject to product liability claims or we may have to engage in a product recall.

We do not carry any business interruption insurance, and have limited property insurance coverage. Therefore, our existing insurance coverage may not be sufficient to cover all risks associated with our business. As a result, we may be required to pay for financial and other losses, damages and liabilities, including those caused by natural disasters and other events beyond our control, out of our own funds, which could have a material adverse effect on our business, financial condition and results of operations. For example, all of the costs we have incurred to date and may incur in the future that are related to our product recall in connection with the melamine contamination incident is not covered by our existing insurance policies.

28

Failure to adequately protect our intellectual property rights may undermine our competitive position, and litigation to protect our intellectual property rights may be costly.

We rely primarily on trade secrets and other contractual restrictions to protect our intellectual property. We have not registered or applied for protections in China for most of our intellectual property or proprietary technologies relating to the formulations of powdered infant formula that we produce. In order to protect our proprietary technology and processes, we also rely in part on nondisclosure agreements with our employees, licensing partners, third-party producers, consultants, agents and other organizations to which we disclose our proprietary information. The actions we have taken to protect our intellectual property rights may not be adequate to provide us with meaningful protection or commercial advantage. As a result, third parties may use the intellectual property or proprietary technologies that we have developed and compete with us, which could have a material adverse effect on our business, financial condition and operating results.

PRC intellectual property-related laws and their implementation are still under development. Accordingly, intellectual property rights and confidentiality protections in China may not be as effective as in the United States or many other countries. In addition, policing unauthorized use of proprietary technology can be difficult and expensive. Litigation may be necessary to enforce our intellectual property rights and the outcome of any such litigation may not be in our favor. Given the relative unpredictability of China’s legal system and potential difficulties enforcing a court judgment in China, there is no guarantee that we would be able to halt the unauthorized use of our intellectual property through litigation in a timely manner or at all. Furthermore, any such litigation may be costly and may divert management attention away from our business and cause us to expend significant resources. An adverse determination in any such litigation will impair our intellectual property rights and may harm our business, prospects and reputation. In addition, we have no insurance coverage against litigation costs and would have to bear all costs arising from such litigation to the extent we are unable to recover them from other parties. The occurrence of any of the foregoing could have a material adverse impact on our business, financial condition and results of operations.

We may be exposed to infringement or misappropriation claims by third parties, which, if determined adversely against us, could disrupt our business and subject us to significant liability to third parties.

Our success largely depends on our ability to use and develop our know-how and product formulations without infringing upon the intellectual property rights of third parties. We may be subject to litigation involving claims of infringement or violation of other intellectual property rights of third parties. The holders of patents and other intellectual property rights potentially relevant to our product offerings may be unknown to us or may otherwise make it difficult for us to acquire a license on commercially acceptable terms.

There may also be technologies licensed to and relied on by us that are subject to infringement or other corresponding allegations or claims by others which could damage our ability to rely on such technologies. In addition, although we endeavor to ensure that companies that work with us possess appropriate intellectual property rights or licenses, we cannot fully avoid the risks of intellectual property rights infringement created by suppliers of raw materials used in our products, our third-party producers, or by companies with which we work in cooperative research and development activities. Our current or potential competitors, many of which have substantial resources and have made substantial investments in competing technologies, may have obtained or may obtain patents that will prevent, limit or interfere with our ability to make, use or sell our products in China or other countries. The defense of intellectual property claims, including patent infringement suits, and related legal and administrative proceedings can be both costly and time-consuming, and may significantly divert the efforts and resources of our technical and management personnel. Furthermore, an adverse determination in any such litigation or proceeding to which we may become a party could cause us to:

· pay damage awards;

· seek licenses from third parties, which may not be available on reasonable terms or at all;

· pay additional ongoing royalties, which could decrease our profit margins;

· redesign our products, which may be costly, if possible at all; or

· be restricted by injunctions.

These factors could effectively prevent us from pursuing some or all of our business and result in our customers or potential customers deferring, canceling or limiting their purchase or use of our products, which could have a material adverse effect on our financial condition and results of operations.

Increased IT security threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products, solutions and services.

Increased global IT security threats and more sophisticated and targeted computer crime pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. While we attempt to mitigate these risks by employing a number of measures, our systems, networks, products, solutions and services remain potentially vulnerable to advanced persistent threats. Depending on their nature and scope, such threats could potentially lead to the compromising of confidential information, improper use of our systems and networks, manipulation and destruction of data, defective products, production downtimes and operational disruptions, which in turn could materially adversely affect our reputation, competitiveness and results of operations.

29

Risks Associated With Doing Business in China

Adverse changes in political and economic policies of the PRC government could impede the overall economic growth of China, which could reduce the demand for our products and damage our business.

We conduct our operations and generate all of our revenues in China. Accordingly, our business, financial condition, results of operations and prospects are affected significantly by economic, political and legal developments in China. The PRC economy differs from the economies of most developed countries in many respects, including:

· the higher level of government involvement and regulation;

· the early stage of development of the market-oriented sector of the economy;

· the rapid growth rate;

· the higher rate of inflation;

· the higher level of control over foreign exchange; and

· government control over the allocation of many resources.

As the PRC economy has been transitioning from a planned economy to a more market-oriented economy, the PRC government has implemented various measures to encourage economic growth and guide the allocation of resources. While these measures may benefit the overall PRC economy, they may also have a negative effect on us.

Although the PRC government has in recent years implemented measures emphasizing the utilization of market forces for economic reform, the PRC government continues to exercise substantial control over virtually every sector of the PRC economy through the allocation of resources, controlling payment of foreign currency-denominated obligations, setting monetary policy and imposing policies that impact particular industries or companies in different ways. Our ability to operate in China may be harmed by changes in PRC laws and regulations, including those relating to how we conduct our business, taxation, import and export tariffs, environmental regulations, land use rights, property and other matters. We believe that our operations in China are in material compliance with all applicable legal and regulatory requirements. However, the central or local governments of the jurisdictions in which we operate may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part to ensure our compliance with such regulations or interpretations.

Accordingly, government actions in the future, including any decision not to continue to support recent economic reforms and to return to a more centrally planned economy or regional or local variations in the implementation of economic policies, could have a significant adverse effect on economic conditions in China or particular regions thereof and could require us to divest ourselves of any interest we then hold in PRC properties or joint ventures.

30

PRC food hygiene and safety laws may become more onerous, which may adversely affect our operations and financial performance and lead to an increase in our costs which we may be unable to pass on to our customers.

Operators within the PRC dairy industry and infant formula sector are subject to compliance with PRC food hygiene and safety laws and regulations. Such laws and regulations require all enterprises engaged in the production of dairy and infant formula products to obtain a hygiene license. They also set out hygiene standards with respect to food and food additives, packaging and containers, and labeling on packaging as well as hygiene requirements for food production and sites, facilities and equipment used for the transportation and the sale of food. Failure to comply with PRC food hygiene and safety laws may result in fines, suspension of operations, loss of hygiene license and, in certain cases, criminal proceedings against an enterprise and its management. Although we are in compliance with current PRC food hygiene and safety laws and regulations, in the event that such laws and regulations become more stringent or widen in scope, we may fail to comply with such laws, or if we comply, our production and distribution costs may increase, and we may be unable to pass these additional costs on to our customers. For example, in response to the melamine contamination incident, the PRC State Council abolished the regulations on inspection exemptions for food on September 18, 2008 so that our products were to be subject to batch by batch inspection going forward. In addition, the PRC State Council promulgated with immediate effect the Regulation on Supervision and Administration of Quality and Safety of Dairy Products on October 9, 2008 which, among other things, imposes more stringent requirements for inspection, production, packaging, labeling and product recall on dairy product producers. These measures have increased our costs in the past and are likely to continue to contribute to our costs in the future, which costs we may be unable to pass on to our customers.

Changes in the regulatory environment for dairy and infant nutrition products in China could negatively impact our business.

The dairy and infant nutrition product industries in China are regulated and regulatory changes may affect both our customers and us. Any changes in regulations that impose additional requirements for construction of new production lines and facilities or expansion of existing facilities will require us to secure additional government approvals for our current production expansion projects. Similarly, additional safety and quality control regulations could impact our costs of production. For example, in December 2013, the Chinese State Food and Drug Administration updated the national guidance for the renewal and re-affirmation of production licenses for manufacturing infant-formula milk powder products in China. This regulation sets forth new rules and raises the bar on infant formula producers in nine areas, including product safety control, purchase of raw materials, formula product inspection, manufacturing process and product traceability. In particular, the requirement on a 100,000 grade clean space to meet the medical grade Good Manufacturing Practices is widely considered as the most challenging requirement. For a more detailed description of these requirements, see “Item 1. Business—Regulation”. Although we believe our existing entities and facilities meet the requirements, it is possible that our entities may fail to meet one or more of the additional requirements in the future. Failure to comply with these or any other changes in regulations affecting our business could have a material adverse effect on our business and our results of operations, including failure to renew our production licenses. In addition, the indirect impact of any such changes could adversely affect our business even if the specific regulations do not directly apply to our products or us.

Uncertainties with respect to the PRC legal system could limit the legal protections available to you and us.

We conduct our business through our operating subsidiaries in China. Our operating subsidiaries are generally subject to laws and regulations applicable to foreign investments in China and, in particular, laws applicable to foreign-invested enterprises. The PRC legal system is based on written statutes, and prior court decisions may be cited for reference, but have limited precedential value. Over the past several decades, a series of new PRC laws and regulations have significantly enhanced the protections afforded to various forms of foreign investments in China. However, since the PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties, which may limit legal protections available to you and us. In addition, any litigation in China may be protracted and result in substantial costs and diversion of resources and management attention.

31

If we are found to have failed to comply with applicable laws, we may incur additional expenditures or be subject to significant fines and penalties.

Our operations are subject to PRC laws and regulations applicable to us. However, many PRC laws and regulations are uncertain in their scope, and the implementation of such laws and regulations in different localities could have significant differences. In certain instances, local implementation rules and/or the actual implementation are not necessarily consistent with the regulations at the national level. Although we strive to comply with all the applicable PRC laws and regulations, we cannot assure you that the relevant PRC government authorities will not later determine that we have not been in compliance with certain laws or regulations. For example, there is a PRC regulation requiring all employees to make contributions to a housing fund based on their salary level and their employers to match such contributions. However, many employees are reluctant to make such contributions as they do not perceive such contribution will benefit them, and this regulation has generally not been rigorously enforced. We have allowed our employees to make contributions on a voluntary basis and then match their contributions. However, we cannot assure you that in the future the PRC government will not start to enforce this regulation more rigorously. Although there are no material penalties stipulated in this regulation, if we are found not to be in compliance, we may be required to bring current any past deficiencies, which could adversely affect our financial condition and results of operations.

In addition, our facilities and products are subject to many laws and regulations administered by the PRC State Administration for Industry and Commerce, the PRC State Administration of Taxation, the PRC Ministry of Health and Hygiene Permitting Office, the PRC General Administration of Quality Supervision, Inspection and Quarantine, and the PRC State Food and Drug Administration Bureau relating to the processing, packaging, storage, distribution, advertising, labeling, quality, and safety of food products. Our failure to comply with these and other applicable laws and regulations in China could subject us to administrative penalties and injunctive relief, as well as civil remedies, including fines, injunctions and recalls of our products. It is possible that changes to such laws, more rigorous enforcement of such laws or with respect to our current or past practices, could have a material adverse effect on our business, operating results and financial condition. Further, additional environmental, health or safety issues relating to matters that are not currently known to management may result in unanticipated liabilities and expenditures.

Restrictions on currency exchange may limit our ability to receive and use our sales revenue effectively.

All of our sales revenue is denominated in Renminbi. Under PRC law, the Renminbi is currently convertible under the “current account,” which includes dividends and trade and service-related foreign exchange transactions, but not under the “capital account,” which includes foreign direct investment and loans. Currently, our PRC operating subsidiaries may purchase foreign currencies for settlement of current account transactions, including payments of dividends to us, without the approval of the PRC State Administration of Foreign Exchange, or SAFE, by complying with certain procedural requirements. However, the relevant PRC government authorities may limit or eliminate our ability to purchase foreign currencies in the future.

The PRC government imposes controls on the convertibility of the RMB into foreign currencies and, in certain cases, the remittance of currency out of China. We receive substantially all of our revenues in RMB. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service related foreign exchange transactions, can be made in foreign currencies without prior SAFE approval by complying with certain procedural requirements. Therefore, after complying with certain procedural requirements, our PRC subsidiaries are able to pay dividends in foreign currencies to us without prior approval from SAFE. However, approval from or registration with appropriate government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may also at its discretion restrict access to foreign currencies for current account transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders.

32

PRC regulations relating to investment activities by, and holdings in entities outside of China of, PRC residents and citizens, may subject our PRC resident and citizen stockholders to personal liability and limit our ability to acquire PRC companies or to inject capital into our PRC subsidiaries, limit our PRC subsidiaries’ ability to distribute profits to us or otherwise materially and adversely affect us.

In October 2005, SAFE issued a public notice, the Notice on Relevant Issues in the Foreign Exchange Control over Financing and Return Investment Through Special Purpose Companies by Residents Inside China, or Notice 75. In May 2007, SAFE issued the Notice of the State Administration of Foreign Exchange on Operating Procedures Concerning Issues Relating to the Administration of Foreign Exchange in Fund Raising and Return Investment Activities of Domestic Residents Conducted via Offshore Special Purpose Companies, or Notice 106. According to Notice 75 and Notice 106, prior registration with the local SAFE branch is required for PRC residents to establish or to control an offshore company for the purposes of financing that offshore company with assets or equity interests in an onshore enterprise located in the PRC. An amendment to registration or filing with the local SAFE branch by such PRC resident is also required for the injection of equity interests or assets of an onshore enterprise in the offshore company or overseas funds raised by such offshore company, or any other material change involving a change in the capital of the offshore company. Moreover, Notice 75 and Notice 106 apply retroactively. As a result, PRC residents who have established or acquired control of offshore companies that have made onshore investments in the PRC in the past were required to complete the relevant registration with the local SAFE branch. If any PRC stockholder of any offshore special purpose company fails to make the required SAFE registration and amendment, the PRC subsidiaries of that offshore special purpose company may be prohibited from distributing their profits and the proceeds from any reduction in capital, share transfer or liquidation to the offshore special purpose company. Moreover, failure to comply with the SAFE registration and amendment requirements described above could result in liability under PRC laws for evasion of applicable foreign exchange restrictions.

Many of the terms and provisions in Notice 75 and Notice 106 remain unclear and implementation by central SAFE and local SAFE branches of Notice 75 and Notice 106 have been inconsistent since their adoption. Based on the advice of our PRC counsel, De Heng Law Offices, and after consultation with relevant SAFE officials, our PRC resident stockholders and the PRC resident beneficial stockholders of Meitek may be required to complete their respective SAFE registrations pursuant to Notice 75 and Notice 106. The local SAFE branch may not accept their applications for SAFE registration until more detailed rules or announcements concerning the penalties for those who failed to make their SAFE registrations are implemented. Moreover, because of uncertainty over how Notice 75 and Notice 106 will be interpreted and implemented, and how or whether SAFE will apply it to us, we cannot predict how it will affect our business operations or future strategies. For example, our present and prospective PRC subsidiaries’ ability to conduct foreign exchange activities, such as the remittance of dividends and foreign currency-denominated borrowings, may be subject to compliance with Notice 75 and Notice 106 by our PRC resident beneficial holders. In addition, such PRC residents may not always be able to complete the necessary registration procedures required by Notice 75 and Notice 106. We also have little control over either our present or prospective direct or indirect stockholders, the PRC resident beneficial stockholders of Meitek, or the outcome of such registration procedures. A failure by our PRC resident beneficial holders or future PRC resident stockholders to comply with the SAFE notice, if SAFE requires it, could subject us to fines or legal sanctions, restrict our overseas or cross-border investment activities, limit our subsidiary’s ability to make distributions or pay dividends or affect our ownership structure, which could adversely affect our business and prospects.

Fluctuations in exchange rates could adversely affect our business and the value of our common stock.

The value of our common stock will be indirectly affected by the foreign exchange rate between the U.S. dollar and the Renminbi and between those currencies and other currencies in which our sales may be denominated. Because our earnings and cash assets are denominated in Renminbi, appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. Fluctuations in the exchange rate will also affect the relative value of any dividend we issue that will be exchanged into U.S. dollars and earnings from, and the value of, any U.S. dollar-denominated investments we make in the future.

Since July 2005, the Renminbi has no longer been pegged to the U.S. dollar. Although the People’s Bank of China, or PBOC, regularly intervenes in the foreign exchange market to prevent significant short-term fluctuations in the exchange rate, the Renminbi may appreciate or depreciate significantly in value against the U.S. dollar in the medium to long-term. Moreover, it is possible that in the future the PRC authorities may lift restrictions on fluctuations in the Renminbi exchange rate and lessen intervention in the foreign exchange market.

Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may enter into hedging transactions in the future, the availability and effectiveness of these transactions may be limited, and we may not be able to successfully hedge our exposure at all. In addition, our foreign currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert Renminbi into foreign currencies.

Currently, some of our raw materials and major equipment are imported. In the event that the U.S. dollar appreciated against the Renminbi, our costs may increase. If we cannot pass the resulting cost increases on to our customers, our profitability and operating results will suffer. In addition, to the extent we enter markets outside China in the future, we may be increasingly subject to the risk of foreign currency fluctuations.

33

Restrictions under PRC law on our PRC subsidiaries’ ability to make dividends and other distributions could materially and adversely affect our ability to grow, make investments or acquisitions that could benefit our business, pay dividends to our shareholders, and otherwise fund and conduct our businesses.

Our revenues are earned by our PRC subsidiaries. However, PRC regulations restrict the ability of our PRC subsidiaries to make dividends and other payments to their offshore parent company. PRC legal restrictions permit payments of dividend by our PRC subsidiaries only out of their accumulated after-tax profits, if any, determined in accordance with PRC accounting standards and regulations. Each of our PRC subsidiaries is also required under PRC laws and regulations to allocate at least 10% of our annual after-tax profits determined in accordance with the generally accepted accounting principles in the PRC (“PRC GAAP”) to a statutory general reserve fund until the amounts in such fund reaches 50% of their registered capitals in China. Allocations to these statutory reserve funds can only be used for specific purposes and are not transferable to us in the form of loans, advances or cash dividends. As of March 31, 2014, the common stock, additional paid-in capital and statutory reserve of PRC subsidiaries were RMB 1,018.7 million, which were equivalent to $165.6 million using the exchange rate as of March 31, 2014. Any limitations on the ability of our PRC subsidiaries to transfer funds to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends and otherwise fund and conduct our business.

Under China’s New Enterprise Income Tax Law (“EIT Law”), we may be classified as a “resident enterprise” of China. This classification could result in unfavorable tax consequences to us and our non-PRC shareholders.

The New EIT Law provides that enterprises established outside of China whose “de facto management bodies” are located in China are considered “resident enterprises” and are generally subject to the uniform 25% enterprise income tax rate on their worldwide income. In addition, a circular issued by the State Administration of Taxation regarding the standards used to classify certain Chinese-invested enterprises established outside of China as “resident enterprises” clarified that dividends and other income paid by such “resident enterprises” will be considered to be PRC source income, subject to PRC withholding tax, currently at a rate of 10%, when recognized by non-PRC shareholders. This circular also subjects such “resident enterprises” to various reporting requirements with the PRC tax authorities. Under the implementation regulations to the enterprise income tax, a “de facto management body” is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances and treasury, and acquisition and disposition of properties and other assets of an enterprise. In addition, the circular mentioned above details that certain Chinese-invested enterprises will be classified as “resident enterprises” if the following are located or reside in China: senior management personnel and departments that are responsible for daily production, operation and management; financial and personnel decision making bodies; key properties, accounting books, company seal, and minutes of board meetings and shareholders’ meetings; and half or more of the directors or senior management having voting rights. If the PRC tax authorities determine that Synutra, Inc. or Synutra International, Inc. are “resident enterprises,” we may be subject to enterprise income tax at the rate of 25% on our worldwide income and dividends paid by us to our non-PRC shareholders and, while less clear, capital gains recognized by them with respect to the sale of our stock, may be subject to a PRC withholding tax. This will have an impact on our effective tax rate, a material adverse effect on our net income and results of operations, and may require us to withhold tax on our non-PRC shareholders. We are actively monitoring the “resident enterprise” classification rules and are evaluating appropriate organizational changes to avoid this treatment, to the extent possible.

If we were treated as a “resident enterprise” by PRC tax authorities, we would be subject to tax in both the U.S. and China, and our PRC tax may not be creditable against our U.S. tax.

34

Our shareholders may have difficulty enforcing judgments against us.

We are a Delaware holding company and most of our assets are located outside of the United States. All of our current operations are conducted in the PRC. In addition, most of our directors and officers are nationals and residents of countries other than the United States. A substantial portion of the assets of these persons is located outside the United States. As a result, it may be difficult for our shareholders to effect service of process within the United States upon these persons. It may also be difficult for our shareholders to enforce in U.S. courts judgments on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors. In addition, there is uncertainty as to whether the courts of the PRC would recognize or enforce judgments of U.S. courts. DeHeng Law Offices, our counsel as to PRC law, has advised us that the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. Courts in China may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based on treaties between China and the country where the judgment is made or on reciprocity between jurisdictions. China does not have any treaties or other arrangements that provide for the reciprocal recognition and enforcement of foreign judgments with the United States. In addition, according to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates basic principles of PRC law or national sovereignty, security or public interest. So it is uncertain whether a PRC court would enforce a judgment rendered by a court in the United States.

The PRC government’s recent measures to curb inflation rates could adversely affect our future results of operations.

In recent years, the Chinese economy has experienced periods of rapid expansion and high rates of inflation. Rapid economic growth can lead to growth in the money supply and rising inflation. For example, in April 2014, the change in China’s Consumer Price Index increased 2.4% from the prior year according to the National Bureau of Statistics of China, or the NBS. If prices for our products rise at a rate that is insufficient to compensate for the rise in the costs of supplies, it may have an adverse effect on our profitability. In addition, our labor costs could increase as a result of inflationary pressures. An increase in our labor costs will increase our operating costs, which we may not be able to pass through to our customers. These factors have led to the adoption by the Chinese government, from time to time, of various corrective measures designed to restrict the availability of credit or regulate growth and constrain inflation. High inflation may in the future cause the Chinese government to impose controls on credit and/or prices, or to take other actions, which could inhibit economic activity in China, and thereby harm the market for our products.

In the last few years, the government of China has undertaken various measures to alleviate the effects of inflation, including imposing national price controls on various products, including milk. The government of China may conclude that the prices of infant formula or our other products are too high and may institute price controls that would limit our ability to set prices for our products. The government of China has also encouraged local governments to institute price controls on similar products. Such price controls could adversely affect our future results of operations and the price of our common stock.

35

The PRC government may deem the control agreements between us and certain of our consolidated affiliated entities to be non-compliant with restrictions on foreign investment and as a result we may be subject to penalties or required to perform a costly restructuring of these entities.

PRC laws and regulations currently restrict foreign entities from establishing clinical business in China. Foreign entities that wish to establish medical clinical businesses in China must have domestic entities as partners. In order to comply with PRC law and avoid restrictions on foreign investment in medical clinical operations, we operate our medical treatment services (mostly pre-natal diagnostics services) through Beijing Syclin Clinical Laboratory Co., Ltd. (the “Entity”) that is not directly owned by us. We control and consolidate this Entity into our group consolidated results through a series of contractual arrangements. See “Item 1, Business—Our Corporate Structure and History” and “Item 13.  Certain Relationships and Related Transactions, and Director Independence.”

The contractual arrangements we have in place are governed by PRC law.  There are substantial uncertainties regarding the interpretation and application of current and future PRC laws and regulations on these contractual agreements and it is possible that the PRC authorities may in the future find these arrangements unlawful. If these arrangements were to be deemed unlawful, the PRC authorities have broad discretion to penalize us, including:

· revoking the business and operating licenses of our PRC subsidiaries and affiliates;

· discontinuing or restricting our PRC subsidiaries’ and affiliates’ operations;

· imposing fines or confiscating the income of our PRC subsidiaries or affiliates;

· requiring us or our PRC subsidiaries and affiliates to restructure the relevant ownership structure or operations; or

· taking other regulatory or enforcement actions that could be harmful to our clinic examination business.

Furthermore, we have no assurance that Jibin Zhang and Yunpeng Jiang, parties to these control agreements, will continue to cooperate with us and honor these control agreements.  There is a risk that they will not always act in our best interests.  If we cannot resolve any conflicts of interest or dispute that may arise between them and us, we may have to take legal action to compel them to fulfill their contractual obligations and there is substantial uncertainty as to the outcome of any such legal proceedings.  It may be difficult for us to change our corporate structure or to bring claims against the Entity if they do not perform their obligations under these contractual arrangements.

The audit reports included in this annual report are prepared by auditors who are not inspected by the U.S. Public Company Accounting Oversight Board and, as such, investors may be deprived of the benefits of such inspection.

As an auditor of companies that are publicly traded in the United States and a firm registered with the U.S. Public Company Accounting Oversight Board, or the PCAOB, our independent registered public accounting firm is required by the laws in the United States to undergo regular inspections by the PCAOB to assess its compliance with the laws of the United States and the professional standards of the PCAOB. However, because our auditor is located in the PRC, a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the Chinese authorities, our auditor is not currently inspected by the PCAOB.

Inspections of other auditors conducted by the PCAOB outside of China have at times identified deficiencies in those auditor’s audit procedures and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. The lack of PCAOB inspections in China prevents the PCAOB from regularly evaluating our auditor's audits and its quality control procedures. In addition, the inability of the PCAOB to conduct auditor inspections in China makes it more difficult to evaluate the effectiveness of our auditor's audit procedures or quality control procedures as compared to auditors located outside of China that are subject to regular PCAOB inspections. As a result, investors may be deprived of the benefits of PCAOB inspections, and may lose confidence in our reported financial information and procedures and the quality of our financial statements.

Proceedings instituted by the SEC against five PRC-based accounting firms, including our independent registered public accounting firm, could result in financial statements being determined to not be in compliance with the requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act.

In late 2012, the SEC commenced administrative proceedings under Rule 102(e) of its Rules of Practice and also under the Sarbanes-Oxley Act of 2002 against the Chinese affiliates of the ‘‘big four’’ accounting firms,(including our auditors) and also against Dahua (the former BDO affiliate in China). The Rule 102(e) proceedings initiated by the SEC relate to these firms’ inability to produce documents, including audit work papers, in response to the request of the SEC pursuant to Section 106 of the Sarbanes-Oxley Act of 2002, as the auditors located in the PRC are not in a position lawfully to produce documents directly to the SEC because of restrictions under PRC law and specific directives issued by the China Securities Regulatory Commission. The issues raised by the proceedings are not specific to our auditors or to us, but affect equally all audit firms based in China and all China-based businesses with securities listed in the United States.

In January 2014, the administrative judge reached an Initial Decision that the "big four" accounting firms should be barred from practicing before the Commission for six months.  However, it is currently impossible to determine the ultimate outcome of this matter as the accounting firms have filed a Petition for Review of the Initial Decision and pending that review the effect of the Initial Decision is suspended. The SEC Commissioners will review the Initial Decision, determine whether there has been any violation and, if so, determine the appropriate remedy to be placed on these audit firms.  Once such an order was made, the accounting firms would have a further right to appeal to the US Federal courts, and the effect of the order might be further stayed pending the outcome of that appeal. 

Depending upon the final outcome, listed companies in the United States with major PRC operations may find it difficult or impossible to retain auditors in respect of their operations in the PRC, which could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including possible delisting. Moreover, any negative news about the proceedings against these audit firms may cause investor uncertainty regarding China-based, United States-listed companies and the market price of our shares may be adversely affected.

36

Risks Related to Our Common Stock

The market price of our common stock is volatile, and its value may be depressed at a time when our stockholders want to sell their holdings.

The market price of our common stock is volatile, and this volatility may continue. For instance, between July 1, 2008 and March 31, 2014, the price of our common stock, as reported on the NASDAQ on which our common stock has traded, ranged between $3.99 and $52.24. Though we believe this dramatic fluctuation resulted mainly from volatility in our earnings, which is attributable to various events including, but not limited to the melamine contamination incident, the prematurity event and the worldwide market disruption, numerous factors, many of which are beyond our control, may cause the market price of our common stock to fluctuate significantly.

In addition to market and industry factors, the price and trading volume for our common stock may be highly volatile for specific business reasons. Factors such as variations in our revenues, earnings and cash flow, announcements of new investments, cooperation arrangements or acquisitions, and fluctuations in market prices for our products could cause the market price for our shares to change substantially. In addition, our stock price may be impacted by the performance, reputation, or stock prices of other Chinese companies that are listed in the U.S.

Securities class action litigation is often instituted against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs to us and divert our management’s attention and resources.

The trading market for our common stock will also be influenced by research or reports that industry or securities analysts publish about us or our business. If one or more analysts who cover us downgrade our common stock, the market price for our common stock would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which, in turn, could cause the market price for our common stock or trading volume to decline.

Furthermore, securities markets may from time to time experience significant price and volume fluctuations for reasons unrelated to operating performance of particular companies. These market fluctuations may adversely affect the price of our common stock and other interests in our company at a time when our stockholders want to sell their interest in us.

Although publicly traded, the trading market in our common stock has been substantially less liquid than the common stock of many companies quoted on the NASDAQ Global Select Market, and this low trading volume may adversely affect the price of our common stock.

Although our common stock is traded on the NASDAQ Global Select Market, the trading volume of our common stock has generally been very low. Reported average daily trading volume in our common stock for the twelve month period ended March 31, 2014 was approximately 50,259 shares. Limited trading volume will subject our shares of common stock to greater price volatility and may make it difficult for our stockholders to sell their shares of common stock at a price that is attractive to them.

Provisions in our charter documents and under Delaware law could discourage a change-of-control that our stockholders may consider favorable.

Provisions in our amended and restated certificate of incorporation and bylaws may have the effect of delaying or preventing a change of control or changes in our management. These provisions include the following:

· our board of directors is divided into three classes, with approximately one-third of our directors elected each year;

· our board of directors has the right to elect directors to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;

· our stockholders must provide timely notice for any stockholder proposals and director nominations;

· we have adopted provisions that eliminate the personal liability of directors for monetary damages for actions taken as a director, with certain exceptions; and

· our board of directors may issue, without stockholder approval, shares of undesignated preferred stock, which makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to acquire us.

As a Delaware corporation, we are also subject to certain Delaware anti-takeover provisions. Under Delaware law, a corporation may not engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Our board of directors could rely on Delaware law to prevent or delay an acquisition of us.

ITEM 1B.  UNRESOLVED STAFF COMMENTS

None.

37

ITEM 2.  PROPERTIES

Our headquarters are currently located in Beijing with around 45,500 square meters of leased office space and with 31,300 square meters of leased land as our management, marketing, and research and development headquarter. Our processing and packaging facilities are located in various locations in China, including Qingdao, Zhangjiakou, Fengzhen and Zhenglanqi. These facilities encompass approximately 137,000 square meters of office, plant, and warehouse space. Our distribution center located in Qingdao includes approximately 25,000 square meters of owned office space. All of our production facilities are built based on the GMP standard, and all of our facilities that have commenced operation have ISO9000 and HACCP series qualifications with some also being ISO14000 certified.

Apart from the properties in China, we are building a drying facility in Carhaix, France. Please refer to Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS – Liquidity and Capital Resources for details.

The following table sets forth certain information with respect to our production, processing and packaging facilities.

Subsidiary	Province/Region	Installed Capacity as of March 31, 2014	Description	Property Right
		(tons per year)
Synutra France	Carhaix, France	Not installed yet	Drying of raw milk and whey, packaging of powdered formula products	Will Buy Land
Shengyuan Nutrition	Qingdao, Shandong	78,000	Dry-mixing of powdered formula products	Land Use Right
		75,000	Packaging of powdered formula products	Land Use Right
Zhangjiakou	Zhangjiakou, Hebei	15,000	High oil whey protein powder processing	Land Use Right
Mengyuan	Fengzhen, Inner Mongolia	3,800	High oil whey protein powder processing	Land Use Right
Inner Mongolia Huiliduo	Zhenglanqi, Inner Mongolia	9,000	Production of prepared foods	Land Use Right
Meitek	Qingdao, Shandong	1,700	Production of nutritional ingredients and supplements	Land Use Right

There is no private land ownership in China. Individuals and companies are permitted to acquire land use rights for specific purposes and for limited periods. Each period may be renewed at the expiration of the initial and any subsequent terms. Granted land use rights are transferable and may be used as security for borrowings and other obligations.

38

ITEM 3.  LEGAL PROCEEDINGS

As of March 31, 2014, the Company is not involved in any legal proceedings which it believes will have the potential for a materially adverse impact on the Company’s business or financial condition, results of operations or cash flows. The Company is subject to legal proceedings and claims which arise in the ordinary course of business. Claims have been made against the Company from time to time. The Company intends to contest each lawsuit vigorously.

ITEM 4.  MINE SAFETY DISCLOSURES

Not applicable.

39

PART II

ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDERS MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Price Range of our Common Stock

Our common stock has been trading on the NASDAQ Global Select Market under the symbol “SYUT” since November 8, 2007. Our common stock was previously quoted on the Over-The-Counter Bulletin Board, or OTCBB, under the trading symbol “SYUT.OB” until April 11, 2007. On April 12, 2007, our common stock was listed on the NASDAQ Global Market and subsequently approved for listing on the NASDAQ Global Select Market on November 8, 2007.

The high and low bid prices reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.

	The NASDAQ Global/Global Select Market Price per Share
	High		Low
Fiscal Year Ended March 31, 2013
First Quarter	$	6.20	$	4.50
Second Quarter		6.27		4.61
Third Quarter		5.15		3.99
Fourth Quarter		4.94		4.36
Fiscal Year Ended March 31, 2014
First Quarter	$	5.37	$	4.39
Second Quarter		5.37		4.39
Third Quarter		9.79		4.39
Fourth Quarter		9.38		6.56

As of May 29, 2014, we had 14 registered stockholders of our common stock on record. This number does not include shares held by brokerage clearing houses, depositories or otherwise in unregistered form or shares held by a custodian for the benefit of our employees.

Dividend Policy

We have never declared or paid any dividends on shares of our common stock. We intend to retain any future earnings to fund the development and growth of our business, and we do not anticipate paying any dividends in the foreseeable future.

Our revenues are earned by our PRC subsidiaries. However, PRC regulations restrict the ability of our PRC subsidiaries to make dividends and other payments to their offshore parent company. PRC legal restrictions permit payments of dividend by our PRC subsidiaries only out of their accumulated after-tax profits, if any, determined in accordance with PRC accounting standards and regulations. Each of our PRC subsidiaries is also required under PRC laws and regulations to allocate at least 10% of our annual after-tax profits determined in accordance with PRC GAAP to a statutory general reserve fund until the amounts in such fund reaches 50% of our registered capital. Allocations to these statutory reserve funds can only be used for specific purposes and are not transferable to us in the form of loans, advances or cash dividends. In addition, there are restrictions on the distribution of share capital from the Company’s PRC subsidiaries. As of March 31, 2014, the common stock, additional paid-in capital and statutory reserve of PRC subsidiaries were RMB 1,018.7 million, which were equivalent to $165.6 million using the exchange rate as of March 31, 2014.

For information on securities authorized for issuance under our equity compensation plans, see “Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.”

Recent Sales of Unregistered Securities

None.

40

ITEM 6.  SELECTED FINANCIAL DATA

The following selected consolidated balance sheets data for the fiscal years ended March 31, 2014 and 2013, and selected consolidated statements of operations data for the fiscal years of 2014, 2013 and 2012 are derived from our audited consolidated financial statements included elsewhere in this Form 10-K. The financial data for the remaining years are derived from audited consolidated financial statements which are not included in this Form 10-K. The results of operations for past accounting periods are not necessarily indicative of the results to be expected for any future accounting period.

The financial data set forth below should be read in conjunction with, and are qualified in their entirety by reference to “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our consolidated financial statements and related notes included elsewhere in this Form 10-K.

	Fiscal Year Ended March 31,
	2014			2013			2012		2011			2010
	(in thousands except earnings per share data)
Selected Consolidated Statement of Income Data:
Net sales	$	370,534		$	265,770		$	342,539	$	248,516		$	291,886
Cost of sales		217,027			171,211			201,618		170,769			208,476
Gross profit		153,507			94,559			140,921		77,747			83,410
Selling and distribution expenses		53,710			51,005			49,628		48,409			43,989
Advertising and promotion expenses		32,912			35,176			30,035		41,420			33,854
General and administrative expenses		25,506			30,220			23,948		28,261			24,509
Impairment of goodwill		0			0			0		1,440			0
Impairment loss from assets disposal		0			0			0		0			5,894
Gain on disposal and liquidation of subsidiaries		367			3,625			0		0			0
Impairment of long-lived assets		1,040			0			0		0			0
Government subsidies		924			4,217			5,484		1,441			894
Income (loss) from operations		41,630			(14,000	)		42,794		(40,342	)		(23,942	)
Interest expense		16,162			15,018			14,276		10,321			8,603
Interest income		4,658			2,326			1,870		820			1,850
Other income (expense), net		352			(343	)		146		277			(1,081	)
Income (loss) before income tax expense (benefit)		30,478			(27,035	)		30,534		(49,566	)		(31,776	)
Income tax expense (benefit)		130			37,186			13,510		(9,306	)		(6,904	)
Net income (loss)		30,348			(64,221	)		17,024		(40,260	)		(24,872	)
Net income (loss) attributable to the noncontrolling interest		(581	)		(333	)		287		(192	)		(257	)
Net income (loss) attributable to common stockholders	$	30,929		$	(63,888	)	$	16,737	$	(40,068	)	$	(24,615	)
Earnings (loss) per share-basic and diluted	$	0.54		$	(1.11	)	$	0.29	$	(0.71	)	$	(0.46	)

	March 31,
	2014			2013			2012		2011			2010
	(in thousands)
Selected Balance Sheets Data:
Cash and cash equivalents	$	90,915		$	79,050		$	64,793	$	48,741		$	48,693
Working capital (deficit)		(25,010	)		(40,006	)		10,565		(479	)		(27,593	)
Inventory		83,986			87,707			75,499		67,372			52,134
Total assets		550,683			476,144			447,913		398,704			349,357
Short-term debt		115,917			127,449			86,614		124,281			98,069
Long-term debt due within one year		91,505			82,663			40,831		38,131			61,194
Long-term debt		160,533			102,164			92,745		62,722			41,018
Capital lease obligation		7,898			7,848			4,726		5,540			5,372
Total long-term liabilities		179,161			120,476			104,243		74,310			52,497
Total equity	$	61,256		$	29,207		$	97,092	$	75,926		$	52,931

41

ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes that appear elsewhere in this Form 10-K. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Form 10-K, particularly in “Item 1A. Risk Factors.”

Overview

We are a leading infant formula company in China. We principally engage in the production, distribution and sale of dairy based nutritional products under the “Shengyuan” or “Synutra” line of brands in the PRC. We focus on selling powdered formula products for infants and adults, and also engage in other nutritional product offerings, such as prepared foods and certain nutritional ingredients and supplements. We sell most of our products through an extensive nationwide sales and distribution network covering all provinces and provincial-level municipalities in mainland China. As of March 31, 2014, this network comprised over 670 independent distributors and over 550 independent sub-distributors who sell our products in approximately 24,000 retail outlets.

We currently have four reportable segments which are:

●  Powdered formula segment: Powdered formula segment covers the sale of powdered infant and adult formula products. Major brands include Super, U-Smart, My Angel and Dutch Cow;

●  Foods segment: Foods segment covers the sale of prepared baby foods for babies, children and adults under the brand of Huiliduo. In June 2013, we introduced prepared adult foods for patients with special nutritional needs after surgical operations;

●  Nutritional ingredients and supplements segment: Nutritional ingredients and supplements segment covers the production and sale of nutritional ingredients and supplements such as chondroitin sulfate to third parties, and microencapsulated Docosahexanoic Acid (“DHA”) and Arachidonic Acid (“ARA”) to powdered formula segment;

●  Other business segment: our other business includes non-core businesses such as ancillary sales of excess or unusable ingredients and materials to industrial customers.

Executive Summary

For the fiscal year ended March 31, 2014, net sales of powdered formula segment increased 40% compared to fiscal year 2013. Earnings per share increased to $0.54 from a loss per share of $1.11, which was primarily attributable to the successful implementation of our “Goldmining” marketing strategy (the “Goldmining Strategy”).

We believe the Goldmining Strategy which was initiated in September 2012 has shown positive effect on our sales channels in the recent quarters. With the inventory tracking system set up, we believe we have largely prevented distributors from selling outside of their designated areas, and exerted order on our sales channels. We are now monitoring our promotional spending and are organizing nation-wide promotional events through a centralized system, which we believe allows us to more efficiently use our resources.

During the fiscal year ended March 31, 2014, we made important progress on the construction and engineering aspects of the French Project. We have signed construction and equipment purchasing contracts with certain suppliers for €106.3 million (equivalent to $146.2 million). We have unused long term loan facilities of €64.5 million (equivalent to $88.7 million) with banks, for €53.0 million of such loans, the bank has required preconditions which included obtaining the formal approval of an environmental impact study. In March 2014, we were informed that the environmental impact study resulted in a positive opinion and expect to obtain formal approval for the study around July 2014. However, the timing of the completion of regulatory approval is not fully within our control.

42

Factors Affecting Our Results of Operations

Our operating results are primarily affected by the following factors:

Perceptions of Product Quality and Safety

Rising consumer wealth in China has contributed to a greater acceptance by consumers in China of and desire for higher-priced products with perceived quality advantages associated with such products. Thus, we believe that infant formula producers with a reputation for quality and safety should be able to command higher average selling prices and thereby generate higher gross margins than competitors that do not possess the same perceived reputation for quality and safety. Conversely, any decrease in consumer perceptions of quality and safety could adversely impact such producers’ sales and gross margins, even if the perception is from misinformation or disinformation. Moreover, a decrease in the quality and safety of any particular product could trigger wider negative perception of the decrease in the quality and safety of all producers, thereby affecting the industry generally. For example, the melamine contamination incident had resulted in a significant reduction in the sales of a number of major dairy product companies in China, including us, and the prematurity event resulted in a significant decline in our sales. If a future market crisis involving any of our products should occur, especially if management failed to respond to such crisis in a timely and effective manner, our brand recognition and reputation could be severely damaged, which could adversely affect our results of operations. See Part I - Item 1A. Risk Factors—Risks Related to Our Business—We are highly dependent upon consumers’ perception of the safety and quality of our products. Any ill effects, product liability claims, recalls, adverse publicity or negative public perception regarding particular ingredients or products or our industry in general could harm our reputation, damage our brand and adversely affect our results of operations.

Brand Recognition and Customer Loyalty

In recent years, there has been growing demand in China for premium infant formula products due to increasing consumer awareness of brand image and nutritional value of the products offered by leading producers. Although the market is still highly competitive, we believe that companies with strong national brands and customer loyalty will increasingly capture market share from regional brands with less brand recognition. Moreover, we believe brand recognition and customer loyalty are predominantly influenced by customer perceptions of the quality and safety of branded products. We believe the melamine contamination incident involving 22 infant formula producers has increased the importance of consumer perception of quality and safety and the need to maintain and increase brand recognition and customer loyalty.

Competition and Market Position

While China’s infant formula market is expected to grow significantly, competition is intense. We face significant competition from domestic and multinational producers. A small number of multinational players enjoy significant market share in China, particularly in the more affluent major urban areas, based on greater brand name recognition among Chinese consumers. In addition, competition from domestic producers has become more intense in recent years, especially from large national milk companies, such as Yili, Yashili, Beingmate and Feihe, which have entered the infant formula market.

We focus on developing and marketing premium products for the infant formula market in China. By leveraging our focused marketing strategy, our brand name and our sales and marketing infrastructure, we have been able to sell infant formula products to consumers in China’s small to mid-size cities and rural areas and aside from the prematurity event, had been perceived to deliver premium quality that justifies our premium prices.

Product Offering and Pricing

Infant formula has been, and is expected to remain, our primary product. Due to rising economic affluence in China, infant formula products have become more affordable, resulting in the rapid growth of the overall market for infant formula in China. Despite the recent rapid growth, we believe much of the market is still underserved with respect to infant formula. We believe this growth in demand will help drive sales for many PRC infant formula producers, but companies with strong brand loyalty and extensive distribution networks in China will have greater ability to capitalize on such growth as well as to increase prices and pass on higher raw material costs to customers. This can be accomplished through launching higher-priced new infant formula product lines or re-launching older product lines with higher prices and improved product features.

Raw Material Supply and Prices

The per unit costs of producing our infant formula are subject to the supply and price volatility of milk powder, whey powder and other raw materials, which are affected by the PRC and global markets. Increases in the price of milk powder and whey powder would negatively impact our gross margins if we are not able to offset such price increases through increases in our selling price or change in product mix. See Part I - Item 1A. Risk Factors—Risks Related to Our Business—Our results of operations may be affected by fluctuations in availability and price of raw materials.

Advertising and Sales Promotion Costs

We have historically relied on our extensive distribution network, our consumer education programs and customer relation services to market and sell our products. We spent aggressively on advertising and promotions to rebuild our brand image and to recover customers and market share after the prematurity event. As our market share has stabilized, we reduced our spending on advertising and promotion, and refocused our efforts to achieve effective market pull-through with new customers by supporting increased activities on the consumer-end and beyond the distribution channels by our field promoters in the communities. For example, we trained our in-store promoters to approach potential consumers more proactively, including conducting more home visits, phone communications and educational programs. We do not expect significant increase in advertising and promotion expenses in near future.

43

Taxation

We file separate tax returns in the United States, Hong Kong, Netherlands, France and China. Income taxes of our subsidiaries are calculated in accordance with taxation principles currently effective in the PRC. For Synutra Illinois and Synutra Delaware, applicable U.S. tax laws are followed. For Synutra International (HK) Company Limited, Unisono B.V. and Synutra France International SAS, applicable local tax laws are followed.

On March 16, 2007, the National People’s Congress of the PRC approved and promulgated a new tax law, which took effect beginning January 1, 2008. The Company’s PRC subsidiaries then measure and pay enterprise income tax pursuant to the new tax law. Under the new tax law, foreign investment enterprise and domestic companies are subject to a uniform income tax rate of 25%. The new tax law provides a five-year transition period from its effective date for those enterprises which were established before the promulgation date of the new tax law and which were entitled to a preferential lower tax rate under the then effective tax laws or regulations.  

Some of the Company’s PRC subsidiaries are eligible for tax holidays. The impact of these tax holidays did not change PRC tax benefit for the fiscal year ended March 31, 2014 and 2013, and decreased PRC tax expense by $194,000 for the fiscal year ended March 31, 2012. The benefit of the tax holidays on basic and diluted earnings (loss) per share was nil, nil, and nearly zero for the fiscal years ended March 31, 2014, 2013 and 2012, respectively.

Some of the Company’s PRC subsidiaries are eligible under the transition rules to continue enjoying tax holidays or reduced tax rate until expiration. The following table illustrates the applicable tax rate and tax holidays of major PRC subsidiaries under the new EIT Law:

Name of Subsidiaries	Statutory Tax Rate Beginning January 1, 2008	Tax Holiday (based on calendar year)
Shengyuan Nutritional Food Co., Ltd.	25%	No tax holiday
Zhangjiakou Chahaer Dairy Co., Ltd.	25%	No tax holiday
Inner Mongolia Huiliduo Food Co., Ltd.	25%	12.5% (2011, 2012)
Inner Mongolia Mengyuan Food Co., Ltd.	25%	No tax holiday
Meitek Technology (Qingdao) Co., Ltd.	25%	12.5% (2011, 2012); high-tech enterprise at 15% (2014, 2015)
Beijing Shengyuan Huiliduo Food Technology Co., Ltd.	25%	No tax holiday
Beijing Shengyuan Huimin Technology Service Co., Ltd.	25%	No tax holiday
Beijing Syclin Clinical Laboratory Co., Ltd.	25%	No tax holiday
Global Food Trading (Shanghai) Co., Ltd.	25%	24% (2011), 25% (2012)

Our income will be derived from dividends we receive from our PRC operating subsidiaries described above. The New EIT Law and its implementing rules generally provide that a 10% withholding tax applies to China-sourced income derived by non-resident enterprises for PRC enterprise income tax purposes. We expect that such 10% withholding tax will apply to dividends paid to us by our PRC subsidiaries but this treatment will depend on our status as a non-resident enterprise. For detailed discussion of PRC tax issues related to resident enterprise status, see Part-I - Item 1A. Risk Factors—Risks Associated with Doing Business in China—Under China’s New Enterprise Income Tax Law (“EIT Law”), we may be classified as a “resident enterprise” of China. This classification could result in unfavorable tax consequences to us and our non-PRC shareholders.

Each of our PRC subsidiaries files stand-alone tax returns and we do not file a consolidated tax return.

Critical Accounting Policies and Estimates

We prepare our financial statements in accordance with US GAAP. The preparation of these financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Management periodically evaluates the estimates and judgments made. Management bases its estimates and judgments on historical experience and on various factors that are believed to be reasonable under the circumstances. Actual results may differ materially from these estimates as a result of different assumptions or conditions.

The following critical accounting policies involve more significant judgments and estimates used in the preparation of our financial statements.

44

Revenue

We recognize revenue when title and risk and rewards for the products are transferred to the customer, price is fixed and determinable and collectability is reasonably assured. At the time of the sale, we also record estimates for a variety of sales deductions, including rebates, discounts and incentives, trade promotions and product returns. Sales deductions are reported as a reduction of revenue. Most of our powdered formula product sales are made through distributors. Under the distributor arrangement, evidenced by purchase order together with advance payment, revenue is realized and earned upon acceptance of delivery of products by the distributors. The revenue recognition of My Angel series, which is directly sold to baby stores, is similar to that of our sales through distributors, and the revenue is realized and earned upon acceptance of the delivered of products by the baby stores. For sales to a limited number of distributors from whom collectability is not reasonably assured, revenue is recognized when the Company received payments.

A small fraction of our powdered formula product sales are through supermarket retailers directly. The revenue arrangement with most of these retailers includes a right of return clause, so we recognize revenue when the supermarkets have paid us.

Our gross sales are subject to various deductions, primarily comprised of rebates and discounts to distributors and retailers. These deductions represent estimates of the related obligations, requiring the use of judgment when estimating the impact of these sales deductions on gross sales for a reporting period. We report these adjustments as a reduction of gross sales to arrive at net sales.

The Company provides discounts or rebates to customers in the following ways:

●  The Company offers product discounts to compensate certain distributors for promotional expenses and slotting fees paid by them. These distributors are responsible for organizing local promotional activities and paying slotting fees to retail outlets within their sales territory, and providing the Company with documentation of their expenditures, which would be recorded as product discounts and a reduction of the receivable from distributors in the applicable month.

●  The Company offers rebates to other distributors and supermarket retailers as sales incentives. These rebate programs provide that distributors and supermarket retailers receive a rebate after attaining certain amount of orders relating to specific products. Since rebates are contractually agreed upon, the Company estimates rebates based on the specific terms in each agreement and anticipated performance for the current year. The Company considers the sales performance of products subject to rebates and applicable rebate rate, and adjusts the provision periodically to reflect actual experience. Actual amounts may differ if actual performance varies from estimates. The Company records rebates as a reduction of revenues in the period in which these programs are offered.

Slotting fees and estimated sales returns due to package damage are also deductions from gross sales:

●  For product sales made directly to supermarket retailers, certain slotting fees, such as shelf display, end-cap placement, bar-coding, banner advertising, are paid to the supermarket retailers. These slotting fees are deducted from revenues.

●  The Company records a provision for estimated sales returns due to package damage. The sales return amount represents management’s best estimates based on the available information at the time of estimate. The provision for estimated sales returns due to package damage was not material as of March 31, 2014 and 2013.

Allowance for Doubtful Accounts

We maintain allowances for doubtful accounts primarily based on the age of receivables and factors surrounding the credit risk of specific customers. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. We perform a risk assessment for each customer, and provide specific allowance for those deemed to have a high risk of uncollectibility. We also record a provision for other customers without specific risks based on a review of the receivables aging and our historical experience. Bad debts are written off as incurred.

45

Inventories

Our inventories are stated at the lower of cost or market. The valuation of inventory requires us to estimate excess and slow moving inventory. The determination of the value of excess and slow moving inventory is based upon assumptions of future demands and market conditions. If actual market conditions are less favorable than those projected by management, inventory write-downs may be required. We routinely evaluate quantities and value of our inventories in light of current market conditions and market trends. We record write-downs against the cost of inventories for a decline in market, which establishes a new cost basis for inventory. In estimating obsolescence, we utilize our backlog information and forecasts of future demand. Market conditions are subject to change and actual consumption of inventories could differ materially from forecasted demand. Furthermore, the price of milk powder is subject to fluctuations based on global supply and demand. If actual market conditions are less favorable or other factors arise that are significantly different from those anticipated by management, additional inventory write-downs or increases in obsolescence reserves may be required.

Income Taxes

The provision for income taxes has been determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax bases of our assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made.

Our tax rate is based on expected income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which we operate. For interim financial reporting, we estimate the annual tax rate based on projected taxable income for the full year and record a quarterly income tax provision in accordance with the anticipated annual rate. As the year progresses, we refine the estimates of the year’s taxable income as new information becomes available, including year-to-date financial results. This continual estimation process often results in a change to our expected effective tax rate for the year. When this occurs, we adjust the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision reflects the expected annual tax rate. Significant judgment is required in determining our effective tax rate and in evaluating our tax positions.

We recognize deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets represent items to be used as a tax deduction or credit in future tax returns for which we have already properly recorded the tax benefit in the income statement. At least quarterly, we assess the likelihood that the deferred tax asset balance will be recovered from future taxable income. We consider positive and negative evidence when determining whether a portion or all of our deferred tax assets will more likely than not be realized. We take into account such factors as prior earnings history, expected future earnings, carry-back and carry-forward periods, the duration of statutory carry forward periods and tax strategies that could potentially enhance the likelihood of a realization of a deferred tax asset. To the extent recovery is unlikely, a valuation allowance is established against the deferred tax asset and increasing our income tax expense in the year such determination is made. As of March 31, 2014, we had deferred tax assets of $38.1 million, mainly generated from net loss carryforward before valuation allowance. We accrued a full valuation allowance since it is more likely than not that the operating loss will not be utilized before expiration. Tax benefits relating to future reversals of the valuation allowance on deferred tax assets, if any, will be recognized as a reduction of income tax expense. 

We periodically evaluate our investment strategies with respect to each foreign tax jurisdiction in which we operate to determine whether foreign earnings will be indefinitely reinvested offshore and, accordingly, whether U.S. income taxes should be provided when such earnings are recorded. As of March 31, 2014, we believed all earnings generated in China, Hong Kong and Netherlands would be indefinitely reinvested and as a result, we did not record any income taxes on such earnings.

We recognize a tax benefit associated with an uncertain tax position when, in our judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, we initially and subsequently measure the tax benefit as the largest amount that we judge to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. Our liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. Our effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. As of March 31, 2014, we had recorded liabilities of $500,000 for our PRC subsidiaries.

We classify interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense. For the fiscal year ended March 31, 2014, the unrecognized tax benefit did not change significantly and the amount of interest and penalties related to uncertain tax position is immaterial.

Impairment of Long-lived Assets

We evaluate our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Factors that we consider in deciding when to perform an impairment review include, but are not limited to significant under-performance of a business or product line in relation to expectations, and significant changes or planned changes in the use of the assets. An impairment analysis is performed at the lower level of identifiable independent cash flows for an asset or asset group. We assess the recoverability of long-lived assets by comparing the carrying amount of the asset group to the estimate of the related total future undiscounted cash flow. If an asset group’s carrying value is not recoverable through the related undiscounted cash flows, the impairment loss is measured by comparing the difference between the asset group’s carrying value and its fair value.

The impairment tests involve the use of accounting estimates and assumptions that management believed to be reasonable, the result of which form the basis for our conclusions. While the current analysis suggested that no impairment was recognized, significant changes to these estimates and assumptions could adversely impact our conclusion to these impairment tests. We will continue to closely monitor our financial performance and projections for the asset groups and the economic conditions of the product end markets. Any significant change in market conditions and estimates of judgments could give rise to impairment in the period that the change becomes known.

46

Results of Operations

Fiscal Year Ended March 31, 2014 Compared to Fiscal Year Ended March 31, 2013

Below is a summary of selected comparative results of operations for the fiscal year ended March 31, 2014 and 2013:

	Fiscal Years Ended March 31,
(In thousands, except per share data)	2014		2013			% Change
Net sales	$	370,534	$	265,770			39%
- Powdered formula segment		314,289		224,423			40%
Cost of sales		217,027		171,211			27%
- Powdered formula segment		156,788		122,175			28%
Gross profit		153,507		94,559			62%
- Powdered formula segment		157,501		102,248			54%
Gross Margin		41%		36%
- Powdered formula segment		50%		46%
Income (loss) from operations		41,630		(14,000	)		*
Interest expense, net		11,504		12,692			-9%
Income (loss) before income tax expense		30,478		(27,035	)		*
Income tax expense		130		37,186			*
- Effective tax rate		0.4%		-137.5%
Net income (loss)		30,348		(64,221	)		*
Net income (loss) attributable to common stockholders	$	30,929	$	(63,888	)		*
Weighted average common stock outstanding – basic and diluted		57,301		57,301
Earnings/(losses) per share – basic and diluted	$	0.54	$	(1.11	)		*

* not meaningful 

Net Sales

Our net sales by reportable segments are shown in the table below:

	Fiscal Years Ended March 31,						% Change in
(In thousands, except percentage data)	2014		2013		% Change		Volume		Price
Powdered formula	$	314,289	$	224,423		40%		18%		19%
Foods		170		350		-51%
Nutritional ingredients and supplements		21,987		6,836		222%
All other		34,088		34,161		0%
Net sales	$	370,534	$	265,770		39%

Net sales of our powdered formula segment include powdered formula products for infants, children and adults. The increase in net sales of our powdered formula products was mainly due to the following factors:

●  Sales volume of powdered formula products for the fiscal year ended March 31, 2014 was 24,162 tons, as compared to 20,521 tons for the prior fiscal year, due primarily to the reduced purchase by distributors in the fiscal year 2013 as the sales channel continued to utilize the products sold prior to the retail price increase on April 1, 2012, and the positive impact of the Goldmining Strategy in fiscal year 2014.

●  The average selling price of our powdered formula products for the fiscal year ended March 31, 2014 was $13,008 per ton, compared to $10,936 per ton for the prior fiscal year. Average selling price is calculated as net sales, after deducting sales discounts and rebates, divided by sales volume. We provided sales discounts and rebates to offset part of the marketing and promotional expenditures incurred at retail outlets. The increase in average selling price was mainly due to our ability to better control discounts as a result of the continued positive impacts of our Goldmining Strategy, and more high premium products sold during the period, such as formulas for infants with caesarean birth or special nutritional needs.

The sales volume and average selling price exclude the amount of free products provided to customers, which is recorded as cost of sales in the period.

The product mix in the foods segment is comprised of prepared baby food and adult food, such as cooked meat and vegetables. In June 2013, we launched prepared adult food under this segment for patients with special nutritional needs after surgical operations. In October 2013, we recruited a sales staff of approximately 100, and placed our adult food products with approximately 3,500 retail outlets in December 2013. We sell adult food products by consignment sales and we recognize sales when we are paid by the retail outlets.

47

The product mix in nutritional ingredients and supplements segment is comprised of external sales of chondroitin sulfate to third parties. Our sales of chondroitin sulfate materials to certain international pharmaceutical companies increased significantly in fiscal year 2014. However, as the price of these materials is negotiated yearly with the customers and the price of raw material has been increasing in a short time frame, we incurred gross loss on our chondroitin sulfate sales.

Our Other business mainly included sales of milk powder of $18.6 million and whey powder of $10.4 million for the fiscal year ended March 31, 2014. Our Other business mainly included sales of milk powder of $21.5 million and whey powder of $8.8 million for the fiscal year ended March 31, 2013. Since we use the dry-mixing production method, we require a higher quality standard for the milk powder than a wet-mixing production method would require. As a result, we screen the milk powder we purchased for excessive micro-organism content, or milk powder that is over-burnt or lacks the ideal consistency. While we do not make use of this raw material, such product meets the quality standard for raw milk powder that can be used in other products such as dairy drinks or bakery. The amount of this ancillary raw milk powder identified through the screening process is approximately 15% of the total material we purchase. In addition, we may also replace older inventory with new orders when the cost of doing so is low, causing higher sales of milk powder and whey protein powder.

Cost of Sales

Our cost of sales by reportable segments is shown in the table below:

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2014		2013		% Change
Powdered formula	$	156,788	$	122,175		28%
Foods		1,977		3,211		-38%
Nutritional ingredients and supplements		24,646		9,646		156%
All other		33,616		36,179		-7%
Cost of sales	$	217,027	$	171,211		27%

The increase in the cost of sales of the powdered formula segment was mainly due to the increase in sales volume and the increased cost of milk powder and whey powder. 

The increase in the cost of sales of nutritional ingredients and supplements segment was mainly due to increased sales volume of chondroitin sulfate to certain international pharmaceutical companies, and increased raw material price as discussed above.

Cost of other business mainly included cost of milk powder of $18.0 million and whey powder of $10.1 million for the fiscal year ended March 31, 2014, and cost of milk powder of $23.0 million and whey powder of $7.6 million for the fiscal year ended March 31, 2013.

48

Gross Profit and Gross Margin

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2014		2013		% Change
Gross profit	$	153,507	$	94,559		62%
- Powdered formula		157,501		102,248		54%
Gross margin		41%		36%
- Powdered formula		50%		46%

The increase in gross margin was mainly due to the margin increase in the powdered formula segment. The increase in gross margin of the powdered formula segment was mainly due to increased average selling price from the continued positive impact of our Goldmining Strategy, partially offset by the increase in raw material price.

Expenses

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2014		2013		% Change
Selling and distribution expenses	$	53,710	$	51,005		5%
Advertising and promotion expenses		32,912		35,176		-6%
- Advertising expenses		6,055		11,928		-49%
- Promotion expenses		26,857		23,248		16%
General and administrative expenses		25,506		30,220		-16%
Government subsidies		924		4,217		-78%

Selling and distribution expenses primarily include compensation expense for sales staff, freight charges and travel expense. The increase in selling and distribution expenses was mainly due to the increase in sales staff compensation.

Advertising expenses primarily include media expenses paid to TV stations and e-commerce providers. Advertising expenses decreased as we believe the influence from traditional TV advertising has diminished recently and as a result we have substantially cut back advertising on TV stations. Instead, we have shifted our advertising focus to e-commerce providers, mostly for our specialty infant formula products with special nutritional focus. Promotion expenses primarily include promotional products provided to end customers, and service charge for our consumer loyalty program administered by a third party. Based on our brand positioning, we believe direct communication with end customers is a more cost effective way to market our product compared to mass media advertising. As a result, we now allocate more resources to such promotional activities. Effective from January 1, 2013, we provided promotional gifts instead of our powdered formula products to end customers for the consumer loyalty program, which also contributed to the increase in promotion expenses. In the fiscal year ended March 31, 2014, local government provided a subsidy of $4.7 million which was recorded as deduction of promotion expenses, as the subsidy was required to be for promotion expense purpose.

General and administrative expenses primarily include salaries for staff and management, depreciation, office rental, office supplies and bad debt expense. The decrease was mainly due to the reversal in bad debt expense as we put more efforts into chasing the long aging receivables, partially offset by the increase in management and staff compensation.

Government subsidies represented the receipt of general purpose subsidies from local governments.

49

Impairment of long-lived assets

Impairment of long-lived assets represented impairment loss of $1.0 million for equipments in the food segment.

Gain on Disposal and Liquidation of Subsidiaries

Gain on disposal of subsidiaries represented gain on the share transfer of a diagnostic subsidiary to a third party of $367,000 in fiscal year 2014, and net foreign currency translation gains of $3.1 million reclassified from accumulated other comprehensive income as a result of the liquidation and disposal of certain subsidiaries in fiscal year 2013, none of which had significant ongoing operations.

Interest Expense and Interest Income

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2014		2013		% Change
Interest expense	$	16,162	$	15,018		8%
Interest income		4,658		2,326		100%

The increase in interest expense was mainly due to an increase in average borrowing balance, partially offset by a decreased average interest rate as we received more U.S. dollar financing via our Hong Kong subsidiary which has a lower interest rate base than financing in mainland China.

The increase in interest income was mainly due to an increase in average restricted cash balance, which earned a higher interest rate than cash and cash equivalents.

Income Tax Expense

We provided a full valuation allowance on the deferred tax assets in fiscal year 2013. In fiscal year 2014, we recognized the tax benefits relating to the reversal of the valuation allowance, and recognized it as a reduction of income tax expense only to the extent of current year income tax expense, considering the volatility associated with our historical performance, including significant losses in recent years and specific risks associated with the powdered formula industry in China.

Net Income (Loss) Attributable to Noncontrolling Interest

Net income (loss) attributable to noncontrolling interest represents the interest held by third parties in Meitek Technology (Qingdao) Co., Ltd.

Net Income (Loss) Attributable to Common Stockholders

As a result of the foregoing, net income attributable to common stockholders was $30.9 million for fiscal year 2014, compared to a net loss attributable to common stockholders of $63.9 million for fiscal year 2013.

50

Fiscal Year Ended March 31, 2013 Compared to Fiscal Year Ended March 31, 2012

Below is a summary of selected comparative results of operations for the fiscal year ended March 31, 2013 and 2012:

	Fiscal Years Ended March 31,
(In thousands, except per share data)	2013			2012		% Change
Net sales	$	265,770		$	342,539		-22%
- Powdered formula segment		224,423			301,664		-26%
Cost of sales		171,211			201,618		-15%
- Powdered formula segment		122,175			159,189		-23%
Gross profit		94,559			140,921		-33%
- Powdered formula segment		102,248			142,475		-28%
Gross Margin		36%			41%
- Powdered formula segment		46%			47%
Income (loss) from operations		(14,000	)		42,794		*
Interest expense, net		12,692			12,406		2%
Income (loss) before income tax expense		(27,035	)		30,534		*
Income tax expense		37,186			13,510		*
- Effective tax rate		-137.5%			44.2%
Net income (loss)		(64,221	)		17,024		*
Net income (loss) attributable to common stockholders	$	(63,888	)	$	16,737		*
Weighted average common stock outstanding – basic and diluted		57,301			57,301
Loss per share – basic and diluted	$	(1.11	)	$	0.29		*

* not meaningful 

Net Sales

Our net sales by reportable segments are shown in the table below:

	Fiscal Years Ended March 31,						% Change in
(In thousands, except percentage data)	2013		2012		% Change		Volume		Price
Powdered formula	$	224,423	$	301,664		-26%		-25%		0%
Foods		350		255		37%
Nutritional ingredients and supplements		6,836		907		654%
All other		34,161		39,713		-14%
Net sales	$	265,770	$	342,539		-22%

Net sales of our powdered formula segment include powdered formula products for infants, children and adults. The decrease in net sales of our powdered formula products was mainly due to the following factors:

●  Sales volume of powdered formula products for the fiscal year ended March 31, 2013 was 20,521 tons, as compared to 27,526 tons for the prior fiscal year, due primarily to significant purchases of our products by distributors prior to our retail price increase effective on April 1, 2012, and reduced orders from distributors as we implemented the Strategy discussed above.

●  The average selling price of our powdered formula products for the fiscal year ended March 31, 2013 was $10,936 per ton, compared to $10,959 per ton for the prior fiscal year. Average selling price is calculated as net sales, after deducting sales discounts and rebates, divided by sales volume. The relatively unchanged average selling price was the result of the combined effect from the retail price increase we instituted on April 1, 2012, and the result of increased sales discounts and rebates per ton. We provided sales discounts and rebates to offset part of the marketing and promotional expenditures incurred at retail outlets. The sales discounts and rebates do not fluctuate directly with current period sales because they are based on a prorated fiscal year basis before the initiation of the Strategy.

The sales volume and average selling price exclude the amount of free products provided to customers, which is recorded as cost of sales in the period.

The product mix in the foods segment is comprised of prepared baby food, such as cooked meat and vegetables. We have focused our efforts on the powdered formula segment since the melamine incident in 2008, followed by the prematurity event in 2010, and have not developed the foods segment as we originally planned, however we plan to launch a new product category under this segment in fiscal 2014 for adults with special nutritional needs, and expect to revitalize this segment going forward.

51

The product mix in nutritional ingredients and supplements segment is comprised of external sales of chondroitin sulfate to third parties. Our sales of chondroitin sulfate materials to certain international customers increased significantly in fiscal year 2013, however, our production cost remained high and we incurred gross loss on our chondroitin sulfate sales as we produced much less quantity than our nominal capacity.

Our Other business mainly included sales of raw milk powder of $21.5 million and whey protein of $8.8 million for the fiscal year ended March 31, 2013. Our Other business mainly included sales of raw milk powder of $27.7 million and raw milk of $3.3 million for the fiscal year ended March 31, 2012. Since we use the dry-mixing production method, we require a higher quality standard for the milk powder than a wet-mixing production method would require. As a result, we screen the milk powder we purchased for excessive micro-organism content, or milk powder that is over-burnt or lacks the ideal consistency. While we do not make use of this raw material, such product meets the quality standard for raw milk powder that can be used in other products such as dairy drinks or bakery. The amount of this ancillary raw milk powder identified through the screening process is approximately 15% of the total material we purchase. In addition, we may also replace older inventory with new orders when the cost of doing so is low, causing higher sales of milk powder and whey protein powder.

Cost of Sales

Our cost of sales by reportable segments is shown in the table below:

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2013		2012		% Change
Powdered formula	$	122,175	$	159,189		-23%
Foods		3,211		2,354		36%
Nutritional ingredients and supplements		9,646		3,265		195%
All other		36,179		36,810		-2%
Cost of sales	$	171,211	$	201,618		-15%

The decrease in the cost of sales of the powdered formula segment was mainly due to the decrease in sales volume and extent of promotions involving free product giveaways, partially offset by the increased cost of whey protein powder. 

The increase in the cost of sales of nutritional ingredients and supplements segment was mainly due to the sales of chondroitin sulfate to certain international pharmaceutical companies as discussed above.

Cost of our Other business mainly included cost of milk powder of $23.0 million and whey protein of $7.6 million for the fiscal year ended March 31, 2013. Cost of our Other business mainly included cost of raw milk powder of $27.1 million and raw milk of $3.3 million for the fiscal year ended March 31, 2012.

52

Gross Profit and Gross Margin

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2013		2012		% Change
Gross profit	$	94,559	$	140,921		-33%
- Powdered formula		102,248		142,475		-28%
Gross margin		36%		41%
- Powdered formula		46%		47%

The decrease in gross margin was mainly due to the margin decrease in Other business. The decrease in gross margin of the powdered formula segment was mainly due to increased cost of whey protein powder in the fiscal year ended March 31, 2013.

Expenses

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2013		2012		% Change
Selling and distribution expenses	$	51,005	$	49,628		3%
Advertising and promotion expenses		35,176		30,035		17%
- Advertising expenses		11,928		11,515		4%
- Promotion expenses		23,248		18,520		26%
General and administrative expenses		30,220		23,948		26%
Government subsidies		4,217		5,484		-23%

Selling and distribution expenses primarily include compensation expense for sales staff, freight charges and travel expense. The increase in selling and distribution expenses in the fiscal year ended March 31, 2013 from the prior fiscal year was mainly due to that we introduced our specialty infant formulas, which are designed for infants with special conditions who cannot use regular infant formulas, to our market.

Advertising expenses primarily include media expenses paid to national and local TV stations, and e-commerce providers. Promotion expenses primarily include promotional products to end customers. The increase in promotion expenses in the fiscal year ended March 31, 2013 was mainly due to more consumer loyalty program expenses for end customers, increased service charge for the consumer loyalty program administered by a third party, and increased service fee to on-site promotion staff.

General and administrative expenses primarily include salaries for staff and management, depreciation, office rental and office supplies in the fiscal year ended March 31, 2013. The increase was mainly due to the increased depreciation expense, office rental and office supplies related to our new headquarter in use.

Government subsidies represented the receipt of general purpose subsidies from local governments.

53

Gain on Disposal and Liquidation of Subsidiaries

Gain on disposal of subsidiaries is primarily comprised of net foreign currency translation gains of $3.1 million reclassified from accumulated other comprehensive income as a result of the liquidation and disposal of certain subsidiaries, none of which had significant ongoing operations.

Interest Expense and Interest Income

	Fiscal Years Ended March 31,
(In thousands, except percentage data)	2013		2012		% Change
Interest expense	$	15,018	$	14,276		5%
Interest income		2,326		1,870		24%

The increase in interest expense was mainly due to an increase in average borrowing balance, partially offset by a decreased average interest rate as we used more trade financing to purchase inventory with lower interest rates.

The increase in interest income was mainly due to an increase in average restricted cash balance, which earned a higher interest rate than cash and cash equivalents.

Income Tax Expense

The increase in income tax expense was primarily due to the $36.5 million charge from the increase in the valuation allowance for deferred tax assets of certain PRC subsidiaries for the fiscal year ended March 31, 2013.

Net Income (Loss) Attributable to Noncontrolling Interest

Net income (loss) attributable to noncontrolling interest mainly represents the interest held by third parties in Meitek Technology (Qingdao) Co., Ltd.

Net Income (Loss) Attributable to Common Stockholders

As a result of the foregoing, net loss attributable to common stockholders for the fiscal year was $63.9 million, compared to a net income of $16.7 million for the prior fiscal year.

54

Liquidity and Capital Resources

Overview

Our primary sources of liquidity are cash on hand, cash from operations and available borrowings. Cash flows from operating activities represent the inflow of cash from our customers and the outflow of cash for inventory purchases, manufacturing, operating expenses, interest and taxes. Cash flows used in investing activities primarily represent capital expenditures for equipment and buildings, and restricted cash used as security against letter of credits, bank acceptance bills and short-term and long-term borrowings. Cash flows from financing activities primarily represent proceeds and repayments of borrowings. In addition, while there can be no assurance that we will be able to refinance our short-term bank borrowings as they become due, historically, we have renewed or rolled over most of our bank loans after the maturity date of the loans and we believe we will continue to be able to do so.

Cash and cash equivalents totaled $90.9 million at March 31, 2014, of which $90.1 million was held outside of the United States.

As of March 31, 2014, the Company has an asset liability ratio of 89%, which is defined as total liabilities divided by total assets, and negative working capital of $25.0 million. However, the Company regards the going concern assumption as appropriate considering the following mitigating factors:

· The Company managed to reverse the trend contributing to losses incurred in the first half of fiscal 2013 with six consecutive quarters of income from operations;

· The Company had positive cash flows from operations since the second half of fiscal 2013. The Company believes that its cash flows from operations will be sufficiently positive for the next twelve months to satisfy its obligations when they fall due in the normal course of operations; and

· As of March 31, 2014, the Company had an unused credit facility of $68.3 million which could be used when purchasing materials and the purchased inventory is used as a pledge. The facility is not unconditionally committed as the bank may refuse to fund if there is a material adverse change to the Company’s operations. However, for normal operational needs, it provides a backup source of liquidity.

Based on the above factors, management believes that adequate sources of liquidity will exist to fund the Company’s working capital and capital expenditure requirements, and to meet its short term debt obligations, other liabilities and commitments as they become due. Accordingly, management believes the Company will be able to realize its assets and satisfy its liabilities in the normal course of business.

On September 17, 2012, the Company entered into a partnership framework agreement, a milk supply agreement, a whey supply agreement, a whey powder supply agreement, and a technical assistance agreement with Sodiaal Union, a French agricultural cooperative company (“Sodiaal”), and/or Euroserum SAS (“Euroserum”), a French subsidiary of Sodiaal, relating to a long-term industrial and commercial partnership between Sodiaal and the Company. Under these agreements, the Company undertakes to build a new drying facility (the “French Project”) in Carhaix, France, intended to manufacture powdered milk and fat-enriched demineralized whey. Pursuant to the partnership framework agreement, the operational commissioning of the new drying facility will take place no later than January 2, 2015. In the event of a delay beyond January 2, 2015 and save for limited exceptions, the Company will undertake to compensate Sodiaal or Euroserum for losses which may be incurred as a result of such delay, depending on the circumstances. The loss incurred by Sodiaal or Euroserum in case of a delay of the operational commissioning of the new drying facility beyond January 2, 2015 shall amount to the loss of profits actually suffered, as the case may be, by Sodiaal or Euroserum under the milk supply agreement or the whey supply agreement. The Company has recently decided to add 50,000 tons of packaging and warehousing capacity for powdered formula products to the French Project. As a result, the updated estimated cost to build the facility is approximately Euro 136.0 million (equivalent to $187.0 million). The Company plans to finance a majority of the cost with long-term project financing, and the remaining part of the project with cash on hand and operating cash flow. The Company committed to purchase, and Sodiaal and Euroserum committed to sell, 288 million liters of milk per year for ten years, an amount of whey equivalent to 24,000 tons of 70% demineralized pre-concentrated dry whey extract per year for ten years, and 6,000 tons of 70% demineralized whey powder per year, or an equivalent quantity of liquid whey, for ten years, at market based prices at the time of purchase, to satisfy the production needs of the new drying facility. If the Company purchases less than the agreed amount, the Company would compensate Sodiaal or Euroserum for the loss suffered.

Recent developments of the French Project include:

· On March 20, 2013, the Company received the required approvals from China's National Development and Reform Commission and Ministry of Commerce for the project;

· In September 2013, the Company received the construction permit for the project from the municipal government of Carhaix;

· We have unused long term loan facilities of €64.5 million (equivalent to $88.7 million) with banks, for €53.0 million of such loans, the bank has required preconditions which included obtaining the formal approval of an environmental impact study;

· In March 2014, we were informed that the environmental impact study resulted in a positive opinion and expect to obtain formal approval for the study around July 2014; and

· We have signed construction and equipment purchasing contracts with suppliers for €106.3 million (equivalent to $146.2 million).

55

Due to the delay in getting governmental approvals, we expect the operational commissioning of the new drying facility to take place in late calendar year 2015, which is later than the deadline of January 2, 2015 specified in the partnership framework agreement. The partnership framework agreement with Sodiaal provides that we will compensate Sodiaal for their losses due to delays in the start of the operation of our project, if such delays are not caused by governmental actions. We have obtained written consent from Euroserum that they understand the delay was mainly caused by government actions, and waived the right for the compensation. As a result, we have not accrued any loss in connection with this matter on our financial statements.

Cash Flows

The following table sets forth, for the periods indicated, certain information relating to our cash flows:

	Fiscal Year Ended March 31,
(In thousands)	2014			2013			2012
Cash flow provided by/(used in):
Operating activities
Net income (loss)	$	30,348		$	(64,221	)	$	17,024
Depreciation and amortization		15,356			14,976			11,751
Bad debt expense (reversal)		(3,193	)		2,423			3,386
Inventory write down		6,487			12,452			8,816
Deferred income tax		0			36,550			13,834
Gain on disposal and liquidation of subsidiaries		(367	)		(3,625	)		0
Other		1,075			337			398
Changes in assets and liabilities		(3,481	)		(4,636	)		10,460
Total operating activities		46,225			(5,744	)		65,669
Investing activities		(86,699	)		(70,012	)		(38,314	)
Financing activities		50,772			89,546			(12,872	)
Effect of foreign currency translation on cash and cash equivalents		1,567			467			1,569
Net change in cash and cash equivalents	$	11,865		$	14,257		$	16,052

Cash Flows from Operating Activities

Cash flow provided by operating activities was a result of the net income incurred of $30.3 million, as adjusted for non-cash expense and income items of $19.4 million, and an increase in working capital of $3.5 million for fiscal year 2014. In fiscal year 2014, we spent $302.4 million to purchase raw materials and other production materials, $45.5 million in staff compensation and social welfare, $41.3 million in taxes, $71.6 million in operating expenses, $17.3 million in interest, $3.2 million in land lease, received $518.3 million from our customers, $5.1 from government subsidies, and $4.2 million from interest payments.

Cash flow used in operating activities was a result of the net loss incurred of $64.2 million, as adjusted for non-cash expense and income items of $63.1 million, and an increase in working capital of $4.6 million for fiscal year 2013. In the fiscal year ended March 31, 2013, we spent $270.1 million to purchase raw materials and other production materials, $48.7 million in staff compensation and social welfare, $30.8 million in taxes, $57.5 million in operating expenses, $13.2 million in interest, received $410.7 million from our customers, and received a $3.9 million subsidy from the local government.

Cash flow provided by operating activities was a result of the net income incurred of $17.0 million, as adjusted for non-cash expense and income items of $38.2 million, and a decrease in working capital of $10.5 million for fiscal year 2012. In the fiscal year ended March 31, 2012, we spent $265.9 million to purchase raw materials and other production materials, $44.7 million in staff compensation and social welfare, $18.1 million in other taxes, $37.4 million in operating expenses, $13.5 million in interest, and received $446.0 million from our customers.

56

Cash Flows from Investing Activities

Cash flow used in investing activities in the fiscal year ended March 31, 2014 mainly represents $29.6 million payment for purchase of property, plant and equipment, and $57.9 million outflow for restricted cash deposited with banks as security against the issuance of letters of credit and bank acceptance bills, and as pledges for certain short-term and long-term borrowings.

Cash flow used in investing activities in the fiscal year ended March 31, 2013 represents $16.1 million payment for purchase of property, plant and equipment, $56.5 million outflow for restricted cash deposited with banks as security against the issuance of letters of credit for the import of raw materials and as pledges for certain short-term and long-term borrowings, $1.6 million in proceeds from disposed assets, and $1.0 million proceeds from disposal of certain PRC subsidiaries.

Cash flow used in investing activities in the fiscal year ended March 31, 2012 mainly represents $27.3 million payment for purchase of property, plant and equipment, and $11.7 million outflow in restricted cash. Restricted cash represents cash deposited with banks as security against the issuance of letters of credit for the import of raw materials and as pledges for certain short-term and long-term borrowings.

Cash Flows from Financing Activities

Cash flow used in financing activities in the fiscal year ended March 31, 2014 mainly represents net cash outflow of $13.4 million from short-term loans and net cash inflow of $65.0 million from long-term loans, and$0.8 million payment for assets under capital leases.

Cash flow used in financing activities in the fiscal year ended March 31, 2013 mainly represents net cash inflow of $40.2 million from short-term loans and net cash inflow of $50.8 million from long-term loans, $1.0 million payment for assets under capital leases and $0.4 million payment to holders of non-controlling interest.

Cash flow used in financing activities in the fiscal year ended March 31, 2012 mainly represents net cash outflow of $44.0 million of short-term loans and net cash inflow of $31.5 million of long-term loans, and $0.3 million payment for capital leased assets.

57

Outstanding Indebtedness

For information on our short-term and long-term borrowings, see “Item 8.  Financial Statements and Supplementary Data – Note 10 to Consolidated Financial Statements.”

Tabular Disclosure of Contractual Obligations

Below is a table setting forth our contractual obligations as of March 31, 2014.

	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
	(in thousands)
Long-term debt and related interest payment obligations	$	267,877	$	102,420	$	165,457	$	0	$	0
Capital lease obligations		19,556		624		1,248		1,248		16,436
Operating lease obligations		57,616		1,819		3,430		3,430		48,937
Purchase commitments		12,457		12,457		0		0		0
Capital expenditure commitments*		134,691		97,152		37,539		0		0
Total	$	492,197	$	214,472	$	207,674	$	4,678	$	65,373

* Including $131.9 million commitments denominated in EUR

As discussed in Liquidity and Capital Resources – Overview, we are building a new drying facility in Carhaix, France, to manufacture powdered milk and fat-enriched demineralized whey. The estimated cost to build the facility is € 136.0 million (approximately $187.0 million). We committed to purchase, and Sodiaal and Euroserum committed to sell, 288 million liters of milk per year for ten years, an amount of whey equivalent to 24,000 tons of 70% demineralized pre-concentrated dry whey extract per year for ten years, and 6,000 tons of 70% demineralized whey powder per year, or an equivalent quantity of liquid whey, for ten years, at market based prices at the time of purchase, to satisfy the production needs of the new drying facility. The above table only included capital expenditures of signed contracts. As the price of raw milk and whey in the next ten years cannot be predicted with precision, the purchase commitment of the new drying facility was not included in the table above.

We computed the long-term debt-related interest based on the interest rate as of March 31, 2014.

As of March 31, 2014, our uncertain income tax liability was $500,000. We are unable to reasonably estimate the timing of the effective settlement of this tax position.

Capital Expenditures

Our capital expenditures were $29.8 million and the corresponding cash outflow was $29.6 million for the fiscal year ended March 31, 2014, which mainly represented expenditure for the French Project.

Off-Balance Sheet Arrangements

We do not have off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Recent Accounting Pronouncements

In April 2014, the FASB issued Accounting Standards Update 2014-08 - Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which amends to change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in the ASU are effective for disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. Early adoption is permitted. The adoption of this ASU is not expected to have a significant effect on the Company’s consolidated financial statements.

58

ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The objective of our policies is to mitigate potential income statement, cash flow and fair value exposures resulting from possible future adverse fluctuations in interest rates and foreign exchange rates. We evaluate our exposure to market risk by assessing the anticipated near-term and long-term fluctuations in interest rates and foreign exchange rates. This evaluation includes the review of leading market indicators, discussions with financial analysts and banks regarding current and future economic conditions and the review of market projections.

Foreign Exchange Risk

The value of the Renminbi against the U.S. dollar and other currencies is affected by, among other things, changes in China’s political and economic conditions. Since July 2005, the Renminbi has no longer been pegged to the U.S. dollar. Although the PBOC regularly intervenes in the foreign exchange market to prevent significant short-term fluctuations in the exchange rate, the Renminbi may appreciate or depreciate significantly in value against the U.S. dollar in the medium to long term. Moreover, it is possible that in the future, PRC authorities may lift restrictions on fluctuations in the Renminbi exchange rate and lessen intervention in the foreign exchange market.

Our financial statements are expressed in U.S. dollars and appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. As a result, we face exposure to adverse movements in currency exchange rates as the financial results of our Chinese operations are translated from local currency into U.S. dollars upon consolidation. If the U.S. dollar weakens against the Renminbi, the translation of our foreign-currency-denominated balances will result in increased net assets, net revenues, operating expenses, and net income or loss. Similarly, our net assets, net revenues, operating expenses, and net income or loss will decrease if the U.S. dollar strengthens against the Renminbi. Considering the RMB balance of our cash and cash equivalents as of March 31, 2014, which amounted to $90.9 million, a 1.0% change in the exchange rates between the Renminbi and the U.S. dollar would result in an increase or decrease of approximately $0.9 million of the balance.

Additionally, all our revenue and most of our expenses are denominated in RMB currently, while a substantial portion of our raw material purchase prices and short-term and long term borrowings are denominated in USD. Foreign exchange rate fluctuations on transactions denominated in Renminbi other than the functional currency results in gains and losses that are reflected in our Consolidated Statement of Income. Our operations are subject to risks typical of international business, including, but not limited to, differing economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility.

To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk as very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations. While we may enter into hedging transactions in the future, the availability and effectiveness of these transactions may be limited, and we may not be able to successfully hedge our exposure at all. In addition, our foreign currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert Renminbi into foreign currencies.

The construction contracts and loans of Synutra France are denominated in Euro. The value of EUR against USD changes from time to time.CurrentlySynutra France isstill at the earlyconstructionstage, andthe impact offoreign exchange rate fluctuationsis immaterial as of March 31, 2014.

Inflation

Inflationary factors, such as increases in the cost of our products and overhead costs, could impair our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain current levels of gross margin and selling, general and administrative expenses as a percentage of sales revenue if the selling prices of our products do not increase with these increased costs.

Interest Rate Risk

Our exposure to interest rate primarily relates to interest expense incurred on our short-term and long-term borrowings. Most of our borrowings are bearing the floating interest rates which are subject to periodical adjustment. We did not experience any material changes in interest rate exposures during the fiscal year ended March 31, 2014. We currently do not use interest rate swaps to manage exposure to interest rate changes.

Concentration of Credit Risk

We are subject to concentrations of credit risk consisting primarily of accounts receivable. We perform ongoing credit evaluations with respect to the financial condition of our debtors, but do not require collateral. In order to determine the value of our accounts receivable, we record a provision for doubtful accounts to cover probable credit losses. Our management reviews and adjusts this allowance periodically based on historical experience and its evaluation of the collectability of outstanding accounts receivable.

Commodities Risk

Imported milk powder and whey powder are the principal raw materials in the Company’s business, accounting for approximately 65% of the Company’s production costs. As such, the Company is exposed to the fluctuations in the price of milk powder and whey powder. During the past two fiscal years, the rise and fall in the prices of these commodities have affected the Company’s business operations and profitability. A significant rise in the prices of these raw materials will adversely affect the gross margin of the Company’s powdered formula products.

59

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm	61
Consolidated Balance Sheets as of March 31, 2014 and 2013	62
Consolidated Statements of Operations for the fiscal years ended March 31, 2014, 2013 and 2012	63
Consolidated Statements of Comprehensive Income (Loss) for the fiscal years ended March 31, 2014, 2013 and 2012	64
Consolidated Statements of Equity for the fiscal years ended March 31, 2014, 2013 and 2012	65
Consolidated Statements of Cash Flows for the fiscal years ended March 31, 2014, 2013 and 2012	66
Notes to Consolidated Financial Statements	67
Schedule I – Financial Information of Parent Company	87
Schedule II – Valuation and Qualifying Accounts	91

60

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Synutra International, Inc.:

We have audited the accompanying consolidated balance sheets of Synutra International, Inc. and subsidiaries (the "Company") as of March 31, 2014 and 2013, and the related consolidated statements of operations and comprehensive income (loss), equity, and cash flows for each of the three years in the period ended March 31, 2014 and financial statement schedules. These financial statements and financial statement schedules are the responsibility of the Company's management. Our responsibility is to express an opinion on the financial statements and financial statement schedules based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of the Company at March 31, 2014 and 2013, and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2014, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, such financial statement schedules, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly, in all material respect, the information set forth therein.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company's internal control over financial reporting as of March 31, 2014, based on the criteria established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated June 16, 2014 expressed an unqualified opinion on the Company's internal control over financial reporting.

/s/ Deloitte Touche Tohmatsu Certified Public Accountants LLP

Shanghai, China

June 16, 2014

61

SYNUTRA INTERNATIONAL, INC.

CONSOLIDATED BALANCE SHEETS

(Dollars and shares in thousands, except per share data)

	March 31, 2014			March 31, 2013
ASSETS
Current Assets:
Cash and cash equivalents	$	90,915		$	79,050
Restricted cash		67,211			68,410
Accounts receivable, net of allowance of $2,851 and $7,515, respectively		17,763			30,183
Inventories		83,986			87,707
Due from related parties		3,109			2,696
Income tax receivable		244			5
Prepayments, tax receivables and others		22,028			18,404
Total current assets		285,256			286,455
Property, plant and equipment, net		145,833			130,121
Land use rights, net		10,957			10,829
Intangible assets, net		4,270			4,135
Restricted cash		100,533			39,883
Due from related parties		2,355			2,981
Other assets		1,479			1,740
TOTAL ASSETS	$	550,683		$	476,144
LIABILITIES AND EQUITY
Current Liabilities:
Short-term debt	$	115,917		$	127,449
Long-term debt due within one year		91,505			82,663
Accounts payable		39,616			48,717
Due to related parties		1,556			1,862
Advances from customers		15,692			12,982
Other current liabilities		45,980			52,788
Total current liabilities		310,266			326,461
Long-term debt		160,533			102,164
Deferred government subsidy		4,247			4,402
Capital lease obligations		7,898			7,848
Other long-term liabilities		6,483			6,062
Total liabilities		489,427			446,937
Commitments and Contingencies (Note15C)
Equity:
Common stockholders’ equity:
Common stock, $.0001 par value: 250,000 authorized; 57,301 and 57,301 issued and outstanding at March 31, 2014 and 2013, respectively		6			6
Additional paid-in capital		135,440			135,440
Accumulated deficit		(104,579	)		(135,508	)
Accumulated other comprehensive income		30,529			28,828
Total common stockholders’ equity		61,396			28,766
Noncontrolling interest		(140	)		441
Total equity		61,256			29,207
TOTAL LIABILITIES AND EQUITY	$	550,683		$	476,144

The accompanying notes are an integral part of the consolidated financial statements.

62

SYNUTRA INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in thousands, except per share data)

	Year Ended March 31,
	2014			2013			2012
Net sales	$	370,534		$	265,770		$	342,539
Cost of sales		217,027			171,211			201,618
Gross profit		153,507			94,559			140,921
Selling and distribution expenses		53,710			51,005			49,628
Advertising and promotion expenses		32,912			35,176			30,035
General and administrative expenses		25,506			30,220			23,948
Impairment of long-lived assets		1,040			0			0
Gain on disposal and liquidation of subsidiaries		367			3,625			0
Government subsidies		924			4,217			5,484
Income (loss) from operations		41,630			(14,000	)		42,794
Interest expense		16,162			15,018			14,276
Interest income		4,658			2,326			1,870
Other income (expense), net		352			(343	)		146
Income (loss) before income tax expense		30,478			(27,035	)		30,534
Income tax expense		130			37,186			13,510
Net income (loss)		30,348			(64,221	)		17,024
Net income (loss) attributable to the noncontrolling interest		(581	)		(333	)		287
Net income (loss) attributable to common stockholders	$	30,929		$	(63,888	)	$	16,737
Weighted average common stock outstanding – basic and diluted		57,301			57,301			57,301
Earnings (loss) per share – basic and diluted	$	0.54		$	(1.11	)	$	0.29

The accompanying notes are an integral part of the consolidated financial statements.

63

SYNUTRA INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Dollars in thousands)

	Year Ended March 31,
	2014			2013			2012
Net income (loss)	$	30,348		$	(64,221	)	$	17,024
Other comprehensive income (loss), net of tax
Currency translation adjustment		1,701			(234	)		4,014
Reclassification of currency translation adjustments realized upon disposal and liquidation of subsidiaries		0			(3,141	)		0
Other comprehensive income (loss)		1,701			(3,375	)		4,014
Comprehensive income (loss)		32,049			(67,596	)		21,038
Less: Comprehensive income (loss) attributable to noncontrolling interest		(581	)		(335	)		304
Comprehensive income (loss) attributable to common stockholders	$	32,630		$	(67,261	)	$	20,734

The accompanying notes are an integral part of the consolidated financial statements.

64

SYNUTRA INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(Dollars and shares in thousands)

	Synutra International, Inc. Stockholders’ Equity
	Common Stock
	Shares		Amount		Additional paid-in capital		Retained earnings (accumulated deficit)			Accumulated other comprehensive income			Noncontrolling Interest			Total equity
Balance, March 31, 2011		57,301		6		135,440		(88,357	)		28,204			633			75,926
Net income		0		0		0		16,737			0			287			17,024
Other comprehensive income, net of tax of nil		0		0		0		0			3,997			17			4,014
Other		0		0		0		0			0			128			128
Balance, March 31, 2012		57,301		6		135,440		(71,620	)		32,201			1,065			97,092
Net loss		0		0		0		(63,888	)		0			(333	)		(64,221	)
Other comprehensive income, net of tax of nil		0		0		0		0			(3,373	)		(2	)		(3,375	)
Derecognition of noncontrolling interest upon liquidation of a subsidiary		0		0		0		0			0			(381	)		(381	)
Other		0		0		0		0			0			92			92
Balance, March 31, 2013		57,301	$	6	$	135,440	$	(135,508	)	$	28,828		$	441		$	29,207
Net income (loss)		0		0		0		30,929			0			(581	)		30,348
Other comprehensive income, net of tax of nil		0		0		0		0			1,701			0			1,701
Balance, March 31, 2014		57,301	$	6	$	135,440	$	(104,579	)	$	30,529		$	(140	)	$	61,256

The accompanying notes are an integral part of the consolidated financial statements.

65

SYNUTRA INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

	Year Ended March 31,
	2014			2013			2012
Operating activities:
Net income (loss)	$	30,348		$	(64,221	)	$	17,024
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		15,356			14,976			11,751
Bad debt expense (reversal)		(3,193	)		2,423			3,386
Inventory write down		6,487			12,452			8,816
Impairment of long-lived assets		1,040			0			0
Deferred income tax		0			36,550			13,834
Gain on disposal and liquidation of subsidiaries		(367	)		(3,625	)		0
Other		35			337			398
Changes in assets and liabilities:
Accounts receivable		16,045			6,698			3,884
Inventories		(1,243	)		(24,476	)		(14,501	)
Due from related parties		(444	)		9,604			419
Prepaid land use right		(181	)		(824	)		(4,358	)
Prepayments, tax receivables and others		(3,184	)		(2,602	)		(2,851	)
Other assets		221			(2,341	)		(2,602	)
Accounts payable		(8,729	)		(16,075	)		10,882
Due to related parties		(301	)		(189	)		1,562
Advances from customers		2,488			6,954			964
Income tax receivable		(239	)		221			14
Other current and noncurrent liabilities		(7,914	)		18,394			17,047
Net cash provided by (used in) operating activities		46,225			(5,744	)		65,669
Investing activities:
Acquisition of property, plant and equipment		(29,582	)		(16,115	)		(27,323	)
Change in restricted cash		(57,861	)		(56,450	)		(11,738	)
Proceeds from assets disposal		111			1,565			747
Proceeds from disposal of subsidiaries		633			988			0
Net cash provided by (used in) investing activities		(86,699	)		(70,012	)		(38,314	)
Financing activities:
Proceeds from short-term debt		181,315			309,115			206,738
Repayment of short-term debt		(194,730	)		(268,901	)		(250,743	)
Proceeds from long-term debt		176,919			111,208			95,729
Repayment of long-term debt		(111,890	)		(60,446	)		(64,263	)
Payment on capital lease obligations		(842	)		(1,044	)		(333	)
Payment to holders of noncontrolling interest upon liquidation of a subsidiary		0			(386	)		0
Net cash provided by (used in) financing activities		50,772			89,546			(12,872	)
Effect of exchange rate changes on cash and cash equivalents		1,567			467			1,569
Net change in cash and cash equivalents		11,865			14,257			16,052
Cash and cash equivalents, beginning of year		79,050			64,793			48,741
Cash and cash equivalents, end of year	$	90,915		$	79,050		$	64,793
Supplemental cash flow information:
Interest paid	$	17,323		$	12,779		$	13,547
Income tax paid		499			606			83
Non-cash investing and financing activities:
Purchase of property, plant and equipment included in accounts payable	$	5,442		$	6,640		$	5,178
Purchase of intangible assets by offsetting accounts receivable		0			0			1,209

The accompanying notes are an integral part of the consolidated financial statements.

66

SYNUTRA INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. ORGANIZATION AND PRINCIPAL ACTIVITIES

Synutra International, Inc. and its subsidiaries (hereinafter collectively referred to as the “Company” or “Synutra”) are principally engaged in production, distribution and sales of dairy based nutritional products under the “Shengyuan” or “Synutra” line of brands in the People’s Republic of China (“China” or “PRC”). The Company focuses on selling powdered formula products for infant and adult, and also engages in other nutritional product offerings, such as prepared foods and certain nutritional ingredients and supplements.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Basis of presentation

The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. Under that assumption, it is expected that assets will be realized and liabilities will be satisfied in the normal course of business.

As of March 31, 2014, the Company has an asset liability ratio of 89%, which is defined as total liabilities divided by total assets, and negative working capital of $25.0 million. However, the Company regards the going concern assumption as appropriate considering the following mitigating factors:

· The Company managed to reverse the trend contributing to losses incurred in first half of fiscal 2013 by six consecutive quarters of income from operations;

· The Company had positive cash flows from operations since the second half of fiscal 2013. The Company believes that its cash flows from operations will be sufficiently positive for the next twelve months to satisfy its obligations when they fall due; and

· As of March 31, 2014, the Company had an unused credit facility of $68.3 million which could be used when purchasing materials and the purchased inventory is used as pledge. The facility is not unconditionally committed as the bank may refuse to fund if there is a material adverse change to the Company’s operations. However, for normal operational needs, it provides a backup source of liquidity.

Based on the above factors, management believes that adequate sources of liquidity will exist to fund the Company’s working capital and capital expenditure requirements, and to meet its short term debt obligations, other liabilities and commitments as they become due. Accordingly, management believes the Company will be able to realize its assets and satisfy its liabilities in the normal course of business.

B. Basis of consolidation

The consolidated financial statements include the financial statements of Synutra International, Inc. and its subsidiaries, its consolidated variable interest entity, Beijing Shengyuan Huimin Technology Service Co., Ltd. (the variable interest entity, or "VIE"), in which it has a controlling financial interest. A controlling financial interest is typically determined when a company holds a majority of the voting equity interest in an entity. US GAAP provides guidance on the identification and financial reporting for entities over which control is achieved through means other than voting interests, which requires certain VIEs to be consolidated by the primary beneficiary of the entity if the equity investors in the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties.  Through the contractual arrangements between the Company and the VIE, the Company controls the operating activities and holds all the beneficial interests of the VIE and has been determined to be the primary beneficiary of the VIE. The Company has concluded that such contractual arrangements are legally enforceable. The operations associated with the consolidated VIE are insignificant and hold de minimis assets and liabilities.

Net income or loss of a subsidiary is attributed to the Company and to the noncontrolling interests either on the basis of relative ownership interest or in accordance with contractual agreements that specify a different allocation, such as in the case of VIE. Noncontrolling interests in subsidiaries are presented separately from the Company's equity therein.

67

C. Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.  Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, inventory valuation, accrued consumer loyalty program obligations, sales rebates, the useful lives of and impairment for property and equipment, impairment of indefinite lived intangible assets, valuation allowance for deferred tax assets and provision for uncertain tax position.

D. Cash and cash equivalents

Cash and cash equivalents consist of cash on hand and highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less when purchased.

E. Restricted cash

Restricted cash are bank demand deposits used as security against letter of credits, bank acceptance bills and short-term and long-term borrowings.

F. Accounts receivable

Accounts receivable are recognized and carried at the original invoice amount less allowance for any uncollectable amounts. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. The Company performs risk assessments for each customer, and provides a specific allowance for those deemed to have high risk of collectability. The Company also records provision for other customers without specific risks by reviewing the aging of the receivables. Bad debts are written off as incurred.

G. Inventories

Inventories are stated at the lower of cost or market. Cost is calculated on the weighted-average basis and includes all costs to acquire and other costs incurred in bringing the inventories to their present location and condition. The Company evaluates the market for its inventories on a regular basis and records a provision for loss to reduce the computed weighted-average cost if it exceeds market. Potential losses from obsolete and slow-moving inventories are recorded when identified.

H. Property, plant and equipment, net

Property, plant and equipment are carried at cost. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized.

When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or, when applicable, the life of the lease, whichever is shorter. The useful lives for property, plant and equipment are as follows:

Buildings and renovations	20 - 40 years
Plant and machinery	5 - 10 years
Office equipment and furnishings	3 - 5 years
Motor vehicles	5 years
Others	5 years

I. Leases

Leases are classified as capital or operating leases. A lease that transfers to the lessee substantially all the benefits and risks incidental to ownership is classified as a capital lease. At inception, a capital lease is recorded at present value of minimum lease payments or the fair value of the asset, whichever is less. Assets under capital leases are amortized on a basis consistent with that of similar fixed assets or the lease term, whichever is shorter. Operating lease costs are recognized on a straight-line basis over the lease term.

J. Construction in progress

Construction in progress represents direct costs of construction or acquisition and design fees incurred. Capitalization of these costs ceases and the construction in progress is transferred to property, plant and equipment when substantially all the activities necessary to prepare the assets for their intended use are completed. No depreciation is provided until it is completed and ready for intended use.

No interest was capitalized for the fiscal year ended March 31, 2014, 2013 and 2012.

K. Impairment of long-lived assets

The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When these events occur, the Company measures impairment by comparing the carrying amount of the assets to future undiscounted net cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss based on the fair value of the assets.

68

L. Impairment of indefinite lived intangible assets

Intangible assets with an indefinite life are tested for impairment on an annual basis or when current facts or circumstances indicate that a potential impairment may exist. The impairment test consists of a comparison of the fair value of the intangible asset to its carrying amount. If the carrying amount exceeds the fair value, an impairment loss is recognized equal in amount to that excess.

Management performs its annual impairment test for intangible assets with indefinite life on March 31. In fiscal year ended March 31, 2014, 2013 and 2012, no intangible assets were impaired.

M. Income taxes

Current income taxes are provided for in accordance with the laws and regulations applicable to the Company as enacted by the relevant tax authorities. Income taxes are accounted for under the asset and liability method. Deferred taxes are determined based upon differences between the financial reporting and tax bases of assets and liabilities at currently enacted statutory tax rates for the years in which the differences are expected to reverse. Net operating losses are carried forward and credited by applying enacted statutory tax rates applicable to future years. A valuation allowance is provided on deferred tax assets to the extent that it is more likely than not that such deferred tax assets will not be realized. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on the characteristics of the underlying assets and liabilities, or the expected timing of their use when they do not relate to a specific asset or liability.

The Company recognizes the impact of an uncertain income tax position at the largest amount that is more-likely-than not to be sustained upon audit by the relevant tax authority. Income tax related interest and penalties is classified as income tax expense.

N. Foreign currency translation

The functional currency and reporting currency of Synutra International, Inc. and Synutra Illinois are United States Dollar (“US Dollar”).

The financial records of the Company’s PRC subsidiaries are maintained in Renminbi (“RMB”), and the financial records of the Company’s Netherland and French subsidiaries are maintained in Euro (“EUR”), which are their functional currencies. Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of the consolidated statements of comprehensive income (loss).

Monetary assets and liabilities denominated in currencies other than the functional currencies are translated into functional currencies at the rates of exchange ruling at the balance sheet date. Transactions in currencies other than the functional currencies during the year are converted into the functional currencies at the applicable rates of exchange prevailing on the day transactions occurred. Transaction gains and losses are recognized in the statement of operations. Transaction gains or losses were $1.9 million gain, $0.8 million gain, and $1.2 million gain for the year ended March 31, 2014, 2013 and 2012, respectively and are recorded in other income (expense), net.

69

O. Revenue recognition

The Company recognizes revenue when title and risk and rewards for the products are transferred to the customer, price is fixed or determinable, and collectability is reasonably assured. At the time of sale, the Company also records estimates for a variety of sales deductions, including value added taxes, rebates, discounts and incentives, trade promotions and product returns. Sales deductions are reported as a reduction of revenue. Most of the Company’s powdered formula product sales are made through distributors. Under the distributor arrangement, evidenced by purchase order, revenue is realized and earned upon acceptance of delivery of products by the distributors. The revenue recognition of My Angel series, which is directly sold to baby stores, is similar to that of distributor sales, and the revenue is realized and earned upon acceptance of delivery of products by the baby stores. For sales to a limited number of distributors from whom collectability is not reasonably assured, revenue is recognized when the Company received payments.

A small fraction of the Company’s powdered formula product sales are through supermarket retailers directly. The Company’s revenue arrangement with some of these retailers includes a right of return clause, so the Company recognizes revenue when the supermarkets have paid the Company.

The Company’s gross sales are subject to various deductions, primarily comprised of rebates and discounts to distributors and retailers. These deductions represent estimates of the related obligations, requiring the use of judgment when estimating the impact of these sales deductions on gross sales for a reporting period. The Company reports these adjustments as a reduction of gross sales to arrive at net sales.

The Company provides discounts or rebates to customers in the following ways:

●  The Company offers product discounts to compensate certain distributors for promotional expenses and slotting fees paid by them. These distributors are responsible for organizing local promotional activities and paying slotting fees to retail outlets within their sales territory, and providing the Company with documentation of their expenditures, which would be recorded as product discounts and a reduction of the receivable from distributors in the applicable month.

●  The Company offers rebates to other distributors and supermarket retailers as sales incentives. These rebate programs provide that distributors and supermarket retailers receive a rebate after attaining certain amount of orders relating to specific products. Since rebates are contractually agreed upon, the Company estimates rebates based on the specific terms in each agreement and anticipated performance for the current year. The Company considers the sales performance of products subject to rebates and applicable rebate rate, and adjusts the provision periodically to reflect actual experience. Actual amounts may differ if actual performance varies from estimates. The Company records rebates as a reduction of revenues in the year in which these programs are offered.

Slotting fees and estimated sales returns due to package damage are also deductions from gross sales:

●  For product sales made directly to supermarket retailers, certain slotting fees, such as shelf display, end-cap placement, bar-coding, banner advertising, are paid to the supermarket retailers. These slotting fees are deducted from revenues.

●  The Company records a provision for estimated sales returns due to package damage. The sales return amount represents management’s best estimates based on the available information at the time of estimate.

70

P. Shipping and handling costs

Shipping and handling costs are expensed as incurred and outbound freight is not billed to customers. Shipping and handling costs are included in selling and distribution expenses. The costs were $4.6 million, $3.9 million and $5.3 million for the fiscal years ended March 31, 2014, 2013 and 2012, respectively.

Q. Advertising and promotion expenses

Advertising and promotion expenses are expensed as incurred The service charge of the consumer loyalty program administrated by a third party was $3.2 million, $2.6 million and $1.6 million for the fiscal year ended March 31, 2014, 2013 and 2012, respectively. We reclassified the fiscal year 2013 and 2012 figure from selling and distribution expenses to advertising and promotion expenses to ensure comparability.

R. Government subsidies

Government subsidies for revenue and/or expenses should be recognized in income when the related revenue and/or expense are recorded. Government subsidies related to property, plant and equipment are deferred and amortized in a manner consistent with the depreciation expense of the related assets over the useful lives of these assets. Government subsidies relating to specific borrowings are recorded as an offset to the interest expense over the term of these borrowings. Unrestricted government subsidies from local governmental agencies allowing the Company full discretion in the fund utilization were $0.9 million, $4.2 million and $5.5 million for the fiscal years ended March 31, 2014, 2013 and 2012, respectively, which were recorded in government subsidy in the consolidated statements of operations. In the fiscal year ended March 31, 2014, a local government provided a subsidy of $4.7 million which was recorded as a deduction of advertising and promotion expenses, as the subsidy was restricted for promotion expense purposes.

S. Employee’s benefits

Mandatory contributions are made to the government’s health, retirement benefit and unemployment schemes at the statutory rates in force during the period, based on gross salary payments. The cost of these payments is charged to the consolidated statements of operations in the same period as the related salary cost.

T. Earnings (loss) per share

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to holders of common stock by the weighted average number of common stock outstanding during the year.  Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Common stock equivalents are excluded from the computation in loss periods and in periods when the average market price of the common stock exceeds the exercise price of the securities or other contracts to issue common stocks as their effects would be anti-dilutive.

U. Comprehensive income (loss)

Comprehensive income (loss) is defined to include all changes in equity of the Company during a period from transactions and other events and circumstances except those resulting from investments by owners and distributions to owners, including currency translation adjustment.

V. Concentration of credit risk

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents, restricted cash, accounts receivable, due from related parties, prepaid expenses and other current assets and other assets. All of the Company’s cash and cash equivalents and restricted cash are held with financial institutions that the Company believes to be high credit quality.

W. Noncontrolling interest

The noncontrolling interest represents the portion of the equity interest in the subsidiaries, Meitek, not directly or indirectly attributable to the Company. The noncontrolling interest reported as equity in the consolidated financial statements, it also reported the consolidated net income at amounts that include the amounts attributable to both the parent and the noncontrolling interest on the face of the consolidated statements of operations and consolidated statements of comprehensive income (loss).

71

X. Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. The fair value measurement guidance provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows:

Level 1 inputs are unadjusted quoted prices in active markets for identical assets that the management has the ability to access at the measurement date.

Level 2 inputs include quoted prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 inputs include unobservable inputs to the valuation methodology that reflect management’s assumptions about the assumptions that market participants would use in pricing the asset. The management develops these inputs based on the best information available, including their own data.

Y. Financial Instruments

The carrying value of financial instruments including cash and cash equivalents, restricted cash, accounts receivable, other current assets, other assets, accounts payable, short-term debt, long-term debt due within one year, other current liabilities and due to and from related parties, approximates their fair value at March 31, 2014 due to the relatively short-term nature of these instruments. The carrying value of long-term debt, capital lease obligations and other long-term liabilities approximates its fair value as their interest rates are at the same level of the current market yield for comparable loans.

Z. Recently issued accounting pronouncements

In April 2014, the FASB issued Accounting Standards Update 2014-08 - Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which amends to change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in the ASU are effective for disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. Early adoption is permitted. The adoption of this ASU is not expected to have a significant effect on the Company’s consolidated financial statements.

72

3. FAIR VALUE MEASUREMENTS

The following table sets forth by level, within the fair value hierarchy, the Company’s assets and liabilities accounted for at fair value on a nonrecurring basis as of March 31, 2014. The Company did not have any items recorded at fair value on a nonrecurring basis as of March 31, 2013. The Company did not have any items recorded at fair value on a recurring basis subsequent to initial recognition as of March 31, 2014 and 2013.

Description	Amount		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)		Total Loss
March 31, 2014:		(In thousands)
Long-lived assets held and used
- Food segment	$	3,605			$	3,605	$	1,040

The Company tested the recoverability of long-lived assets of the food segment, as the food segment incurred current-period operating and cash flow loss combined with a history of operating and cash flow loss. In accordance with the provisions of ASC No.360, Property, Plant and Equipment, certain long-lived assets of Inner Mongolia Huiliduo Food Co., Ltd. (“Huiliduo”) with a carrying amount of $4.6 million were written down to their fair value of $3.6 million, resulting in a loss of $1.0 million, which was included in the impairment of long-lived assets of the food segment for the fiscal year ended March 31, 2014. The fair value of assets was estimated using direct comparison method under the market approach. The direct comparison method is a set of procedures in which a value indication is derived by comparing the second-hand market quotations of the similar assets. The Company has categorized this as a level 3 fair value measurement.

4. INVENTORIES

The Company’s inventories at March 31, 2014 and 2013 are summarized as follows:

(In thousands)	March 31, 2014		March 31, 2013
Raw materials	$	44,981	$	56,607
Work-in-progress		12,342		17,023
Finished goods		26,663		14,077
Total	$	83,986	$	87,707

The value of goods-in-transit included in raw materials was $11.4 million and $15.9 million as of March 31, 2014 and 2013, respectively, which mainly represented the purchase of milk powder and whey protein from international sources.

The Company recorded lower of cost or market provisions for inventory of $6.5 million, $12.5 million and $8.8 million for the years ended March 31, 2014, 2013, and 2012, respectively.

5. RELATED PARTIES AND RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities.

The following entities are considered to be related parties to the Company because they are affiliates of the Company under the common control of the Company’s major shareholder. These related parties act only as the Company’s suppliers or distributors and there are no other relationships wherein the Company has the ability to exercise control or significant influence over the operating and financial policies of these parties. The Company is not obligated to provide any type of financial support to these related parties. The nature of each entity is discussed in the table below:

73

Related Party	Business Nature
Sheng Zhi Da Dairy Group Corporation (“Sheng Zhi Da”)	Engages in buying and selling packaging materials, vitamin and mineral pre-mixes, and other food ingredients.
Beijing Kelqin Dairy Co. Ltd. (“Kelqin”)	Produces and distributes retail-packaged yogurt products in Beijing. Kelqin was sold to a third party in April 2013, and was no longer considered a related party from that date.
St. Angel (Beijing) Business Service Co., Ltd. (“St. Angel (Beijing) Business Service”)	Engages in distribution of the Company's powdered formula products.
Beijing St. Angel Cultural Communication Co., Ltd. (“St. Angel Cultural Communication”)	Engages in television designing and programming.
Beijing Honnete Dairy Co., Ltd. (“Honnete Beijing”)	Engages in importing and distributing whey protein products to commercial customers.
Qingdao Lvyin Waste Disposal Investment Management Co., Ltd. (“Lvyin”)	Engages in waste disposal and sewage treatment activities.
Beijing Dongan Hengxin Property Development Co., Ltd. (“Dongan Hengxin”)	Engages in property development activities.
Beijing Ao Naier Feed Stuff Co., Ltd. (“Ao Naier”)	Engages in feed processing activities.

A. Related party balances

a. Due from related parties, including current and non-current portion

(In thousands)	March 31, 2014		March 31, 2013
Sheng Zhi Da Dairy Group Corporation	$	1,918	$	1,882
Beijing Honnete Dairy Co., Ltd.		2		0
St. Angel (Beijing) Business Service Co. Ltd.		3,451		3,132
Beijing St. Angel Cultural Communication Co., Ltd.		6		0
Beijing Ao Naier Feed Stuff Co., Ltd.		87		663
Total	$	5,464	$	5,677

b. Due to related parties

(In thousands)	March 31, 2014		March 31, 2013
Sheng Zhi Da Dairy Group Corporation	$	876	$	1,107
Beijing Honnete Dairy Co., Ltd.		478		495
Beijing Kelqin Dairy Co. Ltd.		*		6
Beijing St. Angel Cultural Communication Co., Ltd.		202		254
Total	$	1,556	$	1,862

* Kelqin had become a third party since April 2013.

The Company had certain related party borrowings which were recorded in long-term debt due within one year as of March 31, 2013. See Note 10. The amount due to and due from related parties were unsecured and interest free.

74

B. Sales to and services for related parties 

In the fiscal year ended March 31, 2014, the Company’s sales to related parties mainly included feed grade milk powder and whey powder to Ao Naier, and powdered formula products to St. Angel (Beijing) Business Service, and services for related parties including office spaces rented to Honnete Beijing, Ao Naier, St. Angel (Beijing) Business Service, and St. Angel Cultural Communication. In the fiscal year ended March 31, 2013, the Company’s sales to related parties mainly included whey protein powder to Honnete Beijing, feed grade milk powder to Ao Naier, and powdered formula products to St. Angel (Beijing) Business Service, and services for related parties represent office spaces rented to Honnete Beijing, Ao Naier and St. Angel (Beijing) Business Service. In the fiscal year ended March 31, 2012, the Company’s sales to related parties included whey protein to Honnete Beijing, powdered formula products to St. Angel (Beijing) Business Service, feed grade milk powder and whey protein to Ao Naier and chondroitin sulfate to Lvyin.

	Year Ended March 31,
(In thousands)	2014		2013		2012
Beijing Honnete Dairy Co., Ltd.	$	8	$	775	$	1,242
St. Angel (Beijing) Business Service Co., Ltd.		1,780		2,470		9,861
Beijing Ao Naier Feed Stuff Co., Ltd.		524		293		693
Beijing St. Angel Cultural Communication Co., Ltd.		17		0		0
Qingdao Lvyin Waste Disposal Investment Management Co., Ltd.		0		0		1
Total	$	2,329	$	3,538	$	11,797

Sales of powdered formula products from independent distributors to St. Angel (Beijing) Business Service were nil, nil and $7.5 million for the fiscal year ended March 31, 2014, 2013 and 2012, respectively, which were not included in the above transaction amount.

C. Purchases from related parties

In the fiscal year ended March 31, 2014, St. Angel Cultural Communication implemented certain marketing activities for the Company. In the fiscal year ended March 31, 2013, major transactions included (i) the Company purchased Lactose from Honnete Beijing, and (ii) St. Angel Cultural Communication implemented certain marketing activities for the Company. In the fiscal year ended March 31, 2012, the Company’s purchases from related parties mainly included catalogues, brochures, and marketing materials from St. Angel Cultural Communication.

	Year Ended March 31,
(In thousands)	2014		2013		2012
Beijing Honnete Dairy Co., Ltd.	$	0	$	4,674	$	0
Beijing Kelqin Dairy Co., Ltd.*		0		11		0
Beijing St. Angel Cultural Communication Co., Ltd.		460		577		339
Total	$	460	$	5,262	$	339

* Kelqin had become a third party since April 2013.

75

6. PREPAYMENTS, TAX RECEIVABLES AND OTHERS

(In thousands)	March 31, 2014		March 31, 2013
Tax receivables	$	9,287	$	10,051
Prepayments		6,821		2,126
Interest receivable		2,193		2,221
Prepaid expense		2,209		1,129
Other		1,518		2,877
Total	$	22,028	$	18,404

7. PROPERTY, PLANT AND EQUIPMENT, NET

(In thousands)	March 31, 2014		March 31, 2013
Property, plant and equipment, cost:
Capital lease of building	$	5,744	$	5,637
Buildings and renovations		86,769		84,502
Plant and machinery		88,007		84,559
Office equipment and furnishings		11,507		10,809
Motor vehicles		3,452		3,180
Others		1,103		918
Total cost	$	196,582	$	189,605
Less: Accumulated depreciation:
Capital lease of building		813		625
Buildings and renovations		17,986		15,750
Plant and machinery		48,942		40,396
Office equipment and furnishings		6,400		4,190
Motor vehicles		2,491		2,212
Others		637		511
Total accumulated depreciation		77,269		63,684
Construction in progress		26,520		4,200
Property, plant and equipment, net	$	145,833	$	130,121

Construction in progress represents construction and equipment purchase for the French subsidiary and mainland China subsidiaries as of March 31, 2014, and leasehold improvements and manufacturing equipment as of March 31, 2013.

The Company recorded depreciation expense for owned assets and capital leased assets of $15.1 million, $14.7 million and $11.6 million for the fiscal years ended March 31, 2014, 2013 and 2012, respectively.

76

8. LAND USE RIGHTS, NET

There is no private land ownership in China. Companies or individuals are authorized to possess and use the land only through land use rights granted by the PRC government. Land use rights are amortized using the straight-line method over the lease term of 42 to 50 years.

(In thousands)	March 31, 2014		March 31, 2013
Land use rights, cost	$	12,376	$	11,967
Less: Accumulated amortization		1,419		1,138
Land use rights, net	$	10,957	$	10,829

The Company recorded amortization expense of $258,000, $239,000 and $180,000 for the fiscal years ended March 31, 2014, 2013 and 2012, respectively.

9. INTANGIBLE ASSETS, NET

(In thousands)	March 31, 2014		March 31, 2013
Registered trademark (indefinite life)
Gross and net carrying amount	$	4,270	$	4,135

The intangible assets as of March 31, 2014 represent $3.1 million for registered trademark of Dutch Cow and $878,000 for registered trademark of Ausmeadow, which are used for the Company’s powdered formula products; and $337,000 for registered trademark of Huiliduo, which is used for the foods products. The intangible assets as of March 31, 2013 represent $2.9 million for registered trademark of Dutch Cow and $862,000 for registered trademark of Ausmeadow, which are used for the Company’s powdered formula products; and $331,000 for registered trademark of Huiliduo, which is used for the foods products.

77

10. DEBT

As of March 31, 2014 and 2013, the Company had short-term debt from banks in the amount of $115.9 million and $127.4 million, respectively.  The maturity dates of the short-term debt outstanding range from April 2014 to March 2015. The weighted average interest rate on short-term debt outstanding at March 31, 2014 and 2013 was 4.9% and 3.8%, respectively. Certain portion of these debts use floating interest rates, which are calculated based on the benchmark lending interest rate published by China’s central bank or on LIBOR. The short-term debt at March 31, 2014 and 2013 were secured by the pledge of certain inventory purchased under letter of credit of nil and $26.4 million, respectively; the pledge of certain fixed assets totaling $5.3 million and $13.4 million, respectively; the pledge of the Company’s land use right of $3.9 million and $5.4 million, respectively; and the pledge of restricted cash deposits of $17.0 million and $33.0 million, respectively.

As of March 31, 2014 and 2013, the Company had long-term debt, including current portion, from banks in the amount of $252.0 million and $184.8 million, respectively. The maturity dates of the long-term debt outstanding range from May 2014 to February 2016. The weighted average interest rate of outstanding long-term debt at March 31, 2014 and 2013 was 4.6% and 5.6%, respectively. Certain portion of these debts use floating interest rates, which are calculated based on the benchmark lending interest rate published by China’s central bank or on LIBOR. The indebtedness at March 31, 2014 and 2013 was secured by the pledge of certain fixed assets of nil and $15.3 million, respectively; the pledge of land use right of nil and $1.2 million, respectively; and the pledge of restricted cash deposits of $82.0 million and $41.2 million, respectively.

In the year ended March 31, 2014, the Company had repaid a long-term loan from a related party of $2.9 million. The interest expense of related party loans for the year ended March 31, 2014 and 2013 were $215,000 and $286,000, respectively.

Maturities on long-term debt, including current and non-current portion, subject to mandatory redemption are as follows:

(In thousands)	Year Ending March 31,
2015	$	91,505
2016		160,533

The borrowings denominated in currencies other than RMB were $138.3 million and $129.2 million as of March 31, 2014 and 2013, respectively.

The Company has unused long term loan facilities for Synutra France of €64.5 million (equivalent to $88.7 million) with banks, with cash deposit of $16.3 million as a pledge which was recorded under restricted cash noncurrent portion as of March 31, 2014. These debts use floating interest rates, which are calculated based on LIBOR. The maturity periods of these debts range from 59 months to 8 years, commencing from the actual drawdown date.For €53.0 million of such loans, the bank has required preconditions which included obtaining the formal approval of environmental impact study. We expect to receive funding from the bank after the preconditions are met. As of March 31, 2014, none of the above facilities have been drawn down.

11. OTHER CURRENT LIABILITIES

(In thousands)	March 31, 2014		March 31, 2013
Accrued discount, rebate and slotting fee	$	18,911	$	21,314
Payroll and bonus payables		9,469		6,253
Accrued selling expenses		6,793		5,496
Accrued advertising and promotion expenses		5,593		12,034
Other tax payable		0		675
Accrued rental fee		366		1,461
Accrued interest expense		832		2,346
Others		4,016		3,209
Total	$	45,980	$	52,788

12. OBLIGATIONS UNDER CAPITAL LEASE

Future minimum capital lease payments at March 31, 2014 are as follows:

(In thousands)	Year Ending March 31,
2015	$	624
2016		624
2017		624
2018		624
2019		624
2020 and thereafter		16,436
Total minimum lease payments		19,556
Less:  Amount representing interest		11,559
Present value of minimum lease payments		7,997
Current		99
Long-term		7,898
Total	$	7,997

The Company recorded depreciation expense of $176,000, $92,000 and $144,000 for capital leased assets for the fiscal year ended March 31, 2014, 2013 and 2012, respectively, and recorded interest expense of $555,000, $201,000 and $548,000 for the fiscal year ended March 31, 2014, 2013 and 2012, respectively. The interest rates associated with the capital leases are from 6.8% to 7.83% per annum.

78

13. INCOME TAXES

A. Tax law of each tax jurisdiction

United States

Under the federal and state income tax laws of United States, the Company is subject to tax on its income or capital gains. The applicable rate is 34% for fiscal year 2014, 2013 and 2012.

Netherlands

The Company’s subsidiary incorporated in the Netherlands is subject to Netherland’s profit tax. The applicable rate is 20% on the first EUR 200,000 of taxable profits.  For taxable profits exceeding EUR 200,000, the applicable rate is 25% for fiscal year 2014, 2013 and 2012.

France

The Company's subsidiary in France is subject to profit tax at 33 1/3% on assessable income.

Hong Kong

The Company's subsidiary in Hong Kong is subject to profit tax at 16.5% on assessable income.

China

On March 16, 2007, the National People’s Congress of the PRC approved and promulgated the new Enterprise Income Tax Law (“EIT Law”), which took effect beginning January 1, 2008. Under the new EIT law, foreign investment enterprises and domestic companies are subject to a uniform tax rate of 25%. The new tax law provides a transition period from its effective date for certain qualifying enterprises which were established before the promulgation date of the new tax law and which were entitled to certain preferential lower tax rate or tax holiday under the then effective tax laws or regulations.

Some of the Company’s PRC subsidiaries are eligible under the transition rules to continue enjoying tax holidays or reduced tax rate until expiration. The following table illustrates the applicable tax rate and tax holidays of major PRC subsidiaries under the new EIT Law:

Name of Subsidiaries	Statutory Tax Rate Beginning January 1, 2008	Tax Holiday (based on calendar year)
Shengyuan Nutritional Food Co., Ltd.	25%	No tax holiday
Zhangjiakou Chahaer Dairy Co., Ltd.	25%	No tax holiday
Inner Mongolia Huiliduo Food Co., Ltd.	25%	12.5% (2011, 2012)
Inner Mongolia Mengyuan Food Co., Ltd.	25%	No tax holiday
Meitek Technology (Qingdao) Co., Ltd.	25%	12.5% (2011, 2012); high-tech enterprise at 15% (2014, 2015)
Beijing Shengyuan Huiliduo Food Technology Co., Ltd.	25%	No tax holiday
Beijing Shengyuan Huimin Technology Service Co., Ltd.	25%	No tax holiday
Global Food Trading (Shanghai) Co., Ltd.	25%	24% (2011), 25% (2012)

In accordance with the EIT Law, dividends which arise from profits of foreign invested enterprises (“FIEs”) earned after January 1, 2008 are subject to a 10% withholding tax. In addition, under the tax arrangement between the PRC and Hong Kong, if the foreign investor is incorporated in Hong Kong and qualifies as the beneficial owner, the applicable withholding tax rate is reduced from 10% to 5%, if the investor holds at least 25% in the FIE. A deferred tax liability should be recognized for the undistributed profits of PRC companies unless the Company has sufficient evidence to demonstrate that the undistributed dividends will be indefinitely reinvested. As of March 31, 2014, all earnings generated in countries/areas other than United States are intended to be indefinitely reinvested and as a result, the Company did not record any deferred tax liability on such undistributed earnings.

79

B. Components of income (loss) before income tax expense (benefit)

For financial reporting purposes, income (loss) before income tax expense (benefit) includes the following components:

	Year Ended March 31,
(In thousands)	2014			2013			2012
United States	$	1,232		$	(3,045	)	$	854
Netherlands		511			2,338			(30	)
France		(62	)		0			0
Hong Kong		(1,453	)		(866	)		2,808
PRC		30,250			(25,462	)		26,902
	$	30,478		$	(27,035	)	$	30,534

C. Reconciliation from the statutory income tax rate to reported amount of income tax expense (benefit)

The income tax expense (benefit) reconciled to the tax expense (benefit) computed at the US statutory rate was approximately as follows for the years ended March 31, 2014, 2013 and 2012:

	Year Ended March 31,
(In thousands)	2014			2013			2012
Income tax expense (benefit) at US federal statutory rate of 34%	$	10,364		$	(9,192	)	$	10,382
Foreign tax rate differential		(3,206	)		759			(2,593	)
PRC tax holiday effect		73			307			71
Change in valuation allowance		(7,597	)		46,700			2,984
Unrecognized tax benefits		(6	)		(191	)		(502	)
Effect of change in tax rate		754			(1,441	)		1,131
Nondeductible items		(252	)		244			2,037
Total income tax expense (benefit)	$	130		$	37,186		$	13,510

Some of the Company’s PRC subsidiaries are eligible for tax holidays. The impact of these tax holidays did not change PRC tax benefit for the fiscal year ended March 31, 2014 and 2013, and decreased PRC tax expense by $194,000 for the fiscal year ended March 31, 2012. The benefit of the tax holidays on basic and diluted earnings (loss) per share was nil, nil, and nearly zero for the fiscal years ended March 31, 2014, 2013 and 2012, respectively.

D. Deferred tax assets by type of temporary difference, credits and change in valuation allowance

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets are as follows:

(In thousands)	March 31, 2014			March 31, 2013
Deferred tax assets – current
Inventory write-down	$	1,099		$	1,377
Acquisition of assets under fair value		28			27
Net operating loss carryforward		7,469			11,659
Accrued expenses		1,760			677
Bad debt provision		1,004			2,184
Accrued rebate and sales discount		8,805			12,556
Others		1,515			1,250
Subtotal		21,680			29,730
Less: valuation allowance		(21,680	)		(29,730	)
Total	$	0		$	0
Deferred tax assets – non current
Net operating loss carryforward	$	15,279		$	25,487
Acquisition of assets under fair value		171			195
Long-lived assets write-down		851			506
Bad debt provision		571			959
Others		52			94
Subtotal		16,924			27,241
Less: valuation allowance		(16,924	)		(27,241	)
Total	$	0		$	0

80

The net change during the year in the total valuation allowance is as follows:

(In thousands)	March 31, 2014			March 31, 2013
Balance at beginning of year	$	56,971		$	13,589
Additions (releases) during the year		(18,341	)		46,700
Write-off		(26	)		(3,318	)
Balance at end of year	$	38,604		$	56,971

The Company considers positive and negative evidence to determine whether some portion or all of the deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of recent losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company’s experience with tax attributes expiring unused and tax planning alternatives. Valuation allowances have been established for deferred tax assets based on a more likely than not threshold. The Company’s ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carryforward periods provided for under the tax law. The Company considers the following possible sources of taxable income when assessing the realization of deferred tax assets:

- future reversals of existing taxable temporary differences;

-  further taxable income exclusive of reversing temporary differences and carryforwards.

At March 31, 2014, the net operating loss carryforward of Synutra Illinois and Synutra International, Inc., which file a consolidated tax return, is approximately $9.4 million, which will be available to offset future taxable income. If not used, the carryforwards will expire between 2028 and 2033. Subject to the federal income tax rate of 34%, the tax benefit is $3.2 million. Synutra Illinois and Synutra International, Inc. do not have enough profit in the foreseeable future to realize the tax benefit. As a result, the Company believes that it is more likely than not that the benefit from the net operating loss carryforward of Synutra Illinois and Synutra International, Inc. will not be realized. In recognizing this risk, the Company has fully provided a valuation allowance on the deferred tax assets of Synutra Illinois and Synutra International, Inc. The tax expenses relating to valuation allowance incurred for Synutra Illinois and Synutra International, Inc. was $0.5 million for fiscal year 2014. If or when recognized, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets at March 31, 2014 will be recognized as a reduction of income tax expense.

At March 31, 2014, the net operating loss carryforward of PRC subsidiaries is $73.2 million which expires in 2020 at the latest, and the deferred tax asset is $17.7 million. The Company believes that it is more likely than not that the benefit from the deferred tax assets of these PRC subsidiaries will not be realized. In recognizing this risk, the Company has fully provided a valuation allowance on the deferred tax assets of these PRC subsidiaries. The net tax benefits relating to the change of valuation allowance of PRC subsidiaries was $18.8 million for fiscal year 2014. If or when recognized, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets at March 31, 2014 will be further recognized as a reduction of income tax expense.

The Company disposed and liquidated certain subsidiaries in fiscal year 2014 and 2013. As a result, the Company derecognized deferred tax assets and released valuation allowance related to these subsidiaries.

E. Significant components of income tax expense

Income taxes for the PRC subsidiaries are calculated on a separate entity basis. Each of the Company’s PRC subsidiaries files stand-alone tax returns. The income tax expense for the fiscal years ended March 31, 2014, 2013 and 2012 are summarized as follows:

	Year Ended March 31,
(In thousands)	2014			2013			2012
Current tax
- Netherlands	$	67		$	89		$	68
- HK		28			0			0
- PRC		41			738			110
Subtotal		136			827			178
Uncertain tax benefit
- PRC		(6	)		(191	)		(502	)
Subtotal		(6	)		(191	)		(502	)
Deferred tax benefit
- PRC		0			36,550			13,834
Subtotal		0			36,550			13,834
Total	$	130		$	37,186		$	13,510

81

F. Uncertain tax positions

The Company made its assessment of the level of authority for each tax position (including the potential application of interests and penalties) based on the technical merits, and has measured the unrecognized benefits associated with the tax positions. These liabilities are recorded in other long term liabilities in the consolidated balance sheet. The Company recognizes the liability for unrecognized tax benefits, and the associated interest and penalties within the income tax expense line in the accompanying consolidated statement of operations. The Company believes that it is reasonably possible that approximately $272,000 of its currently other remaining unrecognized tax benefits, each of which are individually insignificant, may be recognized by the end of calendar year 2014 as a result of a lapse of the statute of limitations.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits for the years presented:

	March 31,
(In thousands)	2014			2013			2012
Balance at beginning of year	$	506		$	697		$	1,199
Additions in the current year		0			15			55
Release in the current year		(6	)		(206	)		(557	)
Balance at end of year	$	500		$	506		$	697

The reduction of the uncertain tax position of $206,000 in the fiscal year 2013 is related to the tax de-registration of a subsidiary, Heilongjiang Mingshan Dairy Co., Ltd. The balance of unrecognized tax benefits at March 31, 2014, if recognized, would affect the effective tax rate.

According to PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational errors made by the taxpayer or withholding agent. The statute of limitations will be extended to five years under special circumstances, which are not clearly defined (but an underpayment of tax liability exceeding RMB100,000 is specifically listed as a special circumstance). In the case of a related party transaction, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. The Company's PRC subsidiaries are therefore generally subject to examination by the PRC tax authorities from calendar year 2009 through 2013 on non-transfer pricing matters, and from calendar year 2004 through 2013 on transfer pricing matters. The statute of limitations in the US is generally three years.

14. EARNINGS (LOSS) PER SHARE

For purposes of calculating basic and diluted earnings per share, the Company used the following weighted average common stocks outstanding:

	Year Ended March 31,
(In thousands except for per share data)	2014		2013			2012
Net income (loss) attributable to common stockholders	$	30,929	$	(63,888	)	$	16,737
Weighted average common stock outstanding – basic and diluted		57,301		57,301			57,301
Earnings (loss) per share – basic and diluted	$	0.54	$	(1.11	)	$	0.29

The Company granted ABN AMRO Bank N.V., Hong Kong Branch (now known as The Royal Bank of Scotland N.V. ("RBS")) warrants to purchase 400,000 shares of common stock in connection with the RBS Loan in fiscal year 2008. These warrants were excluded from the computation of diluted earnings per share for all periods presented as they would be anti-dilutive. The warrant agreement expired on June 30, 2013.

82

15. COMMITMENTS AND CONTINGENCIES

A. Purchase commitments and Capital commitments

As of March 31, 2014, the Company had outstanding commitments of $571,000 for advertising purchases, and $11.9 million for milk powder and whey powder within the next twelve months. According to the French Project’s contracts with Sodiaal and Euroserum, the Company committed to purchase, and Sodiaal and Euroserum committed to sell, 288 million liters of milk per year for ten years, an amount of whey equivalent to 24,000 tons of 70% demineralized pre-concentrated dry whey extract per year for ten years, and 6,000 tons of 70% demineralized whey powder per year, or an equivalent quantity of liquid whey, for ten years, at market based prices at the time of purchase, to satisfy the production needs of the new drying facility. As the price of raw milk and whey for the next ten year cannot be predicted with precision, the commitment amount above excludes the raw milk and whey purchase commitment of the French Project.

As of March 31, 2014, the Company’s capital purchase commitments of $134.1 million mainly in relation to signed contracts for construction and manufacturing equipment for the French Project.

B. Operating lease commitments

The Company leases certain land use rights, office facilities and warehouses under non-cancellable operating leases. The operating lease commitments of the Company at March 31, 2014 are as follows:

(In thousands)	Year Ending March 31
2015	$	1,819
2016		1,715
2017		1,715
2018		1,715
2019		1,715
2020 and thereafter		48,937
Total	$	57,616

The operating lease expense for the fiscal year ended March 31, 2014, 2013 and 2012 were $2.0 million, $3.2 million and $1.3 million, respectively.

C. Contingencies

On September 17, 2012, the Company entered into a partnership framework agreement, a milk supply agreement, a whey supply agreement, a whey powder supply agreement, and a technical assistance agreement with Sodiaal Union, a French agricultural cooperative company (“Sodiaal”), and/or Euroserum SAS (“Euroserum”), a French subsidiary of Sodiaal, relating to a long-term industrial and commercial partnership between Sodiaal and the Company. Under these agreements, the Company undertakes to build a new drying facility (the “French Project”) in Carhaix, France, intended to manufacture powdered milk and fat-enriched demineralized whey. The Company has recently decided to add 50,000 tons of packaging and warehousing capacity for powdered formula products to the French Project. As a result, the updated estimated cost to build the facility is approximately Euro 136.0 million (equivalent to $187.0 million). Pursuant to the partnership framework agreement, the operational commissioning of the new drying facility will take place no later than January 2, 2015. In the event of a delay beyond January 2, 2015 and save for limited exceptions, the Company will undertake to compensate Sodiaal or Euroserum for losses which may be incurred as a result of such delay, depending on the circumstances. The loss incurred by Sodiaal or Euroserum in case of a delay of the operational commissioning of the new drying facility beyond January 2, 2015 shall amount to the loss of profits actually suffered, as the case may be, by Sodiaal or Euroserum under the milk supply agreement or the whey supply agreement.

We have unused long term loan facilities of €64.5 million (equivalent to $88.7 million) with banks, for €53.0 million of such loans, the bank has required preconditions which included obtaining the formal approval of an environmental impact study. In March 2014, we were informed that the environmental impact study resulted in a positive opinion and expect to obtain formal approval for the study around July 2014. Due to the delay in getting government approvals, we expect the operational commissioning of the new drying facility to take place in late calendar year 2015, which is later than the deadline of January 2, 2015 specified in the partnership framework agreement. The partnership framework agreement with Sodiaal provides that we will compensate Sodiaal for their losses due to delays in the start of the operation of our project, if such delays are not caused by government actions. We have obtained written consent from Euroserum that they understand the delay was mainly caused by government actions, and waived the right for the compensation. As a result, we have not accrued any loss in connection with this matter on our financial statements.

83

16. SEGMENT REPORTING AND GEOGRAPHIC INFORMATION

The Company focuses on selling powdered formula products for infants and adults, and also engages in other nutritional product offerings, such as prepared foods and certain nutritional ingredients and supplements. The activities of each segment are as follows:

Powdered Formula - Sales of powdered infant and adult formula products.

Foods - Sales of prepared foods for babies, children and adult.

Nutritional Ingredients and Supplements - Sales of nutritional ingredients and supplements such as chondroitin sulfate to external customers, and microencapsulated Docosahexanoic Acid (“DHA”) and Arachidonic Acid (“ARA”) to powdered formula segment.

Other business - Other business includes non-core businesses such as ancillary sales of excess or unusable ingredients and materials to industrial customers.

The Company’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting.

	Year Ended March 31,
(In thousands)	2014			2013			2012
NET SALES TO EXTERNAL CUSTOMERS
Powdered formula	$	314,289		$	224,423		$	301,664
Foods		170			350			255
Nutritional ingredients and supplements		21,987			6,836			907
Other business		34,088			34,161			39,713
Net sales	$	370,534		$	265,770		$	342,539
INTERSEGMENT SALES
Powdered formula	$	124		$	19		$	1
Foods		0			403			342
Nutritional ingredients and supplements		10,688			9,212			12,241
Other business		0			51			1,201
Intersegment sales	$	10,812		$	9,685		$	13,785
GROSS PROFIT (LOSS)
Powdered formula	$	157,501		$	102,248		$	142,475
Foods		(1,807	)		(2,861	)		(2,099	)
Nutritional ingredients and supplements		(2,659	)		(2,810	)		(2,358	)
Other business		472			(2,018	)		2,903
Gross profit	$	153,507		$	94,559		$	140,921
Selling and distribution expenses		53,710			51,005			49,628
Advertising and promotion expenses		32,912			35,176			30,035
General and administrative expenses		25,506			30,220			23,948
Impairment of long-lived assets (Foods segment)		1,040			0			0
Gain on disposal and liquidation of subsidiaries		367			3,625			0
Government subsidies		924			4,217			5,484
Income (loss) from operations		41,630			(14,000	)		42,794
Interest expense		16,162			15,018			14,276
Interest income		4,658			2,326			1,870
Other income (expense), net		352			(343	)		146
Income (loss) before income tax expense	$	30,478		$	(27,035	)	$	30,534
CAPITAL EXPENDITURE
Powdered formula	$	28,159		$	11,149		$	35,359
Foods		2			132			109
Nutritional ingredients and supplements		182			102			20
Other business		1,467			23			10
Total	$	29,810		$	11,406		$	35,498
DEPRECIATION AND AMORTIZATION
Powdered formula	$	10,757		$	9,777		$	7,704
Foods		1,745			2,864			1,671
Nutritional ingredients and supplements		2,806			2,016			1,962
Other business		48			319			414
Total	$	15,356		$	14,976		$	11,751

84

(In thousands)	March 31, 2014			March 31, 2013
TOTAL ASSETS
Powdered formula	$	567,051		$	491,079
Foods		16,692			20,150
Nutritional ingredients and supplements		49,039			33,879
Other business		131,876			133,748
Intersegment elimination		(213,975	)		(202,712	)
Total	$	550,683		$	476,144
LONG LIVED ASSETS
Powdered formula	$	124,247		$	104,760
Foods		15,240			17,719
Nutritional ingredients and supplements		15,807			18,271
Other business		1,496			200
Total	$	156,790		$	140,950

Consolidated revenue is generated from sales in the following areas:

	Year Ended March 31,
(In thousands)	2014		2013		2012
Mainland China*	$	355,218	$	260,211	$	342,539
United States*		15,316		5,559		0
Total	$	370,534	$	265,770	$	342,539

* Revenues are attributed to countries based on location of customer

.

The Company’s long-lived assets are located in the following areas:

(In thousands)	March 31, 2014		March 31, 2013
Mainland China	$	137,057	$	140,950
France		19,733		0
Total	$	156,790	$	140,950

No single customer accounts for more than 10% of net sales for the fiscal year ended March 31, 2014, 2013 and 2012.

17. ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated other comprehensive income as of March 31, 2014 and 2013 was comprised entirely of foreign currency translation adjustments. During the year ended March 31, 2014, the Company disposed of one immaterial subsidiary, with no reclassification of currency translation adjustments. During the year ended March 31, 2013, the Company liquidated three subsidiaries which had minimal operations and disposed of two immaterial subsidiaries. In connection with the sale and liquidation of these subsidiaries, the Company reclassified net currency translation adjustments totaling $3.1 million from accumulated other comprehensive income to net income (loss).

18. MAINLAND CHINA CONTRIBUTION PLAN AND RESTRICTED NET ASSETS

A. China Contribution Plan

Full time employees of the Company in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance and other welfare benefits are provided to employees. PRC labor regulations require the Company to accrue for these benefits based on certain percentage of the employees’ salaries. The total contribution for such employee benefits were $7.1 million, $7.0 million and $6.3 million for the fiscal year ended March 31, 2014, 2013 and 2012, respectively.

B. Restricted Net Assets

Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s PRC subsidiaries only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. PRC laws and regulations require that annual appropriations of 10% of after-tax income should be set aside prior to payment of dividends as a general reserve fund. In addition, there are restrictions on the distribution of share capital from the Company’s PRC subsidiaries. As a result of these PRC laws and regulations, the Company’s PRC subsidiaries and PRC affiliates are restricted in their ability to transfer a portion of their net assets to the Company in the form of dividends, loans or advances. As of March 31, 2014, the common stock, additional paid-in capital and statutory reserve of PRC subsidiaries were RMB 1,018.7 million, which were equivalent to $165.6 million using the exchange rate as of March 31, 2014.

85

19. SUBSEQUENT EVENT

On May 12, 2014, Synutra, Inc. and Zhangjiakou Chahaer Dairy Co., Ltd. (“Zhangjiakou”), both subsidiaries of the Company, entered into a share purchase agreement (the “SPA”) with Rightcom Co., Ltd. (the “Purchaser”), a company registered in Hong Kong. Pursuant to the SPA, Synutra, Inc. agreed to sell to the Purchaser all of the equity interests it holds in Zhangjiakou, a raw material processor, for a total payment of RMB173 million (equivalent to $28.1 million). The Purchaser made a 20% deposit payment of RMB34.6 million (equivalent to $5.6 million) in May 2014 according to the terms in the SPA. The Company expects to transfer the control over Zhangjiakou to the Purchaser before June 30, 2014, and close the transaction in fiscal year 2015, subject to customary closing conditions.

20. QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial information in fiscal years ended March 31, 2014 and 2013 is as follows:

	Fiscal Year 2014								Fiscal Year 2013
(In thousands except per share data)	First		Second		Third		Fourth		First			Second			Third			Fourth
Net sales	$	82,205	$	88,556	$	101,034	$	98,739	$	53,586		$	66,100		$	73,228		$	72,856
Gross profit		36,081		38,889		40,303		38,234		17,301			17,474			31,511			28,273
Net income (loss) attributable to common stockholders		4,775		6,073		9,987		10,094		(9,699	)		(44,186	)		(13,270	)		3,267
Weighted average common stock outstanding – basic and diluted		57,301		57,301		57,301		57,301		57,301			57,301			57,301			57,301
Earnings (loss) per share – basic and diluted	$	0.08	$	0.11	$	0.17	$	0.18	$	(0.17	)	$	(0.77	)	$	(0.23	)	$	0.06

86

SYNUTRA INTERNATIONAL, INC.

ADDITIONAL INFORMATION - FINANCIAL STATEMENT SCHEDULE I

FINANCIAL INFORMATION OF PARENT COMPANY

BALANCE SHEETS

(Dollars and shares in thousands, except per share data)

	March 31, 2014			March 31, 2013
ASSETS
Current Assets:
Cash and cash equivalents	$	719		$	1,077
Total current assets		719			1,077
Due from subsidiaries		57,457			57,411
Investments in subsidiaries		6,038			0
Other assets		1,144			1,266
TOTAL ASSETS	$	65,358		$	59,754
LIABILITIES AND EQUITY
Current Liabilities:
Long-term debt due within one year		0			2,860
Other current liabilities		85			1,673
Total current liabilities		85			4,533
Due to subsidiaries		3,877			1,724
Other long-term liabilities		0			24,731
Total liabilities		3,962			30,988
Equity:
Common stockholders’ equity:
Common stock, $.0001 par value: 250,000 authorized; 57,301 and 57,301 issued and outstanding at March 31, 2014 and 2013, respectively		6			6
Additional paid-in capital		135,440			135,440
Accumulated deficit		(104,579	)		(135,508	)
Accumulated other comprehensive income		30,529			28,828
Total equity		61,396			28,766
TOTAL LIABILITIES AND EQUITY	$	65,358		$	59,754

87

FINANCIAL INFORMATION OF PARENT COMPANY

STATEMENTS OF OPERATIONS

(Dollars in thousands, except per share data)

	Year Ended March 31,
	2014		2013			2012
Operating expenses:
General and administrative expenses	$	971	$	1,570		$	1,280
Loss from operations		971		1,570			1,280
Interest expense		214		53			654
Interest income		34		3			3
Dividend income		2,046		0			0
Other income, net		970		0			1,500
Gain on disposal and liquidation of subsidiaries		0		3,625			0
Equity in income (loss) of subsidiaries		29,064		(65,893	)		17,168
Net income (loss) attributable to common stockholders	$	30,929	$	(63,888	)	$	16,737
Weighted average common stock outstanding – basic and diluted		57,301		57,301			57,301
Earnings (loss) per share-basic and diluted	$	0.54	$	(1.11	)	$	0.29

FINANCIAL INFORMATION OF PARENT COMPANY

STATEMENT OF COMPREHENSIVE INCOME (LOSS)

(Dollars in thousands)

	Year Ended March 31,
	2014		2013			2012
Net income (loss) attributable to common stockholders	$	30,929	$	(63,888	)	$	16,737
Other comprehensive income (loss)
Currency translation adjustment		1,701		(232	)		3,997
Reclassification of currency translation adjustments realized upon disposal and liquidation of subsidiaries		0		(3,141	)		0
Other comprehensive income (loss)		1,701		(3,373	)		3,997
Comprehensive income (loss) attributable to common stockholders	$	32,630	$	(67,261	)	$	20,734

88

FINANCIAL INFORMATION OF PARENT COMPANY

STATEMENTS OF CASH FLOWS

(Dollars in thousands)

	Year Ended March 31,
	2014			2013			2012
Cash flow from operating activities:
Net income (loss) attributable to common stockholders	$	30,929		$	(63,888	)	$	16,737
Adjustments to reconcile net income to net cash provided by operating activities:
Equity in (income) loss of subsidiaries		(29,064	)		65,893			(17,168	)
Gain on disposal and liquidation of subsidiaries		0			(3,625	)		0
Dividend income		(2,046	)		0			0
Depreciation and amortization		118			118			115
Changes in assets and liabilities:
Due from subsidiaries		(46	)		(18,103	)		475
Prepaid expenses and other current assets		0			92			(92	)
Due to subsidiaries		2,153			(8,665	)		10,389
Other current liabilities		(1,588	)		1,525			51
Other long term liabilities		0			(1,290	)		387
Net cash provided by (used in) operating activities		456			(27,943	)		10,894
Cash flow from investing activities:
Proceeds from disposal and liquidation of subsidiaries		0			28,246			0
Capital injection at subsidiaries		0			0			(10,000	)
Dividend from subsidiaries		2,046			0			0
Net cash provided by (used in) investing activities		2,046			28,246			(10,000	)
Cash flow from financing activities:
Repayment of long-term loan		(2,860	)		0			(1,000	)
Net cash provided by (used in) financing activities		(2,860	)		0			(1,000	)
Net change in cash and cash equivalents		(358	)		303			(106	)
Cash and cash equivalents, beginning of year		1,077			774			880
Cash and cash equivalents, end of year	$	719		$	1,077		$	774

89

Note to Schedule I

The parent company financial statements have been prepared using the same accounting principles and policies described in the notes to the consolidated financial statements, with the only exception being that the company accounts for its subsidiaries using the equity method. Please refer to the notes to the consolidated financial statements presented above for additional information and disclosures with respect to these financial statements.

Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year.

90

SYNUTRA INTERNATIONAL, INC.

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

(Dollars in thousands)

Description	Balance at Beginning of Year		Charged to Costs and Expenses			Write-off			Balance at End of Year
Allowance for accounts receivable
- 2014	$	7,515	$	(1,494	)	$	(3,170	)	$	2,851
- 2013	$	7,845	$	2,358		$	(2,688	)	$	7,515
- 2012	$	8,779	$	(934	)	$	0		$	7,845
Allowance for other receivables
- 2014	$	2,682	$	(77	)	$	(357	)	$	2,248
- 2013	$	2,164	$	567		$	(49	)	$	2,682
- 2012	$	2,166	$	(2	)	$	0		$	2,164
Allowance for other assets
- 2014	$	3,837	$	(1,622	)	$	71		$	2,286
- 2013	$	4,322	$	(502	)	$	17		$	3,837
- 2012	$	0	$	4,322		$	0		$	4,322
Allowance for deferred tax assets
- 2014	$	56,971	$	(18,341	)	$	(26	)	$	38,604
- 2013	$	13,589	$	46,700		$	(3,318	)	$	56,971
- 2012	$	10,605	$	3,145		$	(161	)	$	13,589

91

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.  CONTROLS AND PROCEDURES

Conclusion Regarding Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this report.

Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2014, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (a) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (b) accumulated and communicated to the our management, including the Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management assessed the effectiveness of our internal control over financial reporting as of March 31, 2014. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (1992). Based on our assessment, management believes that, as of March 31, 2014, our internal control over financial reporting was effective based on those criteria.

Our independent registered public accounting firm, Deloitte Touche Tohmatsu Certified Public Accountants LLP, has issued an attestation report on our internal control over financial reporting. That attestation report appears below.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) in the year ended March 31, 2014, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

92

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Synutra International, Inc.:

We have audited the internal control over financial reporting of Synutra International, Inc. and its subsidiaries (the "Company") as of March 31, 2014, based on the criteria established in Internal Control - Integrated Framework(1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed by, or under the supervision of, the company's principal executive and principal financial officers, or persons performing similar functions, and effected by the company's board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of March 31, 2014, based on the criteria established in Internal Control - Integrated Framework(1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements as of and for the year ended March 31, 2014, of the Company and our report dated June 16, 2014 expressed an unqualified opinion on those financial statements.

/s/ Deloitte Touche Tohmatsu Certified Public Accountants LLP

Shanghai, China

June 16, 2014

93

ITEM 9B.  OTHER INFORMATION

Disclosure pursuant to Section 13(r) of the Securities Exchange Act of 1934

Pursuant to Section 13(r) of the Securities Exchange Act of 1934, we, Synutra International, Inc., may be required to disclose in our annual and quarterly reports to the Securities and Exchange Commission (the “SEC”), whether we or any of our “affiliates” knowingly engaged in certain activities, transactions or dealings relating to Iran or with certain individuals or entities targeted by US economic sanctions. Disclosure is generally required even where the activities, transactions or dealings were conducted in compliance with applicable law. Because the SEC defines the term “affiliate” broadly, it includes any entity under common “control” with us (and the term “control” is also construed broadly by the SEC).

The description of the activities below has been provided to us by Warburg Pincus LLC (“WP”), affiliates of which: (i) beneficially own more than 10% of our outstanding common stock and are members of our board of directors and (ii) beneficially own more than 10% of the equity interests of, and have the right to designate members of the board of directors of Santander Asset Management Investment Holdings Limited (“SAMIH”). SAMIH may therefore be deemed to be under common “control” with us; however, this statement is not meant to be an admission that common control exists.

The disclosure below relates solely to activities conducted by SAMIH and its non-U.S. affiliates that may be deemed to be under common “control” with us.  The disclosure does not relate to any activities conducted by us or by WP and does not involve our or WP’s management.  Neither us nor WP has had any involvement in or control over the disclosed activities of SAMIH, and neither us nor WP has independently verified or participated in the preparation of the disclosure.  Neither us nor WP is representing to the accuracy or completeness of the disclosure nor do we or WP undertake any obligation to correct or update it.

We understands that SAMIH’s affiliates intend to disclose in their next annual or quarterly SEC report that an Iranian national, resident in the U.K., who is currently designated by the U.S. under the Iranian Financial Sanctions Regulations and the NPWMD designation, holds two investment accounts with Santander Asset Management UK Limited. The accounts have remained frozen throughout 2013 and the first quarter of 2014. The investment returns are being automatically reinvested, and no disbursements have been made to the customer. Total revenue for the Santander Group in connection with the investment accounts was £23,017 whilst net profits in the first quarter 2014 were negligible relative to the overall profits of Banco Santander, S.A.

94

PART III

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

EXECUTIVE OFFICERS, DIRECTORS AND SIGNIFICANT EMPLOYEES

The following sets forth information about our directors and executive officers as of June 16, 2014:

Name	Age	Position
Directors and Executive Officers
Liang Zhang	54	Chairman of the Board of Directors and Chief Executive Officer
Ning Cai	38	Chief Financial Officer
Weiguo Zhang	57	President
Xisen Mu	57	Vice President, Production
Feng Zha	51	Vice President, Human resources and administration
Joseph Chow	52	Director
David Hui Li	46	Director
Jinrong Chen	55	Director(1)
Lei Lin	47	Director(1)
Min Zhang	40	Director(1)
Donghao Yang	42	Director

(1) Member of Audit Committee, Compensation Committee and Nominating Committee

Liang Zhang. Liang Zhang is our founder and has served as the chairman of our board of directors and Chief Executive officer since we became a public company in 2005. Mr. Zhang is also currently in charge of our marketing and sales function. Prior to that, Mr. Zhang served as chief executive officer of Synutra Illinois since 2000. Mr. Zhang has worked in the food ingredients industry since the 1980s and founded his first entrepreneurial venture, Honnete Beijing, in the early 1990s. Honnete Beijing has since become the dominant supplier of whey protein products in China. Mr. Zhang has been recognized as a business leader in the dairy industry in China, serving as vice chairman of the China Dairy Industry Association. Mr. Zhang’s experience as founder of Honnete Beijing gives him valuable insight into marketing strategies in our industry, and his service as vice chairman of the China Dairy Industry Association is invaluable to our Board’s discussions of regulatory issues pertaining to the dairy industry. Mr. Zhang received a bachelor’s degree in French language and literature from Nanjing International Relations Institute of China.

Ning Cai. Ning Cai joined us in December 2012. Ms. Cai has fourteen years of experience in corporate finance and investment banking. Ms. Cai joins Synutra from Trina Solar Limited (NYSE: TSL), where she served as a director of investment analysis from April 2010 to April 2012 and as the controller of System Group & China region from May 2012 to December 2012. Before that, Ms. Cai worked for nine years at Scotia Capital, the investment banking arm of Bank of Nova Scotia (NYSE: BNS). Ms. Cai worked on the execution team in Scotia Capital's San Francisco office where she held progressive positions as an Associate from 2001 to 2003, an Associate Director from 2003 to 2006 and as a Director from 2006 to 2009, primarily covering the portfolio management and deal execution for the real estate, gaming & leisure, and technology industries. Ms. Cai started her career with Ernst & Young’s Shanghai office where she was a staff accountant in the tax group from 1997 to 1999.  Ms. Cai earned a Bachelor in Economics from Shanghai International Studies University and an MBA from University of Iowa Tippie Business School. Ms. Cai holds the Chartered Financial Analyst ("CFA") designation. 

Weiguo Zhang. Weiguo Zhang has been our president since 2005 and is primarily responsible for our international market operations, including corporate development, international strategic development, and development of international markets for our nutritional segment. He also serves as our corporate secretary. Mr. Zhang first joined us as president of Synutra Illinois in 2001 to oversee our U.S. operations, including information support in research and technologies and business development. Prior to joining us, Mr. Zhang was the managing director of Bambridge International, Ltd., which he founded in 1995. Mr. Zhang received a bachelor’s degree in English language and literature from the Nanjing International Relations Institute and a master’s degree in international economics and American foreign policy from the School of Advanced International Studies from John Hopkins University.

Xisen Mu. Xisen Mu has served as our vice president of production since January 2007. Before joining us, Mr. Mu worked as general manager of Heilongjiang Dairy Group since 2001. Prior to that, Mr. Mu held senior positions with other major dairy companies in Heilongjiang province. He has more than twenty years of experience in the dairy industry in China. Mr. Mu received a diploma in management from Qiqihar Institute of Light Industry.

Feng Zha. Feng Zha joined us in February 2009 and has served as our vice president of human resources and administration since then. Before joining us, Mr. Zha worked as general manager of PRC Venture Partners LLC from 2006 to 2009. Mr. Zha was one of the major founders of Red Bull business in China, and had been the general manager of Red Bull Vitamin Drink Co. Ltd. from 1995 to 2003. Prior to that, Mr. Zha engaged in food safety monitoring in the Ministry of Health of the People’s Republic of China. Mr. Zha serves as member of market economy committee of the China Dairy Industry Association. Mr. Zha received a master’s degree in Biological statistics and information management from Wuhan Medical University, and an MBA from Concordia University in Canada.

95

Joseph Chow. Joseph Chow has been a managing director of Moelis and Company from June 2011 to March 2014. Mr. Chow had been our interim Chief Financial Officer from November 10, 2009 to June 10, 2010, advisor to our Chairman from June 11, 2010 to June 10, 2011, and has served as a director of our board of directors since May 4, 2010. Mr. Chow has extensive experience in corporate finance, financial advisory and management and has held senior executive and managerial positions in various public and private companies. Prior to joining us, Mr. Chow was a managing director of Goldman Sachs (Asia) LLP from 2008 to 2009. Prior to that, he served as an independent financial consultant from 2006 to 2008, as chief financial officer of Harbor Networks Limited from 2005 to 2006, and as chief financial officer of China Netcom (Holdings) Company Limited from 2001 to 2004. Prior to that Mr. Chow also served as the director of strategic planning of Bombardier Capital, Inc., as vice president of international operations of Citigroup and as the corporate auditor of GE Capital. Mr. Chow currently sits on the board as an independent executive director for China Lodging Group, Limited (NASDAQ: HTHT), and for Intime Department Store (Group) Co., Ltd (HKEx: INTIME). Mr. Chow has extensive knowledge of finance and accounting issues from his experience as Chief Financial Officer at Harbor Networks Limited and China Netcom (Holdings) Company Limited. Mr. Chow obtained a Bachelor of Arts degree in political science from Nanjing Institute of International Relations and an MBA from the University of Maryland at College Park.

David Hui Li. David Hui Li has served as a director of our board of directors since February 8, 2010. Mr. Li is a managing director of Warburg Pincus Asia LLC, a leading global private equity and venture capital firm. Mr. Li has been with Warburg Pincus since 2002. Before joining Warburg Pincus, Mr. Li was an Executive Director of the investment banking division of Goldman Sachs (Asia) LLC and a Vice President and an Associate of Morgan Stanley’s investment banking division in Hong Kong and New York. Mr. Li currently serves as a non-executive director of China Biologic Products, Inc. Between May 2006 and October 2008, Mr. Li served as the non-executive director of Kasen International Holdings Limited and from September 2008 to June 2011, he also served as a non-executive director in Intime Department Store (Group) Company Limited. Mr. Li received his B.S. degree in Economics from Renmin University of China and an MBA from Yale University’s School of Management.

Jinrong Chen. Jinrong Chen has served as a director of our board of directors since June 27, 2006. Ms. Chen has served as associate professor at the School of Economics and Management of Tsinghua University in Beijing since 2001, specializing in corporate finance management, securities analysis, financial operations, corporate governance and controls. In addition to her academic career with top business schools in China, Ms. Chen also advises or sits on the board and audit committee of Bosun Tools Co., Ltd. and Citic Development – Shenyang Commercial Building (Group) Company Limited which are listed in China, and certain private businesses in China. Ms. Chen has extensive knowledge of finance and accounting issues from her experience as professor at the School of Economics and Management of Tsinghua University, and her experience with Bosun Tools Co., Ltd. and Citic Development – Shenyang Commercial Building (Group) Company Limited gives the Board perspective with respect to corporate governance and brand building. Ms. Chen received her bachelor’s degree in accounting from Beijing Institute of Electronics & Information and her MBA degree from Renmin University of China.

Lei Lin. Lei Lin has served as anindependentdirector of our board of directors since October 1, 2007. Mr. Lin is the founder of Sinotrust established in 1992, and which is a leadingmarketing research andconsulting company in China. Mr. Lin is the president and chief executive officer ofSinotrust International Information and Consulting (Beijing) Co., Ltd.Mr. Lin’s experience as the founder and chief executive officer of Sinotrust provides him with deep insight into all aspects of business management. Mr. Lin received his bachelor’s degree in economic information management from Renmin University of China in July 1990.

Min Zhang. Min Zhang has served as a director of our board of directors since February 18, 2011.  Ms. Zhang has served as chief strategy officer of China Lodging Group (NASDAQ: HTHT) since November 2013, and as chief financial officer since March 2008, which operates Hanting Inns business hotel chain in China. She has more than ten years of experience in finance and consulting with multinational companies. Between 2005 and 2007, she was Finance Director of Eli Lilly (Asia) Inc., Thailand Branch, and between 2003 and 2005 she worked as Planning and Business Development manager at Eli Lilly & Company, China, and as Senior Financial Analyst at Eli Lilly & Company, Latin America in 2003.  She served as the Chief Financial Officer of ASIMCO Casting (Beijing) Company, Ltd., between 1998 and 2000.  She also worked with McKinsey & Company, Inc. as a consultant between 2000 and 2001. Ms. Zhang is the chairperson of our audit committee because of her extensive experience and background in finance and consulting, including her experience serving as Finance Director of Eli Lilly (Asia), Thailand Branch, and CFO of ASIMCO. Ms. Zhang obtained her Masters of Business Administration degree from Harvard Business School in 2003, and between 1990 and 1997 she received both Master’s and Bachelor’s degrees from the University of International Business and Economics, Beijing, China.

Donghao Yang. Donghao Yang served as our Chief Financial Officer from June 10, 2010 to August 29, 2011. Mr. Yang has served as a director of our board of directors since August 29, 2011. Mr. Yang has extensive experience in corporate finance, commodity trading and international business development. Mr. Yang has held senior executive and managerial positions in various public and private companies, including serving as Chief Financial Officer of VIP shop (NASDAQ: VPS) from August 2011 until now, Chief Financial Officer of Greater China of Tyson Foods, Inc. (NYSE: TSN) from March 2007 to April 2010, as Finance Director of Asia Pacific of Valmont Industries, Inc. (NYSE: VMI) from October 2003 to March 2007, and as Director in China Minerals Brazil Holding Limited from January 1999 to April 2001. Mr. Yang earned a Bachelor of Arts degree in Economics from Nankai University in 1993 and a Master of Business Administration degree from Harvard Business School in 2003.

Our directors have a term of office expiring at the next annual general meeting, unless re-elected or earlier vacated in accordance with our bylaws. Our officers are appointed by and serve at the discretion of the board of directors. All officers have a term of office lasting until their removal or replacement by our board of directors. There are no family relationships among our directors or officers.

96

Board of Directors

Our board of directors currently has seven directors, consisting of five independent directors, all of whom are independent as defined by the applicable listing requirements of the NASDAQ Global Select Market.

On June 11, 2008, our board of directors and stockholders approved our amended and restated certificate of incorporation, which became effective on October 17, 2008. Our amended and restated certificate of incorporation provides that our board of directors shall be divided into three classes of directors. The three classes, which are required to be as nearly equal in number as possible, will be designated class I, class II and class III. The directors serve staggered three-year terms and hold office until their term of office expires or until such time as they are removed from office by resolution of our stockholders. As of the date of this Form 10-K, Liang Zhang, Joseph Chow and Donghao Yang are class I directors; Jinrong Chen and David Hui Li are class II directors; and Lei Lin and Min Zhang are class III directors.

Board Committees

Our board has established the committees described below and may establish others from time to time.

Audit Committee

Our audit committee consists of Jinrong Chen, Lei Lin and Min Zhang, whom are independent as defined by the applicable listing requirements of the NASDAQ Global Select Market. Ms. Zhang is the chairperson of our audit committee and serves as the financial expert of the committee. The audit committee oversees our accounting and financial reporting processes and the audits of our financial statements. The audit committee is responsible for, among other things:

●  reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures;

●  coordinating the oversight and reviewing the adequacy of our internal control over financial reporting with both management and the independent registered public accounting firm;

●  establishing policies and procedures for the receipt and retention of accounting related complaints and concerns, including a confidential, anonymous mechanism for the submission of concerns by employees;

●  periodically reviewing legal compliance matters, including securities trading policies, periodically reviewing significant accounting and other risks or exposures to our company, reviewing and, if appropriate, approving all transactions between our company or its subsidiaries and any related party (as described in Item 404 of Regulation S-K) and periodically reviewing business expenses of our chief executive officer; and

●  establishing policies for the hiring of employees and former employees of the independent registered public accounting firm.

97

Compensation Committee

Our compensation committee consists of Jinrong Chen, Lei Lin and Min Zhang. Ms. Chen is the chairperson of our compensation committee. The purpose of our compensation committee is to discharge the responsibilities of our board of directors relating to compensation of our executive officers. Specific responsibilities of our compensation committee include:

●  reviewing and recommending approval of compensation of our executive officers;

●  administering our stock incentive and employee stock purchase plans; and

●  reviewing and making recommendations to our board with respect to incentive compensation and equity plans.

Nominating Committee

Our nominating committee consists of Jinrong Chen, Lei Lin and Min Zhang. Mr. Lin is the chairperson of our nominating committee. The purpose of our nominating committee is to be primarily responsible for identifying individuals qualified to serve as members of the board of directors and recommending to the board the persons to be nominated by the board as nominees for director at each annual meeting of our stockholders. Specific responsibilities of our nominating committee include:

●  developing and recommending to the board of directors criteria for board of directors and committee membership;

●  identifying individuals qualified to become board of directors members;

●  recommending to the board of directors the persons to be nominated for election as directors and to each of the board of directors’ committees;

●  developing and recommending to the board of directors a code of ethical conduct and a set of corporate governance policies and practices; and

●  monitoring and evaluating the performance of the board of directors.

Section 16(a) Beneficial Ownership Reporting Requirements

Section 16(a) of the Securities Exchange Act of 1934 requires our executive officers, directors and persons who beneficially own more than ten percent of a registered class of our equity securities to file reports of ownership and changes in ownership with the Securities and Exchange Commission. Based solely upon our review of these reports furnished to the Company, we believe that during the year ended March 31, 2014, our officers, directors and greater than ten percent beneficial owners complied with the Section 16(a) filing requirements.

Code of Ethics

The Company has a code of ethics that applies to all of the Company’s employees, including its principal executive officer, principal financial officer and principal accounting officer, and the Board of Directors. A copy of this code is available on the Company’s website at www.synutra.com, and is included as Exhibit 14.1 to our Annual Report on Form 10-K filed on June 16, 2008. A copy of our code of ethics may be obtained free of charge by writing to Investor Relations, 2275 Research Blvd., Suite 500, Rockville, Maryland 20850. The Company intends to disclose any changes in or waivers from its code of ethics by posting such information on its website or by filing a Form 8-K.

98

ITEM 11.  EXECUTIVE COMPENSATION

COMPENSATION DISCUSSION AND ANALYSIS

This section describes the material elements of compensation earned by our named executive officers during the fiscal year ended March 31, 2014. Our executive compensation programs are determined and approved by the compensation committee of our board of directors.

Our “named executive officers” for the fiscal year ended March 31, 2014, include:

·  Liang Zhang, who serves as our chairman and chief executive officer;

·  Ning Cai, who serves as our chief financial officer;

·  Weiguo Zhang, who serves as our president and served as our interim chief financial officer prior to the appointment of Ning Cai as of December 18, 2012;

·  Xisen Mu, who serves as vice president for production management; and

·  Feng Zha, who serves as vice president for human resources and administration.

Unless otherwise noted, the amounts reported in this Form 10-K have been converted from Renminbi to U.S. dollars based on the conversion rate as of March 31, 2014 of RMB 6.1521 to $1.00.

Overview of Executive Compensation Program

The compensation committee has responsibility for establishing, implementing and monitoring our executive compensation program philosophy and practices. The compensation committee seeks to ensure that the total compensation paid to our executive officers is fair, reasonable and competitive.

Compensation Philosophy and Objectives

The compensation committee believes that an effective executive compensation program should provide base annual compensation that is reasonable in relation to the individual executive’s job responsibilities and reward the achievement of both annual and long-term strategic goals of our company. Because of the size of our company, the small number of executive officers in our company, and our company’s financial priorities, the compensation committee has decided not to implement or offer any retirement plans, deferred compensation plans or other similar plans for our named executive officers. Accordingly, for the fiscal year ended March 31, 2014, the components of our executive compensation program consisted of cash salary only. We note, however, that since 2008, the Company has maintained the 2008 Stock Incentive Plan (the “Plan”). The Plan provides the Company with the ability to grant stock-based awards to all employees, officers and directors. Although the compensation committee has not to date granted any stock-based awards, the compensation committee may in future years reassess the levels of equity and cash compensation offered to our executives in light of our profitability and other performance factors.

Role of Named Executive Officers in Compensation Decisions

Our compensation committee annually reviews the performance of each named executive officer. The compensation committee makes all decisions with respect to compensation for the chief executive officer. Decisions regarding the compensation of our named executive officers other than our chief executive officer are made by our chief executive officer. According to our Compensation Committee Charter, the compensation committee shall have primary authority and responsibility for determining the type and level of compensation of the Chief Executive Officer. The Chief Executive Officer in consultation with the Compensation Committee shall have primary responsibility for determining the type and level of compensation of the other named executive officers.

Setting Named Executive Officer Compensation

In making its compensation decisions, neither the Company nor the compensation committee retains outside compensation consultants. Instead, the compensation committee reviews compensation data for executives of other listed companies located in China but the Company does not use this data to benchmark the compensation of its executives. The compensation committee utilizes this data to set compensation for our named executive officers at levels targeted at or around the average of the compensation amounts provided to similarly situated executives at comparable local companies considering, for each executive, his or her individual experience level and the responsibilities of his or her position with us. There is no pre-established policy or target for the allocation between cash and non-cash incentive compensation.

Employment Agreements

We have entered into standard employment agreements with each of our named executive officers. The terms and conditions of each employment agreement are the result of negotiations between the executive officer and us, and the framework and structure of the agreements are intended to comply with applicable PRC labor and employment laws.

Liang Zhang’s employment agreement has an indefinite term and provides for an annual base salary of approximately $292,583. Ning Cai’s employment agreement will end on December 17, 2014, unless extended upon mutual agreement, and provides for an annual base salary of $107,280. Weiguo Zhang’s employment agreement has an indefinite term, and his position as president provides for an annual base salary of $95,000. Xisen Mu’s employment agreement will end on August 31, 2014, unless extended upon mutual agreement, and provides for an annual base salary of $102,404. Feng Zha’s employment agreement has an indefinite term and provides for an annual base salary of $146,291.

99

Fiscal Year 2014 Named Executive Officer Compensation Components

For the fiscal year ended March 31, 2014, the principal component of compensation for our named executive officers was their base salary and bonus. We provide named executive officers with a base salary to compensate them for services rendered during the fiscal year. The base salaries of our named executive officers vary. The base salary for each named executive officer is based on his or her position and responsibility. The bonus is based on his or her position and our annual overall performance, including certain sales expectations.

During its review of base salaries for executive officers, the compensation committee and the Chief Executive Officer primarily consider:

●  the negotiated terms of each executive officer’s employment agreement;

●  internal review of the executive officer’s compensation, both individually and relative to other executive officers; and

●  individual performance of the executive officers.

Salary levels are typically considered annually as part of our performance review process, as well as upon a change in job responsibility. Merit-based increases to salaries are based on the compensation committee’s assessment of the individual’s performance.

Our named executive officers did not receive any equity-based compensation for the fiscal year ended March 31, 2014.

Consideration of Say-On-Pay Vote

At our 2013 Annual Meeting of Stockholders, almost 100% of votes were cast, on an advisory basis, in favor of the “say-on-pay” vote on executive compensation. As such, the compensation committee has concluded that our stockholders are satisfied with our existing compensation program. Based on this result and our ongoing review of our compensation policies, we believe that our existing executive compensation program effectively aligns the interests of our named executive officers with the long term goals of the Company.

Compensation Risk Assessment

Our management team has reviewed our compensation policies and practices for all of our employees with our compensation committee. The compensation committee has determined, based on this review, that our compensation policies and practices are not reasonably likely to have a material adverse effect on our Company.

Compensation Committee Report

The compensation committee has reviewed and discussed with management the “Compensation Discussion and Analysis” required by Item 402(b) of Regulation S-K and, based on such review and discussions, has recommended to our board of directors that the foregoing “Compensation Discussion and Analysis” be included in this Annual Report.

Compensation Committee of the Board of Directors

Jinrong Chen (Chairperson)

Lei Lin

Min Zhang

Summary Compensation Table — Fiscal Year Ended March 31, 2014

The following table presents information regarding compensation of our named executive officers for services rendered during the fiscal year ended March 31, 2014, 2013 and 2012. The amounts reported in this table for the fiscal year ended March 31, 2014 have been converted from Renminbi to U.S. dollars based on the March 31, 2014 conversion rate of RMB6.1521 to $1.00.

Name and Principal Position	Year ended March 31	Salary ($)		Bonus ($)		Total ($)
Liang Zhang	2014		292,583		88,750		381,333
Chairman of the Board and	2013		172,279		—		172,279
Chief Executive Officer	2012		190,649		—		190,649
Ning Cai	2014		107,280		—		107,280
Chief Financial Officer	2013		30,354		—		30,354
Weiguo Zhang	2014		95,000		17,750		112,750
President and	2013		117,500		13,400		130,900
Former Interim Chief Financial Officer	2012		103,333		18,672		122,005
Xisen Mu	2014		123,080		12,425		135,505
Vice President, Production	2013		120,787		—		120,787
	2012		133,454		—		133,454
Feng Zha	2014		146,487		44,375		190,862
Vice President, Human Resources	2013		74,049		40,209		114,258
and Administration	2012		73,703		56,030		129,733

(1)  Messrs. Mu and Zha, along with our chief executive officer, chief financial officer and president, are our Company’s only executive officers who earned or were paid more than $100,000 with respect to fiscal year 2014.

100

Plan-Based Awards — Fiscal Year Ended March 31, 2014

None of our named executive officers received any grants of options or other stock-based awards during the fiscal year ended March 31, 2014. Additionally, none of our named executive officers held any outstanding options or other stock-based awards as of the last day of the fiscal year ended March 31, 2014, nor did any of our named executive officers exercise any options or hold any other stock awards that vested during the fiscal year ended March 31, 2014.

Potential Payments upon Termination of Employment or Change of Control

We have not entered into any arrangements with our named executive officers that provide for severance or change of control benefits. Upon a termination of employment by us, any employee, including our named executive officers, is generally entitled under PRC labor law to one month’s severance pay for each full year he or she has been employed with us (with a minimum of one month’s severance pay and a maximum of 12 months’ severance pay).

Director Compensation — Fiscal Year Ended March 31, 2014

The following table presents information regarding the compensation for the fiscal year ended March 31, 2014 to members of our board of directors who were not also employed by us (referred to as our “non-employee directors”) during the fiscal year ended March 31, 2014. None of our non-employee directors held any outstanding options or other stock-based awards as of the last day of the fiscal year ended March 31, 2014. Liang Zhang did not receive any compensation for his services as a director for the fiscal year ended March 31, 2014.

Name	Fees Earned or Paid in Cash ($)	Total ($)
Jinrong Chen	44,863	44,863
Joseph Chow	40,000	40,000
Lei Lin	44,863	44,863
Min Zhang	44,863	44,863
David Hui Li	－	－
Donghao Yang	44,863	44,863

Non-Employee Director Compensation

Currently, our non-employee directors are entitled to receive an annual cash retainer for his or her services as a director as specified in the above table. In addition, our non-employee directors are reimbursed for travel, lodging and other reasonable out-of-pocket business expenses incurred in attending meetings of the board and board committees. Our non-employee directors do not receive any equity-based awards or any other compensation for their service as directors.

Compensation Committee Interlocks and Insider Participation

Jinrong Chen, Lei Lin and Min Zhang each served on the compensation committee during the fiscal year ended March 31, 2014. None of these directors is or was an executive officer of our company or had any relationships requiring disclosure by us under the SEC’s rules requiring disclosure of certain relationships and related-party transactions. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, the executive officers of which served as a director or member of our compensation committee during the fiscal year ended March 31, 2014.

101

ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Security Ownership of Certain Beneficial Owners

The following table sets forth information, as of June 16, 2014, regarding the beneficial ownership of our common stock by:

●  each person known by us to be a beneficial owner of more than five percent of our outstanding common stock;

●  each of our directors and director nominees;

●  each of our named executive officers; and

●  all directors and executive officers as a group.

The amounts and percentage of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a “beneficial owner” of a security if that person has or shares “voting power,” which includes the power to vote or to direct the voting of such security, or “investment power,” which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days after June 16, 2014. Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed a beneficial owner of securities as to which he has no economic interest. Except as indicated by footnote, the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them.

Percentage of class is based on 57,300,713 shares of common stock outstanding as of June 16, 2014. Unless otherwise noted below, the address of the persons listed on the table is 2275 Research Blvd., Suite 500, Rockville, Maryland 20850.

	Shares Beneficially Owned
Name	Number		Percent
OFFICERS AND DIRECTORS
Liang Zhang, Director and Chief Executive Officer(1)		36,000,000		62.83%
Ning Cai, Chief Financial Officer		—		—
Weiguo Zhang, President		2,000		*
Xisen Mu, Vice President		—		—
Feng Zha, Vice President		—		—
Joseph Chow, Director and Former Advisor to Chairman		—		—
Donghao Yang, Director and Former Chief Financial Officer		1,200		*
David Hui Li, Director(2)		4,000,000		6.98%
Jinrong Chen, Director		—		—
Lei Lin, Director		—		—
Min Zhang, Director		—		—
All Officers and Directors as a Group		40,003,200		69.81%
PRINCIPAL STOCKHOLDER
Warburg Pincus Private Equity IX, L.P.(3)		4,000,000		6.98%

*  Less than 1%

(1)  This amount includes 36,000,000 shares owned by Beams Power Investment Limited, or Beams, a British Virgin Islands company which are pledged to certain lenders under a facility agreement. Liang Zhang has dispositive and voting power over investments by Beams. Liang Zhang’s wife, Xiuqing Meng, is the sole shareholder and director of Beams. See “Item 13. Certain Relationships and Related Transactions, and Director Independence.”

(2)  Mr. David Hui Li is a Managing Director and Member of WP LLC. All shares indicated as owned by Mr. Li are included because of his affiliation with the Warburg Pincus entities.  Joseph P. Landy and Charles R. Kaye are Managing General Partners of WP and Managing Members and Co-Presidents of WP LLC and may be deemed to control the Warburg Pincus entities.  Messrs. Kaye, Landy, and Li disclaim beneficial ownership of all shares held by the Warburg Pincus entities.

(3)  According to a Schedule 13D/A filed by Warburg Pincus Private Equity IX, L.P., or Warburg, with the SEC on September 1, 2008, Warburg Pincus IX LLC, or WP IX LLC, is the sole general partner of Warburg. Warburg Pincus Partners LLC, or WP Partners, is the sole managing member of WP IX LLC, and Warburg Pincus & Co., or WP, is the sole managing member of WP Partners. Charles R. Kaye and Joseph P. Landy are each a managing general partner of WP and a managing member and Co-Chief Executive Officer of Warburg Pincus LLC, or WP LLC, which manages Warburg. WP, WP Partners, WP IX LLC, Warburg and WP LLC are collectively referred to as the “Warburg Pincus Entities.” Messrs. Kaye and Landy may be deemed to indirectly beneficially own the shares held by Warburg because of their affiliation with the Warburg Pincus Entities. Messrs. Kaye and Landy disclaim beneficial ownership of the shares held by Warburg except to the extent of their indirect pecuniary interest therein. The address of the Warburg Pincus Entities is 466 Lexington Avenue, New York, New York, 10017. This amount represents the shares of common stock held directly by the Warburg Pincus Entities.

102

Securities Authorized for Issuance under Equity Compensation Plans

We currently have a 2008 Stock Incentive Plan which has been approved by our shareholders. The plan will terminate on June 10, 2018. To date, we have not issued any awards under the Plan.

The following table sets forth the number of common stocks remaining available for future issuance under the plan as of March 31, 2014.

Plan Category	Number of Common Stocks to Be Issued Upon Exercise of Outstanding Options, Warrants and Rights		Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights		Number of Common Stocks Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Stocks Reflected in the First Column)
Equity compensation plans approved by shareholders		—		—		12,500,000
Equity compensation plans not approved by shareholders		—		—		—
Total		—		—		12,500,000

103

ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Transactions with Affiliate Companies controlled by Liang Zhang

Our chairman, chief executive officer and principal stockholder, Liang Zhang, and his immediate family, controls several other companies in China.

In the fiscal year ended March 31, 2014 and 2013, the Company’s sales to related parties mainly included feed grade milk powder and whey powder to Ao Naier, and powdered formula products to St. Angel (Beijing) Business Service, and services for related parties represent office spaces rented to Honnete Beijing, Ao Naier, St. Angel (Beijing) Business Service, and St. Angel Cultural Communication. In the fiscal year ended March 31, 2014 and 2013, the Company’s services for related parties consist of office spaces rented to Honnete Beijing, Ao Naier, St. Angel (Beijing) Business Service and St Angel Cultural communication. The following table sets forth the value of our sales to our related parties for the fiscal year ended March 31, 2014 and 2013:

	Year Ended March 31,
(In thousands)	2014		2013
Beijing Honnete Dairy Co., Ltd.	$	8	$	775
St. Angel (Beijing) Business Service Co., Ltd.		1,780		2,470
Beijing Ao Naier Feed Stuff Co., Ltd.		524		293
Beijing St. Angel Cultural Communication Co., Ltd.		17		0
Total	$	2,329	$	3,538

In the fiscal year ended March 31, 2014, St. Angel Cultural Communication implemented certain marketing activities for the Company. In the fiscal year ended March 31, 2013, major purchases included (i) the Company purchased Lactose from Honnete Beijing, and (ii) St. Angel Cultural Communication implemented certain marketing activities for the Company. The following table sets forth the value of our purchases from our related parties for the fiscal year ended March 31, 2014 and 2013:

	Year Ended March 31,
(In thousands)	2014		2013
Beijing Honnete Dairy Co., Ltd.	$	0	$	4,674
Beijing Kelqin Dairy Co., Ltd.*		0		11
Beijing St. Angel Cultural Communication Co. Ltd.		460		577
Total	$	460	$	5,262

* Kelqin had become a third party since April 2013

We had indebtedness from related parties controlled by Liang Zhang. The following table sets forth the amount of indebtedness principal outstanding during the fiscal years ended March 31, 2014 and 2013:

	Year Ended March 31,
(In thousands)	2014		2013
Balance at beginning of the year	$	2,860	$	2,860
Repayment to related parties		2,860		—
Balance at end of the year	$	—	$	2,860

The principal of long term loan from related parties of $2.9 million and accumulated interest was repaid in full in fiscal year 2014. The interest expense of related party loans for the year ended March 31, 2014 and 2013 were $215,000 and $286,000, respectively. The interest rate for the loan was 10.0%.

104

Registration Rights Agreement

On February 21, 2014, Beams entered into a two-year facility agreement, as borrower therein, with Nomura Singapore Limited as mandated lead arranger, Deutsche Bank AG, Hong Kong Branch as facility agent (the “Facility Agent”), DB Trustees (Hong Kong) Limited as international security agent (the “International Security Agent”), Deutsche Bank Trust Company Americas as New York security agent (the “New York Security Agent”) and the Original Lender(s) as defined therein (the “Facility Agreement”), for credit in an aggregate amount of fifty-five million dollars (US$55,000,000). The Facility Agreement is secured by 36,000,000 shares of our common stock (as adjusted pursuant to the terms and conditions of the Facility Agreement, the “Pledged Shares”), par value US$0.0001 per share, held by Beams.

In connection with Beams’ pledging of the Pledged Shares and entering into the Facility Agreement, we entered into a registration rights agreement with the Facility Agent and Beams (the “Registration Rights Agreement”) on March 3, 2014, pursuant to which we agreed, (i) as soon as practicable after an event of default under the Facility Agreement has occurred and is continuing or the New York Security Agent has become the owner of the shares in accordance with the terms of the Pledge Agreement, to file with the Securities and Exchange Commission a registration statement for the resale of the shares and the Pledged Shares (collectively the “Registrable Securities”), to use commercially reasonable efforts to have the registration statement declared effective as soon as practicable, and to maintain the effectiveness of the registration statement until the earlier of (A) the date on which all Registrable Securities have been sold pursuant to the registration statement, (B) the date on which all Registrable Securities have been sold under Rule 144 under the Securities Act, or (C) the passage of four years from March 3, 2014, and (ii) to grant the Facility Agent or its permitted assignees or transferees the right to two demand registrations and unlimited piggyback registrations, subject to certain conditions; provided that in each case, we will pay all expenses associated with each registration.

Control Agreements with Affiliated Entities

In order to comply with PRC law and avoid restrictions on foreign investment in medical clinical operations, we operate our medical treatment services (mostly pre-natal diagnostics services) through Beijing Syclin Clinical Laboratory Co., Ltd., a subsidiary of Beijing Shengyuan Huimin Technology Service Co., Ltd., that is not directly owned by us. We control and consolidate these entities into our group consolidated results through a series of contractual arrangements which are summarized below.

(a)    Exclusive Consulting and Service Agreement entered into by and between Shengyuan Nutritional Food Co., Ltd. (“Nutritional”) and Beijing Shengyuan Huimin Technology Service Co., Ltd. (“Huimin”). Pursuant to this agreement, Nutritional agrees to provide to Huimin certain consulting services for which Huimin shall pay Nutritional a service fee in an amount equal to 10%-50% of Huimin’s monthly net sale, the exact percentage to be determined by the two parties. The term of the agreement is 10 years unless Nutritional terminates it before its expiration and Nutritional shall have the right to extend the Agreement before it expires.

(b)    Business Operating Agreement entered into by and among Nutritional, Huimin, Jibin Zhang (who is our Director of Treasury) and Yunpeng Jiang (who is our Director of Strategic Acquisitions). Pursuant to this agreement, Huimin agrees to conduct its business in a way that is consistent with Nutritional’s direction. In addition, Jibin Zhang and Yunpeng Jiang authorize Nutritional to exercise all of their respective shareholders’ rights in Huimin.

(c)    Call Option Agreement entered into by and among Nutritional, Huimin, Jibin Zhang and Yunpeng Jiang. Pursuant to this agreement, within a ten-year period and any extended period as requested by Nutritional, Nutritional is entitled to an irrevocable and exclusive right to purchase or authorize any third party to purchase the shares of Huimin held by Jibin Zhang and Yunpeng Jiang at the lowest feasible price according to PRC laws and regulations. In addition, Nutritional is entitled to call part or all of the option right at any time during the effective period of this agreement and there is no limit on the number of calls until Nutritional hold 100% of Huimin’s shares.

(d)    Pledge Agreement entered into by and among Nutritional, Jibin Zhang and Yunpeng Jiang. To ensure the performance of the Exclusive Consulting and Service Agreement, Call Option Agreement and Business Operating Agreement, Jibin Zhang and Yunpeng Jiang, as pledgers under this agreement, pledge all of their shares and corresponding interests and rights in Huimin to Nutritional, as pledgee under this agreement.

(e)   Entrustment Agreement entered into by and among Nutritional, Jibin Zhang and Yunpeng Jiang. Pursuant to this agreement, Nutritional loans Jibin Zhang and Yunpeng Jiang each RMB15,000,000 to establish companies for pre-natal diagnostic services in China. Jibin Zhang and Yunpeng Jiang are the nominal shareholders of these companies and Nutritional is the actual shareholder of these companies.

105

Review, Approval or Ratification of Transactions with Related Parties

According to the audit committee charter, the audit committee must approve any new class of transactions involving the Company in which any of our directors, director nominees, executive officers, greater than five percent beneficial owners and their respective immediate family members has a direct or indirect material interest. In doing so, the Board takes into account, among other factors it deems appropriate:

●  The related person’s interest in the transaction;

●  The approximate dollar value of the amount involved in the transaction;

●  The approximate dollar value of the amount of the related person’s interest in the transaction without regard to the amount of any profit or loss;

●  Whether the transaction was undertaken in the ordinary course of our business;

●  Whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than terms that could have been reached with an unrelated third party;

●  The purpose of, and the potential benefits to us of, the transaction; and

●  Any other information regarding the transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.

Director Independence

The Board has determined all Board members, excluding Liang Zhang and Donghao Yang, are independent under the applicable NASDAQ rules. The Board has also determined the members of audit committee, compensation committee and nominating committee of the Board are independent under the listing standards of the NASDAQ Global Select Market. See Item 10. Directors, Executive Officers and Corporate Governance – Board Committees – Audit Committee. In making these determinations, the Board considered, among other things, the types and amounts of the commercial dealings between the Company and the companies and organizations with which the directors are affiliated.

106

ITEM 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES

We have engaged Deloitte Touche Tohmatsu Certified Public Accountants LLP (“Deloitte”) as our independent auditors. The engagement was approved by the audit committee of our Board of Directors. No relationship existed in any manner between Deloitte and us prior to the date we engaged Deloitte.

Audit Fees

Deloitte was paid aggregate fees of approximately $1,121,284 and $1,080,000 for the fiscal years ended March 31, 2014 and 2013, respectively, for professional services rendered for the audit of our annual financial statements included in Form 10-K and for the reviews of the financial statements included in our quarterly reports on Form 10-Q, or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for the fiscal years ended March 31, 2014 and 2013.

Audit-related Fees

Deloitte was paid no fees for the fiscal years ended March 31, 2014 and 2013, for audit related service.

Tax Fees

Deloitte was paid no fees for the fiscal years ended March 31, 2014 and 2013, for tax related service.

All Other Fees

Deloitte was paid no other fees for any other services rendered to us for the fiscal years ended March 31, 2014 and 2013.

Audit Committee Pre-approval Policies and Procedures

Our audit committee’s policy is to pre-approve all audit and permissible non-audit services provided by our independent auditors. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services. The independent auditor and management are required to periodically report to the audit committee regarding the extent of services provided by the independent auditor in accordance with this pre-approval.

107

PART IV

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) List of Documents Filed as a Part of this Annual Report on Form 10-K:

1. See Index to Consolidated Financial Statements in Item 8 of this Report.

2. See Index to Consolidated Financial Statements in Item 8 of this Report, and the Consolidated Financial Schedules listed on such index filed as part of this Report are filed as part of this Report.

3. The exhibits listed on the exhibit index filed as part of this Report are filed or incorporated by reference as part of this Report.

108

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SYNUTRA INTERNATIONAL, INC.
Date: June 16, 2014	By:	/s/ Liang Zhang
		Name:	Liang Zhang
		Title:	Chief Executive Officer and Chairman

Each person whose signature appears below appoints each of Liang Zhang and Ning Cai, severally and not jointly, to be his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any amendments to our Annual Report on Form 10-K for the fiscal year ended March 31, 2014; granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Name	Position	Date
/s/ Liang Zhang
Liang Zhang	Chief Executive Officer, and Chairman (Principal Executive Officer)	June 16, 2014
/s/ Ning Cai
Ning Cai	Chief Financial Officer (Principal Financial and Accounting Officer)	June 16, 2014
/s/ Joseph Chow
Joseph Chow	Director	June 16, 2014
/s/ David Hui Li
David Hui Li	Director	June 16, 2014
/s/ Jinrong Chen
Jinrong Chen	Director	June 16, 2014
/s/ Lei Lin
Lei Lin	Director	June 16, 2014
/s/ Min Zhang
Min Zhang	Director	June 16, 2014
/s/ Donghao Yang
Donghao Yang	Director	June 16, 2014

109

EXHIBITS INDEX

Exhibit Number	Description
3.1	Amended and Restated Certificate of Incorporation of Synutra International, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on November 11, 2008)
3.2	Amended and Restated Bylaws of Synutra International, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q filed on November 11, 2008)
4.1	Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K filed on June 16, 2008)
10.1	Employment Agreement between Shengyuan Nutritional Food and Liang Zhang, dated December 21, 2008 (incorporated by reference to Exhibit 10.1 to the Registrant’s Annual Report on Form 10-K filed on June 9, 2010)
10.2	Employment Agreement between Shengyuan Nutritional and Weiguo Zhang, dated June 4, 2010 (incorporated by reference to Exhibit 10.2 to the Registrant’s Annual Report on Form 10-K filed on June 9, 2010)
10.3	Employment Agreement between Sheng Yuan Nutritional Food Co., Ltd., Beijing R&D Center and Xisen Mu, dated September 1, 2011(incorporated by reference to Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K filed on June 14, 2012)
10.4	Employment Agreement between Sheng Yuan Nutritional Food Co., Ltd., Beijing R&D Center and Feng Zha, dated February 29, 2012(incorporated by reference to Exhibit 10.6 to the Registrant’s Annual Report on Form 10-K filed on June 14, 2012)
10.5	Employment Agreement between Sheng Yuan Nutritional Food Co., Ltd., Beijing R&D Center and Ning Cai, dated December 18, 2012 (incorporated by reference to Exhibit 10.5 to the Registrant’s Annual Report on Form 10-K filed on June 13, 2013)
10.6	Common Stock Purchase Agreement between Synutra International, Inc. and Warburg Pincus Private Equity IX, L.P. , dated May 24, 2007 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K/A filed on June 1, 2007)
10.7	Voting and Co-Sale Agreement among Synutra International, Inc., Beams Power Investment Limited, and Warburg Pincus Private Equity IX, L.P., dated June 15, 2007 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K/A filed on June 1, 2007)
10.8	Synutra International, Inc. 2008 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 17, 2008)

110

Exhibit Number	Description
10.9A	Form of Incentive Stock Option Agreement under Synutra International, Inc. 2008 Stock Incentive Plan (incorporated by reference to Exhibit 10.16A to the Registrant’s Annual Report on Form 10-K filed on June 15, 2009)
10.9B	Form of Nonqualified Stock Option Agreement under Synutra International, Inc., 2008 Stock Incentive Plan (incorporated by reference to Exhibit 10.16B to the Registrant’s Annual Report on Form 10-K filed on June 15, 2009)
10.10	Exclusive Consulting and Service Agreement entered into by and between Shengyuan Nutritional Food Co., Ltd. and Beijing Shengyuan Huimin Technology Service Co., Ltd. dated July 20, 2008 (incorporated by reference to Exhibit 10.17 to the Registrant’s Annual Report on Form 10-K filed on June 9, 2010)
10.11	Business Operating Agreement entered into by and among Shengyuan Nutritional Food Co., Ltd., Beijing Shengyuan Huimin Technology Service Co., Ltd. and Jibin Zhang and Yunpeng Jiang dated July 20, 2008 (incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K filed on June 9, 2010)
10.12	Equity Disposal Agreement entered into by and among Shengyuan Nutritional Food Co., Ltd., Beijing Shengyuan Huimin Technology Service Co., Ltd. and Jibin Zhang and Yunpeng Jiang dated July 20, 2008 (incorporated by reference to Exhibit 10.19 to the Registrant’s Annual Report on Form 10-K filed on June 9, 2010)
10.13	Share Pledge Agreement entered into by and among Shengyuan Nutritional Food Co., Ltd. and Jibin Zhang and Yunpeng Jiang dated July 20, 2008 (incorporated by reference to Exhibit 10.20 to the Registrant’s Annual Report on Form 10-K filed on June 9, 2010)
10.14	Entrustment Agreement entered into by and among Shengyuan Nutritional Food Co., Ltd. and Jibin Zhang and Yunpeng Jiang dated July 20, 2008 (incorporated by reference to Exhibit 10.21 to the Registrant’s Annual Report on Form 10-K filed on June 9, 2010)

10.15 Registration Rights Agreement, dated March 3, 2014, by and among Synutra International, Inc., Deutsche Bank AG, Hong Kong Branch and Beams Power Investment Limited (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on March 5, 2014)

14.1	Code of Ethics for Chief Executive Officer and Senior Financial Officers (incorporated by reference to Exhibit 14. 1 to the Registrant’s Annual Report on Form 10-K filed on June 16, 2008)
21.1	List of Subsidiaries
24.1	Power of Attorney (included on the Signature Page of this Annual Report on Form 10-K)
31.1	Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended
31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)
101	Interactive data files pursuant to Rule 405 of Regulation S-T: (i) the Consolidated Balance Sheets—March 31, 2014 and 2013, (ii) the Consolidated Statements of Operations—Year Ended March 31, 2014, 2013 and 2012, (iii) the Consolidated Statements of Comprehensive Income(Loss)—Year Ended March 31, 2014, 2013 and 2012, (iv) the Consolidated Statements of Equity—Year Ended March 31, 2014, 2013 and 2012, (v) the Consolidated Statements of Cash Flows—Year Ended March 31, 2014, 2013 and 2012, and (vi) Notes to Consolidated Financial Statements.

111